0000313143-25-000025 | 10-K | XBRL Viewer

GOODWILL AND INTANGIBLE ASSETS

12 Months Ended

Mar. 29, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

The changes in the carrying amount of goodwill by operating segment for fiscal 2025 and 2024 are as follows:


(In thousands)	Plasma		Blood Center		Hospital		Total
Carrying amount as of April 1, 2023	$	29,043	$	33,855	$	403,333	$	466,231



Acquisitions	—		—		87,079		87,079
Purchase accounting adjustments	—		—		12,283		12,283
Currency translation	—		(371)		(140)		(511)
Carrying amount as of March 30, 2024	29,043		33,484		502,555		565,082


Divestitures	—		(6,381)		—		(6,381)
Acquisitions	—		—		69,542		69,542
Purchase accounting adjustments	—		—		(19,248)		(19,248)
Currency translation	—		(136)		(4,590)		(4,726)
Carrying amount as of March 29, 2025	$	29,043	$	26,967	$	548,259	$	604,269

The decrease in goodwill of $19.2 million for purchase accounting adjustments was primarily related to the Company obtaining additional facts and information to finalize the pre-acquisition tax returns and associated analyses for OpSens. This resulted in the Company revising its estimate of the net deferred tax liability recorded as of the acquisition date. Refer to Note 3, Acquisitions, Divestitures and Strategic Investments, for additional information regarding the acquisitions of OpSens and Attune Medical.

In the fourth quarter of fiscal 2025, the Company completed the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were sold. The goodwill related to the divestiture of $6.4 million has been removed from the Consolidated Balance Sheets. Refer to Note 3, Acquisitions, Divestitures and Strategic Investments, for additional information regarding the divestiture of its Whole Blood product line.

The results of the Company’s goodwill impairment test performed in the fourth quarter of fiscal 2025, 2024 and 2023 indicated that the estimated fair value of all reporting units exceeded their respective carrying values. There were no reporting units at risk of impairment as of the fiscal 2025, 2024 and 2023 annual test dates.

The gross carrying amount of intangible assets and the related accumulated amortization as of March 29, 2025 and March 30, 2024 is as follows:


(In thousands)	Gross Carrying Amount		Accumulated Amortization		Net

As of March 29, 2025
Amortizable:
Developed technology	$	506,143	$	156,123	$	350,020
Customer contracts and related relationships	135,561		70,842		64,719
Capitalized software	85,528		76,185		9,343
Patents and other	19,678		6,796		12,882
Trade names	15,955		6,367		9,588
Total	$	762,865	$	316,313	$	446,552
Non-amortizable:

In-process software development	9,190

Total	$	9,190


(In thousands)	Gross Carrying Amount		Accumulated Amortization		Net

As of March 30, 2024
Amortizable:
Developed technology	$	464,291	$	178,413	$	285,878
Customer contracts and related relationships	255,144		190,033		65,111
Capitalized software	84,837		69,491		15,346
Patents and other	24,504		11,820		12,684
Trade names	14,320		5,456		8,864
Total	$	843,096	$	455,213	$	387,883
Non-amortizable:
In-process research and development	$	13,667
In-process software development	4,567

Total	$	18,234

During fiscal 2025, the Company acquired Attune Medical and recorded $96.1 million of developed technology, $7.8 million of customer contracts and related relationships and $1.9 million of trade name intangibles based on the purchase accounting valuation. Refer to Note 3 Acquisitions, Divestitures and Strategic Investments, for additional information regarding the acquisition.

In the first quarter of fiscal 2025, the Company announced the commercialization of MVP XL and moved the related in-process research and development intangible asset to developed technologies and commenced amortization. In the second quarter of fiscal 2024, the Company recorded an intangible asset impairment charge of $10.4 million related to the intangibles acquired as part of the enicor GmbH acquisition completed in fiscal 2021 within the Hospital business unit.

In the fourth quarter of fiscal 2025, the Company completed the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were sold. The related intangible assets are fully amortized and have a net book value of zero. The gross intangible assets value was $185.6 million. Refer to Note 3 Acquisitions, Divestitures and Strategic Investments, for additional information regarding the divestiture.

In fiscal 2024, the Company acquired OpSens and recorded $114.9 million of developed technology, $52.3 million of customer contracts and related relationships and $4.8 million of trade names. Refer to Note 3, Acquisitions, Divestitures and Strategic Investments, for additional information regarding the acquisition.

Intangible assets include the value assigned to license rights and developed technology, patents, customer contracts and relationships and trade names. The estimated useful lives for all of these intangible assets are approximately 5 to 15 years.

Aggregate amortization expense for amortized intangible assets for fiscal 2025, 2024 and 2023 was $55.6 million, $41.4 million and $42.1 million, respectively.

Amortization expense on intangible assets for the next five years is estimated to be as follows:


(In thousands)
Fiscal 2026	$	51,563
Fiscal 2027	$	47,344
Fiscal 2028	$	45,568
Fiscal 2029	$	44,320
Fiscal 2030	$	43,410

For costs incurred related to the development of software to be sold, leased, or otherwise marketed, the Company applies the provisions of ASC Topic 985-20, Software - Costs of Software to be Sold, Leased or Marketed, which specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be

capitalized until the product is available for general release to customers. The costs capitalized for each project are included in intangible assets in the consolidated financial statements.

The Company capitalized $7.7 million and $6.6 million in software development costs for ongoing initiatives during fiscal 2025 and 2024, respectively. At March 29, 2025 and March 30, 2024, the Company had a total of $94.7 million and $89.4 million of software costs capitalized, of which $9.2 million and $4.6 million are related to in process software development initiatives, respectively, and the remaining balance represents in-service assets that are being amortized over their useful lives. Amortization expense for capitalized software was $6.7 million, $8.6 million and $8.5 million for fiscal 2025, 2024 and 2023, respectively.

RETIREMENT PLANS (Schedule of Estimated Future Benefit Payments) (Details) $ in Thousands	Mar. 29, 2025 USD ($)
Expected Benefit Payments
Fiscal 2026	$ 1,553
Fiscal 2027	1,551
Fiscal 2028	1,599
Fiscal 2029	1,756
Fiscal 2030	2,274
Fiscal 2031-2035	$ 11,174

REVENUE	12 Months Ended
REVENUE	Mar. 29, 2025
Revenue from Contract with Customer [Abstract]
REVENUE	REVENUE As of March 29, 2025, the Company had $33.1 million of transaction price allocated to remaining performance obligations related to executed contracts with an original duration of one year or more. The Company expects to recognize approximately 80% of this amount as revenue within the next twelve months and the remaining balance thereafter. Contract Balances The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables and contract assets, as well as customer advances, customer deposits and deferred revenue (contract liabilities) on the consolidated balance sheets. The difference in timing between billing and revenue recognition primarily occurs in software licensing arrangements, resulting in contract assets and contract liabilities. As of March 29, 2025 and March 30, 2024, the Company had contract liabilities of $43.3 million and $31.2 million, respectively. During fiscal 2025, we recognized $29.1 million of revenue that was included in the above March 30, 2024 contract liability balance. Contract liabilities are classified as other current liabilities and other long-term liabilities on the consolidated balance sheet. As of March 29, 2025 and March 30, 2024, the Company’s contract assets were $11.6 million and $5.2 million, respectively.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/606/tableOfContent

+ Details

ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Purchase Price Allocation (Details) - USD ($) $ in Thousands			12 Months Ended
	Apr. 01, 2024	Dec. 12, 2023	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Business Acquisition [Line Items]
Goodwill			$ 604,269	$ 565,082	$ 466,231
Acquisitions			150,906	243,852	$ 2,850
OpSens, Inc.
Business Acquisition [Line Items]
Business combination, purchase price, net of cash acquired		$ 10,600
Accounts receivable		5,960
Inventories		12,075
Prepaid expenses and other current assets		2,062
Property, plant and equipment		3,028
Intangible assets		172,000
Goodwill		79,400
Other long-term assets		4,705
Total assets acquired		279,230
Accounts payable		3,251
Accrued payroll and related costs		1,723
Other liabilities		9,746
Deferred tax liability		14,805
Other long-term liabilities		5,853
Total liabilities assumed		35,378
Net assets acquired		243,852
Intangible assets acquired		172,000
Acquisitions		$ 243,900
OpSens, Inc. \| Technology-Based Intangible Assets
Business Acquisition [Line Items]
Weighted-Average Amortization Period		15 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation		20.50%
Intangible assets acquired		$ 114,900		114,900
OpSens, Inc. \| Customer Relationships
Business Acquisition [Line Items]
Weighted-Average Amortization Period		15 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation		18.90%
Intangible assets acquired		$ 52,300		52,300
OpSens, Inc. \| Trademarks
Business Acquisition [Line Items]
Weighted-Average Amortization Period		15 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation		20.50%
Intangible assets acquired		$ 4,800		$ 4,800
Attune Medical
Business Acquisition [Line Items]
Business combination, purchase price, net of cash acquired	$ 11,500
Accounts receivable	3,784
Inventories	26,300
Prepaid expenses and other current assets	906
Property, plant and equipment	200
Intangible assets	105,800
Goodwill	70,256
Total assets acquired	207,246
Accounts payable	2,260
Accrued payroll and related costs	2,129
Other liabilities	496
Deferred tax liability	26,155
Total liabilities assumed	31,040
Acquisitions	150,500
Business Combination, Contingent Consideration, Liability	25,300
Business Combination, Working Capital Adjustment	400
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	$ 176,206
Attune Medical \| Technology-Based Intangible Assets
Business Acquisition [Line Items]
Weighted-Average Amortization Period	10 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation	22.00%
Intangible assets acquired			96,100
Attune Medical \| Customer Relationships
Business Acquisition [Line Items]
Weighted-Average Amortization Period	10 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation	21.50%
Intangible assets acquired			$ 7,800

NOTES PAYABLE AND LONG-TERM DEBT (Narrative) (Details) - USD ($)				1 Months Ended	12 Months Ended
	May 28, 2024	Apr. 30, 2024	Jul. 26, 2022	Mar. 31, 2021	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023	Mar. 05, 2021	Jun. 15, 2018
Debt Instrument [Line Items]
Proceeds from issuance of convertible notes					$ 700,000,000	$ 0	$ 0
Total debt maturities					1,246,120,000
Interest expense					35,900,000	19,500,000	13,000,000.0
Repayments of Long-term Debt					4,688,000	12,250,000	9,625,000
Debt Instrument, Percent of Principal Amount Due In Years 1 through 3		2.50%
Debt Instrument, Percent of Principal Amount Due In Year 4		5.00%
Debt Instrument, Percent of Principal Amount Due In Year 5		7.50%
Gain (Loss) on Repurchase of Debt Instrument					12,600,000	0	$ 0
2026					306,349,000
2026 Notes Capped Calls
Debt Instrument [Line Items]
Debt Instrument, Convertible, Capped Call Transaction, Initial Strike Price				$ 175.34
Debt Instrument, Convertible, Capped Call Transaction, Initial Cap Price				$ 250.48
Debt Instrument, Convertible, Capped Call Transaction, Anti-Dilution Adjustment, Shares				2,850,000
2029 Notes Capped Calls
Debt Instrument [Line Items]
Debt Instrument, Convertible, Capped Call Transaction, Initial Strike Price				$ 117.12
Debt Instrument, Convertible, Capped Call Transaction, Initial Cap Price				$ 180.18
Debt Instrument, Convertible, Capped Call Transaction, Anti-Dilution Adjustment, Shares				5,980,000
Purchase Of Capped Call Related To Convertible Notes	$ 88,200,000
Convertible notes
Debt Instrument [Line Items]
Face amount of debt					700,000,000			$ 500,000,000
Debt Instrument, Interest Rate, Stated Percentage								0.00%
Debt Instrument, Redemption Price, Percentage				130.00%
Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed				98.00%
Debt Instrument, Redemption Price, Percentage of Previous Closing Price				10.00%
Debt Instrument, Convertible, Conversion Rate	5.7033
Debt Instrument, Convertible, Conversion Price	$ 175.34
Debt discount					(14,600,000)
Total debt maturities					983,951,000	494,813,000
Interest expense					17,300,000
Convertible notes \| Convertible Senior Notes Due 2026
Debt Instrument [Line Items]
Total debt maturities					298,500,000
Interest expense					$ 1,400,000
Effective interest rate					0.50%
Debt Instrument, Repurchased Face Amount	$ 200,000,000
Debt Instrument, Repurchase Amount	185,500,000
Gain (Loss) on Extinguishment of Debt, before Debt Issuance Cost Writeoff	14,500,000
Deferred Debt Issuance Cost, Writeoff	1,900,000
Gain (Loss) on Repurchase of Debt Instrument	12,600,000
Long-Term Debt, Gross					$ 300,000,000
Debt Issuance Costs, Net					1,500,000
Convertible notes \| Convertible Senior Notes Due 2029
Debt Instrument [Line Items]
Face amount of debt	$ 700,000,000
Debt Instrument, Interest Rate, Stated Percentage	2.50%
Proceeds from issuance of convertible notes	$ 682,800,000
Debt Instrument, Redemption Price, Percentage	130.00%
Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed	98.00%
Debt Instrument, Redemption Price, Percentage of Previous Closing Price	10.00%
Debt Instrument, Convertible, Conversion Rate	8.5385
Debt Instrument, Convertible, Conversion Price	$ 117.12
Total debt maturities					685,400,000
Effective interest rate	3.00%
Debt Issuance Costs, Gross	$ 17,200,000
Convertible notes \| Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage				130.00%
Convertible notes \| Debt Instrument, Redemption, Period One \| Convertible Senior Notes Due 2029
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage	130.00%
Convertible notes \| Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage				100.00%
Convertible notes \| Debt Instrument, Redemption, Period Two \| Convertible Senior Notes Due 2029
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage	100.00%
Term Loan
Debt Instrument [Line Items]
Face amount of debt									$ 750,000,000.0
Term Loan \| 2024 Revised Credit Agreement
Debt Instrument [Line Items]
Repayments of Long-term Debt		$ 12,500,000
Term Loan \| Minimum \| 2024 Revised Credit Agreement
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		1.125%
Term Loan \| Maximum \| 2024 Revised Credit Agreement
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		1.75%
Line of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity					18,900,000
Total debt maturities					0
Line of Credit \| Minimum \| Revised Credit Agreement \| Revolving Credit Facility
Debt Instrument [Line Items]
Commitment fee			0.125%
Line of Credit \| Maximum \| Revised Credit Agreement \| Revolving Credit Facility
Debt Instrument [Line Items]
Commitment fee			0.25%
Term Loan
Debt Instrument [Line Items]
Debt discount					(5,300,000)
Total debt maturities					$ 245,300,000
Effective interest rate					5.70%
Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity									$ 420,000,000.0
Total debt maturities					$ 0	50,000,000
Commitment fee					0.20%
Revolving Credit Facility \| 2024 Revised Credit Agreement
Debt Instrument [Line Items]
Consolidated total leverage ratio					4.0
Consolidated interest coverage ratio					4.5
Revolving Credit Facility \| Minimum
Debt Instrument [Line Items]
Commitment fee					0.125%
Revolving Credit Facility \| Maximum
Debt Instrument [Line Items]
Commitment fee					0.25%
Term loan, net of financing fees
Debt Instrument [Line Items]
Total debt maturities					$ 240,028,000	$ 261,971,000
Unsecured Debt \| Revised Credit Agreement
Debt Instrument [Line Items]
Face amount of debt			$ 250,000,000
Unsecured Debt \| Minimum \| Revised Credit Agreement
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			1.125%
Debt Instrument, Interest Rate, Floor			0.00%
Unsecured Debt \| Maximum \| Revised Credit Agreement
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			1.75%

EARNINGS PER SHARE

12 Months Ended

Mar. 29, 2025

Earnings Per Share [Abstract]

EARNINGS PER SHARE

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.


(In thousands, except per share amounts)	2025		2024		2023
Basic EPS
Net income	$	167,679	$	117,558	$	115,401
Weighted average shares	50,330		50,706		50,783
Basic income per share	$	3.33	$	2.32	$	2.27
Diluted EPS
Net income	$	167,679	$	117,558	$	115,401
Basic weighted average shares	50,330		50,706		50,783
Net effect of common stock equivalents	400		691		637
Diluted weighted average shares	50,730		51,397		51,420
Diluted income per share	$	3.31	$	2.29	$	2.24

Basic earnings per share is calculated using the Company’s weighted-average outstanding common shares. Diluted earnings per share is calculated using its weighted-average outstanding common shares including the dilutive effect of stock awards as determined under the treasury stock method and the outstanding convertible senior notes as determined under the net share settlement method. From the time of the issuance of the convertible senior notes, the average market price of the Company’s common shares has been less than the applicable initial conversion price, and consequently no shares have been included in diluted earnings per share for the conversion values of both the convertible senior notes. For fiscal 2025, 2024 and 2023, weighted average shares outstanding, assuming dilution, excludes the impact of 0.8 million, 0.6 million and 0.6 million anti-dilutive shares, respectively.

Share Repurchase Program

In August 2022, the Company announced that its Board of Directors had approved a three-year share repurchase program authorizing the repurchase of up to $300.0 million of Haemonetics common stock (the “Share Repurchase Authorization”), based on market conditions, through August 2025. Under the Share Repurchase Authorization, the Company is authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions. The actual timing, number and value of shares repurchased will be determined by the Company at its discretion and will depend on a number of factors, including market conditions, applicable legal requirements and compliance with the terms of loan covenants. The Share Repurchase Authorization may be suspended, modified or discontinued at any time, and the Company has no obligation to repurchase any amount of its common stock under the program.

In fiscal 2023, the Company completed a $75.0 million repurchase of its common stock pursuant to an accelerated share repurchase agreement (“ASR”) entered into with Citibank N.A. (“Citibank”) in August 2022. The total number of shares repurchased under the ASR was 1.0 million at an average price per share upon final settlement of $75.20.

In October 2024, the Company completed a $75.0 million repurchase of its common stock pursuant to an ASR entered into with Citibank in August 2024. The total number of shares repurchased under the ASR was 1.0 million at an average price per share upon final settlement of $74.36.

In February 2025, the Company entered into an ASR with Goldman Sachs & Co. (“Goldman Sachs”) to repurchase $150.0 million of the Company’s common stock. Pursuant to the ASR, in February 2025, the Company paid Citibank $150.0 million and received an additional delivery of 2.0 million shares of the Company’s common stock based on a closing market price on the New York Stock Exchange on February 7, 2025 of $59.34, which represented 80% of the total contract. The ASR was completed in April 2025, subsequent to the end of the fourth quarter of fiscal 2025, and 0.4 million additional shares were delivered upon settlement. As of March 29, 2025, we have fully funded the $300.0 million Share Repurchase Authorization.

Share Repurchase Authorization

In April 2025 the Company’s Board of Directors approved a new share repurchase authorization of up to $500 million of Haemonetics common stock over the next three years. This new share repurchase program will help to offset the dilutive impact of recent and future employee equity grants. In addition to this share repurchase activity, the Company’s capital allocation strategy continues to prioritize funding of planned internal investments to support the business as well as inorganic opportunities to accelerate its long-term growth plans. Under the share repurchase program, the Company is authorized to repurchase, from time to time, outstanding shares of common stock in accordance with applicable laws on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and in privately negotiated transactions. The actual timing, number and value of shares repurchased will be determined by the Company at its discretion and will depend on a number of factors, including market conditions, applicable legal requirements and compliance with the terms of loan covenants. The share repurchase program may be suspended, modified or discontinued at any time, and the Company has no obligation to repurchase any amount of its common stock under the program.

INCOME TAXES (Schedule of Effective Income Tax Rate Reconciliation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Income Tax Disclosure [Abstract]
Tax at federal statutory rate	$ 44,535	$ 31,892	$ 29,695
Tax at federal statutory rate	21.00%	21.00%	21.00%
Impact of foreign operations	$ (732)	$ (3,631)	$ (2,408)
Impact of foreign operations	(0.30%)	(2.40%)	(1.70%)
State income taxes net of federal benefit	$ 7,505	$ 7,037	$ 2,939
State income taxes net of federal benefit	3.50%	4.60%	2.10%
Change in uncertain tax positions	$ (1,227)	$ (107)	$ 81
Change in uncertain tax positions	(0.60%)	(0.10%)	0.10%
Global intangible low taxed income	$ (1,380)	$ (555)	$ (828)
Global intangible low taxed income	(0.70%)	(0.40%)	(0.60%)
Unremitted earnings	$ 163	$ 171	$ (91)
Unremitted earnings	0.10%	0.10%	(0.10%)
Deferred statutory rate changes	$ 543	$ (159)	$ 82
Deferred statutory rate changes	0.30%	(0.10%)	0.10%
Non-deductible executive compensation	$ 5,130	$ 3,256	$ 1,439
Non-deductible executive compensation	(2.40%)	(2.10%)	(1.00%)
Non-deductible expenses	$ 2,845	$ 2,355	$ 827
Non-deductible expenses	1.30%	1.60%	0.60%
Stock compensation shortfalls (benefits)	$ (4,469)	$ (1,841)	$ 1,883
Stock compensation shortfalls (benefits)	(2.10%)	(1.20%)	1.30%
Research credits	$ (2,411)	$ (1,378)	$ (2,073)
Research credits	(1.10%)	(0.90%)	(1.50%)
Contingent consideration	$ (4,774)	$ 0	$ 0
Contingent consideration	(2.30%)	0.00%	0.00%
Effective Income Tax Rate Reconciliation, Cantonal step-up attribute carryforward, Percent	(1.30%)	(1.80%)	0.00%
Effective Income Tax Rate Reconciliation, Cantonal step-up attribute carryforward, Amount	$ (2,707)	$ (2,739)	$ 0
Valuation allowance	$ 1,744	$ (393)	$ (5,135)
Valuation allowance	0.90%	(0.20%)	(3.60%)
Other, net	$ (373)	$ 399	$ (409)
Other, net	(0.20%)	0.30%	(0.30%)
Income tax provision	$ 44,392	$ 34,307	$ 26,002
Income tax provision	20.90%	22.60%	18.40%

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023	Apr. 02, 2022
Summary of Significant Accounting Pronouncements [Line Items]
Optional exemption term	1 year
Cash and cash equivalents maximum maturity period	3 months
Capitalized implementation costs	$ 44,000,000.0	$ 22,900,000
Amortization expense	2,300,000	900,000	$ 0
Impairment charges related to the discontinuance of certain capitalized software projects	0	0	0
Other Liabilities
Contract liabilities	43,348,000	31,242,000
All other	104,785,000	104,846,000
Total	148,133,000	136,088,000
Advertising expense	7,700,000	7,100,000	7,200,000
Foreign currency losses	900,000	4,000,000.0	1,000,000.0
Gain (Loss) on Investments	0	0	0
Stockholders' Equity Attributable to Parent	(820,836,000)	(959,959,000)	(817,997,000)	$ (749,424,000)
Deferred Income Tax Liabilities, Net	(62,575,000)	(62,644,000)
Additional Paid-in Capital
Other Liabilities
Stockholders' Equity Attributable to Parent	(523,264,000)	(634,627,000)	(594,706,000)	(572,476,000)
Retained Earnings
Other Liabilities
Stockholders' Equity Attributable to Parent	$ (352,174,000)	$ (360,456,000)	$ (253,168,000)	$ (202,391,000)
Minimum
Summary of Significant Accounting Pronouncements [Line Items]
Software capitalization term	5 years
Maximum
Summary of Significant Accounting Pronouncements [Line Items]
Software capitalization term	10 years
Building \| Minimum
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life	30 years
Building \| Maximum
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life	40 years
Building improvements \| Minimum
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life	5 years
Building improvements \| Maximum
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life	20 years
Plant equipment and machinery \| Minimum
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life	3 years
Plant equipment and machinery \| Maximum
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life	15 years
Office equipment and information technology \| Minimum
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life	3 years
Office equipment and information technology \| Maximum
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life	10 years
Haemonetics equipment \| Minimum
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life	3 years
Haemonetics equipment \| Maximum
Summary of Significant Accounting Pronouncements [Line Items]
Property, plant and equipment, useful life	7 years
Net Revenues \| Customer Concentration Risk \| Ten Largest Customers
Other Liabilities
Concentration risk	42.00%	48.00%	48.00%
Net Revenues \| Customer Concentration Risk \| Two Customers
Other Liabilities
Concentration risk	10.00%
Net Revenues \| Customer Concentration Risk \| Plasma Customer, CSL Limited (CSL), Two Customers
Other Liabilities
Concentration risk	10.00%

RETIREMENT PLANS (Tables)

12 Months Ended

Mar. 29, 2025

Retirement Benefits [Abstract]

Schedule of Components of Net Periodic Benefit Costs of Defined Benefit Pension Plans

Some of the Company’s foreign subsidiaries have defined benefit pension plans covering substantially all full time employees at those subsidiaries. Net periodic benefit costs for the plans in the aggregate include the following components:


(In thousands)	2025		2024		2023
Service cost	$	1,630	$	1,316	$	1,453
Interest cost on benefit obligation	630		684		409
Expected return on plan assets	(314)		(264)		(180)
Actuarial loss (gain)	17		(180)		19
Amortization of unrecognized prior service cost	(219)		(215)		(180)
Plan settlements	(104)		—		(330)
Totals	$	1,640	$	1,341	$	1,191

Schedule of Activity Under Defined Benefit Plans

The activity under those defined benefit plans are as follows:


(In thousands)	March 29, 2025		March 30, 2024
Change in Benefit Obligation:
Benefit Obligation, beginning of year	$	(32,323)	$	(25,465)
Service cost	(1,630)		(1,316)
Interest cost	(630)		(684)
Benefits paid	851		2,253
Actuarial loss	(336)		(2,392)
Employee and plan participants contribution	(3,568)		(3,423)
Plan settlements	6,419		34
Foreign currency changes	261		(1,330)
Benefit obligation, end of year	$	(30,956)	$	(32,323)
Change in Plan Assets:
Fair value of plan assets, beginning of year	$	21,851	$	18,463
Company contributions	1,627		1,584
Benefits paid	(663)		(1,788)
Gain on plan assets	482		238
Employee and plan participants contribution	3,600		3,368
Plan settlements	(6,451)		—
Foreign currency changes	392		(14)
Fair value of plan assets, end of year	$	20,838	$	21,851
Funded Status*	$	(10,118)	$	(10,472)
Unrecognized net actuarial gain	(1,056)		(1,288)
Unrecognized prior service cost	(705)		(969)
Net amount recognized	$	(11,879)	$	(12,729)
* Substantially all of the unfunded status is non-current

Schedule of Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax

The components of the change recorded in the Company’s accumulated other comprehensive loss related to its defined benefit plans, net of tax, are as follows (in thousands):


Balance as of April 2, 2022	$	1,619

Actuarial gain	2,695
Prior service cost	$	46

Plan settlements	(285)
Balance as of April 1, 2023	$	4,075
Actuarial gain	(2,157)
Prior service cost	(170)

Balance as of March 30, 2024	$	1,748
Actuarial loss	(268)
Prior service credit	(242)
Plan settlements	(89)
Balance as of March 29, 2025	$	1,149

Schedule of Weighted Average Rates Used to Determine Net Periodic Benefit Costs

The weighted average rates used to determine the net periodic benefit costs and projected benefit obligations were as follows:


	2025		2024		2023
Discount rate	1.87	%	2.05	%	2.43	%
Rate of increased salary levels	2.71	%	1.86	%	1.94	%
Expected long-term rate of return on assets	0.88	%	0.94	%	0.87	%

Schedule of Estimated Future Benefit Payments

Estimated future benefit payments are as follows:


(In thousands)
Fiscal 2026	$	1,553
Fiscal 2027	$	1,551
Fiscal 2028	$	1,599
Fiscal 2029	$	1,756
Fiscal 2030	$	2,274
Fiscal 2031-2035	$	11,174

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Mar. 29, 2025

Accounting Standards Update and Change in Accounting Principle [Abstract]

Schedule of Property, Plant and Equipment Estimated Useful Lives

Property, plant and equipment is recorded at historical cost. The Company provides for depreciation and amortization by charges to operations using the straight-line method in amounts estimated to recover the cost of the building and improvements, equipment and furniture and fixtures over their estimated useful lives as follows:


Asset Classification						Estimated Useful Lives
Building						30-40 Years
Building improvements						5-20 Years
Plant equipment and machinery						3-15 Years
Office equipment and information technology						3-10 Years
Haemonetics equipment						3-7 Years

Schedule of Other Accrued Liabilities

Other Current Liabilities

Other current liabilities represent items payable or expected to settle within the next twelve months. The items included in the fiscal year end balances were:


(In thousands)	March 29, 2025		March 30, 2024


Contract liabilities	43,348		31,242




All other	104,785		104,846
Total	$	148,133	$	136,088

Other Long-Term Liabilities

Other long-term liabilities represent items that are not payable or expected to settle within the next twelve months.

CAPITAL STOCK (Narrative) (Details) $ / shares in Units, $ in Millions			12 Months Ended
	Aug. 04, 2023 shares	Jul. 25, 2019 shares	Mar. 29, 2025 USD ($) period $ / shares shares	Mar. 30, 2024 USD ($) $ / shares shares	Apr. 01, 2023 USD ($) $ / shares	Aug. 03, 2023 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for grant (in shares)			4,496,411
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)			3,200,000
Number of purchase periods (in purchase periods) \| period			2
Percentage of purchase price for shares of common stock at fair market value (as a percent)			85.00%
Weighted average grant date fair value of the six-month option inherent in the Purchase Plan (in dollars per share) \| $ / shares			$ 19.13	$ 20.27	$ 18.10
Expected term			6 months	6 months	6 months
Employee Stock Purchase Plan \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares purchased through payroll deductions (as a percent)			2.00%
Employee Stock Purchase Plan \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of shares purchased through payroll deductions (as a percent)			15.00%
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)			993,587	1,067,004
Award expiration period			7 years
Total intrinsic value of options exercised \| $			$ 6.4	$ 12.4	$ 1.9
Total unrecognized compensation cost related to non vested awards \| $			$ 10.4
Total unrecognized compensation cost related to non vested stock options, weighted average period of recognition (in years)			2 years 3 months 18 days
Expected term			5 years 2 months 12 days	5 years 1 month 6 days	5 years
Stock Options \| Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			4 years
Stock Options \| Non-employee director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			1 year
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity instruments other than options outstanding (in shares)			303,003	338,008
Total unrecognized compensation cost related to non vested awards \| $			$ 14.7
Total unrecognized compensation cost related to non vested stock options, weighted average period of recognition (in years)			1 year 7 months 6 days
Shares, Vested (in shares)			143,680
Weighted Average Grant Date Fair Value (in dollars per share), Granted \| $ / shares			$ 95.09	$ 89.21	$ 59.36
Restricted Stock Units (RSUs) \| Employees \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			3 years
Restricted Stock Units (RSUs) \| Employees \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			4 years
Restricted Stock Units (RSUs) \| Non-employee director
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period			1 year
Performance Share Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)			671,686
Equity instruments other than options outstanding (in shares)			335,843	369,800
Total unrecognized compensation cost related to non vested awards \| $			$ 19.1
Total unrecognized compensation cost related to non vested stock options, weighted average period of recognition (in years)			1 year 7 months 6 days
Shares, Vested (in shares)			233,384
Award performance period			3 years
Performance shares target, percentage			100.00%
Weighted Average Grant Date Fair Value (in dollars per share), Granted \| $ / shares			$ 128.25	$ 128.83	$ 84.96
Performance Share Units (PSUs) \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance shares target, percentage			0.00%
Performance Share Units (PSUs) \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance shares target, percentage			200.00%
2019 Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized		2,700,000
2019 Equity Plan [Member] \| Share-based Payment Arrangement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)		5,759,433
Incentive Compensation Plan 2005 \| Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options counted against maximum number of award shares for every share option issued (in shares)			2.76
Amended and Restated 2019 Equity Plan \| Share-based Payment Arrangement
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares available for award (in shares)	4,942,201					1,975,970
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized	2,966,231

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain on cash flow hedges, net of tax	$ (935)	$ 4,912	$ 4,269
Designated as Hedging Instrument \| Cash Flow Hedging
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Earnings	11
Designated as Hedging Instrument \| Cash Flow Hedging \| Net revenues, COGS and SG&A
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain on cash flow hedges, net of tax	(1,508)
Designated as Hedging Instrument \| Cash Flow Hedging \| Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain Excluded from Effectiveness Testing	1,743
Designated as Hedging Instrument \| Interest Rate Swap
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Earnings	(67)
Amount of Gain Excluded from Effectiveness Testing	0
Designated as Hedging Instrument \| Interest Rate Swap \| Net revenues, COGS and SG&A
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain on cash flow hedges, net of tax	600
Designated as Hedging Instrument \| Interest Rate Swap \| Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain on cash flow hedges, net of tax	573
Not Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain on cash flow hedges, net of tax	0
Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Earnings	0
Not Designated as Hedging Instrument \| Foreign Exchange Contract \| Interest and other expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gain Excluded from Effectiveness Testing	$ (1,534)

ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Additional Information (Details) - USD ($)			3 Months Ended	12 Months Ended
	Apr. 01, 2024	Dec. 12, 2023	Jun. 29, 2024	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Business Acquisition [Line Items]
Acquisitions				$ 150,906,000	$ 243,852,000	$ 2,850,000
Term loan borrowings				250,000,000	0	280,000,000
Goodwill				604,269,000	565,082,000	466,231,000
Gain (Loss) on Investments				0	$ 0	0
Convertible Senior Notes Due 2026 \| Level 2
Business Acquisition [Line Items]
Convertible Debt, Fair Value Disclosures				286,300,000
Convertible Senior Notes Due 2029 \| Level 2
Business Acquisition [Line Items]
Convertible Debt, Fair Value Disclosures				$ 668,400,000
Attune Medical
Business Acquisition [Line Items]
Business combination, consideration transferred	$ 187,700,000
Payments to Acquire Businesses, Gross	162,000,000
Acquisitions	150,500,000
Business Combination, Contingent Consideration, Liability	25,300,000
Goodwill	70,256,000
Deferred tax liability	$ 26,155,000
Attune Medical \| Selling, general and administrative expenses
Business Acquisition [Line Items]
Business Combination, Acquisition Related Costs			$ 9,800,000
OpSens, Inc.
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross		$ 254,500,000
Acquisitions		243,900,000
Goodwill		79,400,000
Deferred tax liability		$ 14,805,000
Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed						$ 6,600,000

Insider Trading Arrangements

3 Months Ended

Mar. 29, 2025

Trading Arrangements, by Individual

Non-Rule 10b5-1 Arrangement Adopted

false

Rule 10b5-1 Arrangement Terminated

false

Non-Rule 10b5-1 Arrangement Terminated

false

Stewart W. Strong [Member]

Trading Arrangements, by Individual

Material Terms of Trading Arrangement

During the three months ended March 29, 2025, certain of our directors and officers (as defined under Rule 16a-1(f) under the Securities Exchange Act of 1934) adopted or terminated trading arrangements for the sale of shares of our common stock as follows:

Trading Arrangement

Name and Title

Action

Date(1)

Rule 10b5-1*

Non-Rule 10b5-1**

Number of Shares to be Sold(2)

Expiration Date(3)

Stewart W. Strong, President, Global Hospital

Adoption

2/14/2025

11,997(4)

6/13/2025

* Intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934.

** Not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934.

(1) Reflects the fully-executed date of each trading arrangement, which may differ from the date of first execution by an officer or director.

(2) The number of shares of common stock sold under each trading arrangement, if any, will be net of shares withheld for applicable tax obligations upon the vesting and/or exercise of covered securities as well as for payment of the exercise price upon the exercise of stock options, which amounts are not yet determinable.

(3) Except as otherwise indicated by footnote, each trading arrangement expires upon the earlier of (a) completion of all authorized transactions thereunder and (b) the expiration date listed above.

(4) Includes 8,246 target shares subject to a performance share unit (“PSU”) award previously granted to Mr. Strong on May 16, 2022. The actual number of shares to be earned under the PSU award, and subject to sale under this trading arrangement, may range from 0% to a maximum of 200% of the target award depending upon the Company’s total shareholder return relative to the components of the S&P MidCap 400 index during a three-year performance period from May 16, 2022 to May 15, 2025.

Arrangement Duration

443 days

Aggregate Available

11,997

Officer Trading Arrangement [Member] | Stewart W. Strong [Member]

Trading Arrangements, by Individual

Name

Stewart W. Strong

Title

President, Global Hospital

Rule 10b5-1 Arrangement Adopted

true

Adoption Date

2/14/2025

Expiration Date

6/13/2025

RETIREMENT PLANS (Narrative) (Details) - USD ($)	12 Months Ended
RETIREMENT PLANS (Narrative) (Details) - USD ($)	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Benefit obligation, plan funded by company	$ 7,400,000	$ 7,800,000
Reinsurance contracts asset value	7,000,000.0	7,000,000.0
Accumulated benefit obligation	29,100,000	30,100,000
Amount expected to be amortized from accumulated other comprehensive loss in next fiscal year	300,000
Subsidiaries
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company contributions	1,000,000.0	700,000	$ 600,000
Savings Plus Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company contributions	8,200,000	8,100,000	6,900,000
401k Plan
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company contributions	$ 0	$ 0	$ 0

INCOME TAXES (Schedule of Net Deferred Tax Asset) (Details) - USD ($) $ in Thousands	Mar. 29, 2025	Mar. 30, 2024
Income Tax Disclosure [Abstract]
Depreciation	$ 97	$ 1,817
Amortization of intangibles	4,796	3,715
Inventory	2,846	5,502
Accruals, reserves and other deferred tax assets	14,801	18,777
Net operating loss carry-forward	8,842	16,221
Stock based compensation	4,897	3,965
Operating lease liabilities	14,906	16,132
Tax credit carry-forward, net	6,713	7,766
Deferred Tax Assets, Research Expenses Capitalized	39,219	31,370
Gross deferred tax assets	97,117	105,265
Less valuation allowance	(11,930)	(10,239)
Total deferred tax assets (after valuation allowance)	85,187	95,026
Depreciation	(35,006)	(35,279)
Amortization of goodwill and intangibles	(87,905)	(96,597)
Unremitted earnings	(1,497)	(1,334)
Operating lease assets	(12,033)	(13,341)
Other deferred tax liabilities	(3,518)	(3,380)
Total deferred tax liabilities	(139,959)	(149,931)
Net deferred tax liabilities	$ (54,772)	$ (54,905)

GOODWILL AND INTANGIBLE ASSETS (Tables)

12 Months Ended

Mar. 29, 2025

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill


(In thousands)	Plasma		Blood Center		Hospital		Total
Carrying amount as of April 1, 2023	$	29,043	$	33,855	$	403,333	$	466,231



Acquisitions	—		—		87,079		87,079
Purchase accounting adjustments	—		—		12,283		12,283
Currency translation	—		(371)		(140)		(511)
Carrying amount as of March 30, 2024	29,043		33,484		502,555		565,082


Divestitures	—		(6,381)		—		(6,381)
Acquisitions	—		—		69,542		69,542
Purchase accounting adjustments	—		—		(19,248)		(19,248)
Currency translation	—		(136)		(4,590)		(4,726)
Carrying amount as of March 29, 2025	$	29,043	$	26,967	$	548,259	$	604,269

Schedule of Amoritized Intangibles

The gross carrying amount of intangible assets and the related accumulated amortization as of March 29, 2025 and March 30, 2024 is as follows:


(In thousands)	Gross Carrying Amount		Accumulated Amortization		Net

As of March 29, 2025
Amortizable:
Developed technology	$	506,143	$	156,123	$	350,020
Customer contracts and related relationships	135,561		70,842		64,719
Capitalized software	85,528		76,185		9,343
Patents and other	19,678		6,796		12,882
Trade names	15,955		6,367		9,588
Total	$	762,865	$	316,313	$	446,552
Non-amortizable:

In-process software development	9,190

Total	$	9,190


(In thousands)	Gross Carrying Amount		Accumulated Amortization		Net

As of March 30, 2024
Amortizable:
Developed technology	$	464,291	$	178,413	$	285,878
Customer contracts and related relationships	255,144		190,033		65,111
Capitalized software	84,837		69,491		15,346
Patents and other	24,504		11,820		12,684
Trade names	14,320		5,456		8,864
Total	$	843,096	$	455,213	$	387,883
Non-amortizable:
In-process research and development	$	13,667
In-process software development	4,567

Total	$	18,234

Schedule of Future Amortization Expense

Amortization expense on intangible assets for the next five years is estimated to be as follows:


(In thousands)
Fiscal 2026	$	51,563
Fiscal 2027	$	47,344
Fiscal 2028	$	45,568
Fiscal 2029	$	44,320
Fiscal 2030	$	43,410

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

+ Details

SEGMENT AND ENTERPRISE-WIDE INFORMATION - Segment Information By Geographic Region (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	$ 284,052	$ 311,362
Net revenues	1,360,824	1,309,055	$ 1,168,660
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	217,212	246,473
Net revenues	1,010,918	970,007	842,897
Japan
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	1,250	1,597
Net revenues	62,408	58,087	61,295
Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	20,024	15,310
Net revenues	175,655	160,142	156,680
Rest of Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	28,705	26,728
Net revenues	92,305	107,536	104,135
Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Total long-lived assets	16,861	21,254
Net revenues	$ 19,538	$ 13,283	$ 3,653

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Insider Trading Policies and Procedures	12 Months Ended
Insider Trading Policies and Procedures	Mar. 29, 2025
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($) $ in Thousands	Mar. 29, 2025	Mar. 30, 2024
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 6,300	$ 5,695
Intangible assets, accumulated amortization	$ 316,313	$ 455,213
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	48,215,899	50,787,859
Common stock, outstanding (in shares)	48,215,899	50,787,859

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details) - USD ($)		12 Months Ended
	Sep. 27, 2024	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023	Apr. 01, 2024	Sep. 23, 2022	Jun. 15, 2018
Derivative [Line Items]
Total debt maturities		$ 1,246,120,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Value At Acquisition Date		25,000,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Adjustment		$ 300,000
Fair Value, Recurring Basis, Unobservable Input Reconciliation, Liability, Gain (Loss), Statement Of Income, Extensible List, Not Disclosed Flag		Change in fair value
Contingent Consideration, Acquisition Date Fair Value		$ (23,022,000)
Unrealized gain on cash flow hedges, net of tax		(935,000)	$ 4,912,000	$ 4,269,000
Attune Medical
Derivative [Line Items]
Business Combination, Contingent Consideration, Liability					$ 25,300,000
Revolving Credit Facility
Derivative [Line Items]
Maximum borrowing capacity							$ 420,000,000.0
Total debt maturities		$ 0	$ 50,000,000
Foreign Exchange Contract
Derivative [Line Items]
Percentage of sales generated outside the US		25.70%	25.90%	27.90%
Maturity period for foreign currency contracts		1 year
Interest Rate Swap
Derivative [Line Items]
Notional amount		$ 204,497,000				$ 219,800,000
Derivative, Blended Fixed Interest Rate	3.31%
Derivative, Percentage Of Notional Value Of Debt	80.00%
Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative [Line Items]
Designated foreign currency hedge contracts outstanding		23,600,000	$ 74,000,000.0
Designated as Hedging Instrument \| Cash Flow Hedging \| Net revenues, COGS and SG&A
Derivative [Line Items]
Unrealized gain on cash flow hedges, net of tax		(1,508,000)
Designated as Hedging Instrument \| Interest Rate Swap \| Net revenues, COGS and SG&A
Derivative [Line Items]
Unrealized gain on cash flow hedges, net of tax		600,000
Designated as Hedging Instrument \| Interest Rate Swap \| Interest and other expense, net
Derivative [Line Items]
Unrealized gain on cash flow hedges, net of tax		573,000
Not Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative [Line Items]
Non-designated foreign currency hedge contracts outstanding		89,600,000	39,900,000
Unrealized gain on cash flow hedges, net of tax		0
Fair Value, Measurements, Recurring
Derivative [Line Items]
Liabilities fair value		2,774,000	931,000
Fair Value, Measurements, Recurring \| Contingent Consideration
Derivative [Line Items]
Liabilities fair value		2,278,000
Fair Value, Measurements, Recurring \| Designated as Hedging Instrument
Derivative [Line Items]
Derivative Liabilities		496,000	931,000
Fair Value, Measurements, Recurring \| Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative [Line Items]
Derivative Liabilities		471,000	395,000
Fair Value, Measurements, Recurring \| Designated as Hedging Instrument \| Foreign Exchange Contract \| Other Current Liabilities
Derivative [Line Items]
Derivative Liabilities			395,000
Fair Value, Measurements, Recurring \| Not Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative [Line Items]
Derivative Liabilities		25,000	536,000
Fair Value, Measurements, Recurring \| Not Designated as Hedging Instrument \| Foreign Exchange Contract \| Other Current Liabilities
Derivative [Line Items]
Derivative Liabilities			536,000
Fair Value, Measurements, Recurring \| Level 2
Derivative [Line Items]
Liabilities fair value		496,000	931,000
Fair Value, Measurements, Recurring \| Level 2 \| Designated as Hedging Instrument \| Foreign Exchange Contract
Derivative [Line Items]
Derivative Liabilities			395,000
Fair Value, Measurements, Recurring \| Level 2 \| Designated as Hedging Instrument \| Foreign Exchange Contract \| Other Current Liabilities
Derivative [Line Items]
Derivative Liabilities		471,000
Fair Value, Measurements, Recurring \| Level 2 \| Not Designated as Hedging Instrument \| Foreign Exchange Contract \| Other Current Liabilities
Derivative [Line Items]
Derivative Liabilities		25,000	536,000
Fair Value, Measurements, Recurring \| Fair Value, Inputs, Level 3
Derivative [Line Items]
Liabilities fair value		2,278,000	0
Fair Value, Measurements, Recurring \| Fair Value, Inputs, Level 3 \| Contingent Consideration
Derivative [Line Items]
Liabilities fair value		2,278,000	$ 0
Fair Value, Measurements, Recurring \| Fair Value, Inputs, Level 3 \| Contingent Consideration \| Revenue-based payments
Derivative [Line Items]
Liabilities fair value		$ 1,214,000
Contingent Consideration Fair Value, Risk-Adjusted Discount Rate		6.30%
Fair Value, Measurements, Recurring \| Fair Value, Inputs, Level 3 \| Contingent Consideration \| Regulatory-based payment
Derivative [Line Items]
Liabilities fair value		$ 0
Fair Value, Measurements, Recurring \| Fair Value, Inputs, Level 3 \| Contingent Consideration \| Event-based payment
Derivative [Line Items]
Liabilities fair value		$ 1,064,000
Contingent Consideration Fair Value, Risk-Adjusted Discount Rate		5.80%

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Feb. 29, 2024	Jun. 29, 2024	Mar. 29, 2025
Loss Contingencies [Line Items]
Loss in period	$ 8,700
Payments for legal settlements		$ 8,700
Product Recall 2
Loss Contingencies [Line Items]
Loss in period			$ 6,800

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

INCOME TAXES (Schedule Domestic and Foreign Income Before Provision for Income Tax) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Income Tax Disclosure [Abstract]
Domestic	$ 161,800	$ 112,563	$ 85,657
Foreign	50,271	39,302	55,746
Income before provision for income taxes	$ 212,071	$ 151,865	$ 141,403

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

INCOME TAXES (Summary of Gross Unrecognized Tax Benefits) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Unrecognized Tax Benefits [Roll Forward]
Beginning Balance	$ 3,743	$ 3,941	$ 3,939
Additions for tax positions of the current year	315	234	292
Additions for tax positions of a prior year	1,242	0	0
Additions for tax positions related to acquired businesses	91	0	0
Reductions of tax positions	(64)	(198)	(290)
Expiration of statute of limitations	(2,505)	(234)	0
Ending Balance	$ 2,822	$ 3,743	$ 3,941

PROPERTY, PLANT AND EQUIPMENT (Tables)

12 Months Ended

Mar. 29, 2025

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment

Property, plant and equipment consisted of the following:


(In thousands)	March 29, 2025		March 30, 2024
Land	$	1,985	$	4,130
Building and building improvements	105,079		124,338
Plant equipment and machinery	181,825		204,622
Office equipment and information technology	130,924		129,979
Haemonetics equipment	395,152		456,414
Construction in progress	22,229		39,694
Total	837,194		959,177
Less: accumulated depreciation	(553,142)		(647,815)
Property, plant and equipment, net	$	284,052	$	311,362

INVENTORIES (Tables)

12 Months Ended

Mar. 29, 2025

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories are stated at the lower of cost or net realizable value and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method.


(In thousands)	March 29, 2025		March 30, 2024
Raw materials	$	128,574	$	134,150
Work-in-process	14,956		15,488
Finished goods	221,611		167,564
Total inventories	$	365,141	$	317,202

In fiscal 2024, the Company issued a voluntary recall of certain products within the Whole Blood portion of our Blood Center business unit sold to customers in the U.S. and certain foreign jurisdictions. The Company has recorded charges of $4.4 million related to inventory.

ACCUMULATED OTHER COMPREHENSIVE LOSS (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023	Apr. 02, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance, value	$ (35,632)
Other comprehensive loss before reclassifications	(19,508)	$ (1,754)
Amounts reclassified from accumulated other comprehensive income (loss)	56	(3,497)
Other comprehensive (loss) income	(19,452)	(5,251)	$ (4,427)
OCI, before Reclassifications, Net of Tax, Attributable to Parent	820,836	959,959	817,997	$ 749,424
Balance, value	(55,084)	(35,632)
Foreign currency
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive loss before reclassifications	(17,974)	(4,339)
Amounts reclassified from accumulated other comprehensive income (loss)	0	0
Other comprehensive (loss) income	(17,974)	(4,339)
OCI, before Reclassifications, Net of Tax, Attributable to Parent	(56,248)	(38,274)	(33,935)
Defined benefit plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive loss before reclassifications	(599)	(2,327)
Amounts reclassified from accumulated other comprehensive income (loss)	0	0
Other comprehensive (loss) income	(599)	(2,327)
OCI, before Reclassifications, Net of Tax, Attributable to Parent	1,149	1,748	4,075
Net Unrealized Gain (Loss) on Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive loss before reclassifications	(935)	4,912
Amounts reclassified from accumulated other comprehensive income (loss)	56	(3,497)
Other comprehensive (loss) income	(879)	1,415
OCI, before Reclassifications, Net of Tax, Attributable to Parent	15	894	(521)
Accumulated Other Comprehensive Income/(Loss)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive (loss) income	(19,452)	(5,251)	(4,427)
OCI, before Reclassifications, Net of Tax, Attributable to Parent	$ (55,084)	$ (35,632)	$ (30,381)	$ (25,954)

EARNINGS PER SHARE (Tables)

12 Months Ended

Mar. 29, 2025

Earnings Per Share [Abstract]

Schedule of Earnings Per Share Reconciliation

The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations.


(In thousands, except per share amounts)	2025		2024		2023
Basic EPS
Net income	$	167,679	$	117,558	$	115,401
Weighted average shares	50,330		50,706		50,783
Basic income per share	$	3.33	$	2.32	$	2.27
Diluted EPS
Net income	$	167,679	$	117,558	$	115,401
Basic weighted average shares	50,330		50,706		50,783
Net effect of common stock equivalents	400		691		637
Diluted weighted average shares	50,730		51,397		51,420
Diluted income per share	$	3.31	$	2.29	$	2.24

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Interest Rate Swaps) (Details) $ in Thousands	Mar. 29, 2025 USD ($)	Sep. 27, 2024 swap	Sep. 23, 2022 USD ($)
Derivative [Line Items]
Number Of Interest Rate Swaps Remaining \| swap		2
Interest Rate Swap, 4.08% Fixed Interest Rate
Derivative [Line Items]
Notional amount	$ 102,944		$ 109,900
Derivative fixed interest rate	3.32%
Derivative, Fair Value, Net	$ 1,076
Interest Rate Swap, 4.15% Fixed Interest Rate
Derivative [Line Items]
Notional amount	$ 101,553		109,900
Derivative fixed interest rate	3.30%
Derivative, Fair Value, Net	$ 1,250
Interest Rate Swap
Derivative [Line Items]
Notional amount	204,497		$ 219,800
Derivative, Fair Value, Net	$ 2,326

EARNINGS PER SHARE (Schedule of Earnings Per Share Reconciliation) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Basic EPS
Net income	$ 167,679	$ 117,558	$ 115,401
Basic weighted average shares (in shares)	50,330	50,706	50,783
Basic income per share (in dollars per share)	$ 3.33	$ 2.32	$ 2.27
Diluted EPS
Net income	$ 167,679	$ 117,558	$ 115,401
Basic weighted average shares (in shares)	50,330	50,706	50,783
Net effect of common stock equivalents (in shares)	400	691	637
Diluted weighted average shares (in shares)	50,730	51,397	51,420
Diluted income per share (in dollars per share)	$ 3.31	$ 2.29	$ 2.24
Anti-dilutive shares (in shares)	800	600	600

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

RESTRUCTURING (Tables)

12 Months Ended

Mar. 29, 2025

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Transformation Costs by Type of Cost

The following table summarizes the activity for restructuring reserves related to the portfolio rationalization initiatives, 2020 Program and market and regional alignment initiative for the fiscal years ended March 29, 2025, March 30, 2024 and April 1, 2023, substantially all of which relates to employee severance, other employee costs, inventory reserves and lease termination fees:


(In thousands)	Portfolio Rationalization		2020 Program		Market and Regional Alignment		Prior Programs		Total
Balance at April 2, 2022	$	—	$	2,460	$	—	$	345	$	2,805
Costs incurred, net of reversals	—		576		—		81		657
Payments	—		(1,226)		—		(86)		(1,312)

Balance at April 1, 2023	$	—	$	1,810	$	—	$	340	$	2,150
Costs incurred, net of reversals	13,915		450		—		(276)		14,089
Payments	(2,606)		(1,775)		—		(64)		(4,445)

Balance at March 30, 2024	$	11,309	$	485	$	—	$	—	$	11,794
Costs incurred, net of reversals	12,797		566		550		—		13,913
Payments	(12,755)		(761)		(550)		—		(14,066)
Non-cash adjustments	(8,616)		—		—		—		(8,616)
Balance at March 29, 2025	$	2,735	$	290	$	—	$	—	$	3,025

The following presents the restructuring costs by line item during fiscal 2025, 2024 and 2023 within our accompanying consolidated statements of income and comprehensive income:


(In thousands)	2025		2024		2023
Cost of goods sold	$	11,328	$	11,286	$	(215)
Research and development	(61)		456		—
Selling, general and administrative expenses	2,646		2,347		872
Total	$	13,913	$	14,089	$	657

Restructuring and Related Costs by Segment

The following presents the restructuring related costs by line item during fiscal 2025, 2024 and 2023 within our accompanying consolidated statements of income and comprehensive income:


(In thousands)	2025		2024		2023
Cost of goods sold	$	3,304	$	5,734	$	7,991
Research and development	1,649		1,750		1,050
Selling, general and administrative expenses	2,292		2,015		1,851
Total	$	7,245	$	9,499	$	10,892

The tables below present restructuring and restructuring related costs by reportable segment:


Restructuring costs
(In thousands)	2025		2024		2023
Plasma	$	258	$	1,015	$	(48)
Blood Center	4,742		5,606		—
Hospital	1,664		3,863		165
Corporate	7,249		3,605		540
Total	$	13,913	$	14,089	$	657

Restructuring related costs
(In thousands)	2025		2024		2023
Plasma	$	281	$	1,050	$	1,385
Blood Center	154		286		75
Hospital	143		408		546
Corporate	6,667		7,755		8,886
Total	$	7,245	$	9,499	$	10,892

Total restructuring and restructuring related costs	$	21,158	$	23,588	$	11,549

DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION	12 Months Ended
DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION	Mar. 29, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]
DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION	DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. When used in this report, the terms “we,” “us,” “our,” “Haemonetics” and the “Company” mean Haemonetics Corporation. Haemonetics manages its business in three principal reporting segments: Plasma, Blood Center and Hospital. For that purpose, “Plasma” includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. “Blood Center” includes blood collection and processing devices and disposables for plasma, red cells and platelets. “Hospital” is comprised of Interventional Technologies, which includes Vascular Closure, Sensor-Guided Technologies and Esophageal Protection product lines, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management product lines. The accompanying consolidated financial statements present separately the Company’s consolidated financial position, results of operations, cash flows and changes in shareholders’ equity. The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). All amounts presented, except per share amounts, are stated in thousands of U.S. dollars, unless otherwise indicated. The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized or unrecognized subsequent events except as described in Note 7, Earnings per Share and Note 5, Restructuring.

ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Divestiture of Whole Blood Product Line and Strategic Investments (Details) € in Thousands		12 Months Ended
	Jan. 13, 2025 USD ($)	Mar. 29, 2025 USD ($)	Mar. 29, 2025 EUR (€)	Mar. 30, 2024 USD ($)	Mar. 30, 2024 EUR (€)	Apr. 01, 2023 USD ($)	Apr. 01, 2023 EUR (€)
Schedule of Investments [Line Items]
Proceeds from divestiture and sale of assets		$ 43,291,000		$ 1,500,000		$ 850,000
Inventories, net		(365,141,000)		(317,202,000)
Property, plant and equipment, net		284,052,000		311,362,000
Goodwill		604,269,000		565,082,000		466,231,000
Gain (Loss) on Investments		0		0		$ 0
Strategic Investments		7,000,000		$ 7,600,000
Revision of Prior Period, Reclassification, Adjustment
Schedule of Investments [Line Items]
Inventories, net		26,400,000
Property, plant and equipment, net		(7,800,000)
Goodwill		(6,400,000)
Accrued Liabilities		$ (100,000)
Disposal Group, Not Discontinued Operations \| Whole Blood
Schedule of Investments [Line Items]
Proceeds from divestiture and sale of assets	$ 43,300,000
Business Combination, Contingent Consideration, Asset	$ 22,500,000
Vivasure Medical LTD
Schedule of Investments [Line Items]
Strategic Investments \| €			€ 9,500		€ 5,000		€ 30,000

CAPITAL STOCK (Schedule of Summary of Stock Option Activity) (Details) - Stock Options - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options Outstanding, (in shares), Beginning Balance	1,067,004
Options Outstanding, (in shares), Granted	159,318
Options Outstanding, (in shares), Exercised	(158,135)
Options Outstanding, (in shares), Forfeited	(74,600)
Options Outstanding, (in shares), Ending Balance	993,587	1,067,004
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted Average Exercise Price (in dollars per share), Beginning Balance	$ 74.86
Weighted Average Exercise Price (in dollars per share), Granted	95.73
Weighted Average Exercise Price (in dollars per share), Exercised	47.61
Weighted Average Exercise Price (in dollars per share), Forfeited	85.78
Weighted Average Exercise Price (in dollars per share), Ending Balance	$ 81.75	$ 74.86
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted Average Remaining Life, Balance	3 years 6 months	3 years 8 months 4 days
Aggregate Intrinsic Value, Balance	$ 2,249	$ 16,820
Options Outstanding, (in shares), Exercisable and End of Period	568,514
Weighted Average Exercise Price (in dollars per share), Exercisable at End of Period	$ 83.49
Weighted Average Remaining Life, Exercisable at End of Period	2 years 4 months 17 days
Aggregate Intrinsic Value, Exercisable at End of Period	$ 1,283
Options Outstanding, (in shares), Vested and Expected to Vest at End of Period	914,406
Weighted Average Exercise Price (in dollars per share), Vested or Expected to Vest at End of Period	$ 81.47
Weighted Average Remaining Life, Vested or Expected to Vest at End of Period	3 years 4 months 24 days
Aggregate Intrinsic Value, Vested and Expected to Vest at End of Period	$ 2,144

REVENUE - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024
Revenue from Contract with Customer [Abstract]
Performance obligation amount	$ 33,100
Optional exemption term	1 year
Performance obligation percent	80.00%
Contract liabilities	$ 43,300	$ 31,200
Revenue recognized	29,100
Contract assets	$ 11,600	$ 5,200

SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables)

12 Months Ended

Mar. 29, 2025

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

Selected information by reportable segment is presented below:


(In thousands)	2025		2024		2023
Net sales
Plasma	$	535,431	$	569,535	$	499,916
Blood Center	261,124		283,231		287,034
Hospital	564,269		456,289		381,710
Net sales by business unit	$	1,360,824	$	1,309,055	$	1,168,660



Significant segment expenses and operating performance
Plasma
Cost of goods sold	$	237,050	$	264,042	$	254,474
Selling, general and administrative	98,418		109,729		106,006
Research and development	15,453		13,797		14,690
Plasma operating income	$	184,510	$	181,967	$	124,746
Blood Center
Cost of goods sold	$	142,512	$	165,564	$	144,364
Selling, general and administrative	60,023		67,339		74,024
Research and development	5,770		7,956		4,374
Blood Center operating income	$	52,819	$	42,372	$	64,272
Hospital
Cost of goods sold	$	199,499	$	167,172	$	147,831
Selling, general and administrative	241,760		209,680		181,368
Research and development	34,035		27,239		23,096
Hospital operating income	$	88,975	$	52,198	$	29,415



Corporate and unallocated expenses
Amortization of acquired assets	$	(63,217)	$	(35,378)	$	(32,640)
Acquisition, integration and divestiture related costs	(22,904)		(11,249)		411
Restructuring and restructuring related costs	(21,158)		(23,588)		(11,549)
Digital transformation costs	(20,273)		(15,667)		(4,536)
Contingent Consideration	23,022		—		—







Other(1)	43		(25,772)		(14,086)
Operating income	221,817		164,883		156,033
Interest and other expense, net	(9,746)		(13,018)		(14,630)
Income before provision for income taxes	$	212,071	$	151,865	$	141,403

(1) Comprised of write downs of certain assets, MDR and IVDR costs, Litigation-related charges, gain on repurchase of convertible notes, gain on sale of property, plant and equipment, impairment of intangible assets, PCS2® related charges and gain on divestiture.

Net revenues by business unit are as follows:


(In thousands)		2025		2024		2023
	Plasma	$	535,431	$	569,535	$	499,916

	Apheresis	213,134		211,173		207,618
	Whole Blood	47,990		72,058		79,416
	Blood Center	261,124		283,231		287,034

	Interventional Technologies	255,019		174,285		126,717
	Blood Management Technologies	309,250		282,004		254,993

	Hospital	$	564,269	$	456,289	$	381,710



Total net revenues		$	1,360,824	$	1,309,055	$	1,168,660


(In thousands)	2025		2024		2023
Depreciation and amortization
Plasma	$	48,264	$	45,712	$	41,612
Blood Center	10,077		13,391		13,927
Hospital	57,245		38,112		37,768
Total depreciation and amortization (excluding impairment charges)	$	115,586	$	97,215	$	93,307


(In thousands)	March 29, 2025		March 30, 2024
Long-lived assets(1)
Plasma	$	189,833	$	211,121
Blood Center	40,337		54,262
Hospital	53,882		45,979
Total long-lived assets	$	284,052	$	311,362
(1) Long-lived assets are comprised of property, plant and equipment.

Segment Information by Geographic Area

Selected information by operating regions is presented below:


(In thousands)	March 29, 2025		March 30, 2024
Long-lived assets(1)
United States	$	217,212	$	246,473
Japan	1,250		1,597
Europe	20,024		15,310
Rest of Asia	28,705		26,728
Other	16,861		21,254
Total long-lived assets	$	284,052	$	311,362
(1) Long-lived assets are comprised of property, plant and equipment.


(In thousands)	2025		2024		2023
Net revenues
United States	$	1,010,918	$	970,007	$	842,897
Japan	62,408		58,087		61,295
Europe	175,655		160,142		156,680
Rest of Asia	92,305		107,536		104,135
Other	19,538		13,283		3,653
Total net revenues	$	1,360,824	$	1,309,055	$	1,168,660

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income/(Loss)
Balance, shares (in shares) at Apr. 02, 2022		51,124
Balance, value at Apr. 02, 2022	$ 749,424	$ 511	$ 572,476	$ 202,391	$ (25,954)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan (in shares)		102
Employee stock purchase plan	4,378	$ 0	4,378
Exercise of stock options (in shares)		59
Exercise of stock options	$ 2,638	$ 1	2,637
Shares repurchased (in shares)	(997)
Shares repurchased	$ (75,000)	$ (10)	(10,366)
Shares repurchased				64,624
Issuance of restricted stock, net of cancellations (in shares)		161
Issuance of restricted stock, net of cancellations	0	$ 2	(2)
Share-based compensation expense	25,583		25,583
Net income	115,401			115,401
Other comprehensive income (loss)	(4,427)				(4,427)
Balance, shares (in shares) at Apr. 01, 2023		50,449
Balance, value at Apr. 01, 2023	817,997	$ 504	594,706	253,168	(30,381)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan (in shares)		79
Employee stock purchase plan	5,604	$ 1	5,603
Exercise of stock options (in shares)		163
Exercise of stock options				(5,208)
Exercise of stock options	1,610	$ 2	6,816
Issuance of restricted stock, net of cancellations (in shares)		166
Issuance of restricted stock, net of cancellations	0	$ 2	(2)
Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation		$ (1)		(5,062)
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation		(69)
Share-based compensation expense	(5,891)		(828)
Share-based compensation expense	28,332		28,332
Net income	117,558			117,558
Other comprehensive income (loss)	(5,251)				(5,251)
Balance, shares (in shares) at Mar. 30, 2024		50,788
Balance, value at Mar. 30, 2024	959,959	$ 508	634,627	360,456	(35,632)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock purchase plan (in shares)		97
Employee stock purchase plan	6,476	$ 0	6,476
Exercise of stock options (in shares)		92
Exercise of stock options				(4,781)
Exercise of stock options	$ 1,857	$ 1	6,637
Shares repurchased (in shares)	(3,031)
Shares repurchased	$ (226,848)	$ (30)	(64,533)
Shares repurchased				162,285
Issuance of restricted stock, net of cancellations (in shares)		306
Issuance of restricted stock, net of cancellations	0	$ 3	(3)
Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation	(10,271)	$ 0	(1,376)	(8,895)
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation		(36)
Share-based compensation expense	29,636		29,636
Purchase of capped call related to convertible notes	(88,200)		(88,200)
Net income	167,679
Other comprehensive income (loss)	(19,452)				(19,452)
Balance, shares (in shares) at Mar. 29, 2025		48,216
Balance, value at Mar. 29, 2025	$ 820,836	$ 482	$ 523,264	$ 352,174	$ (55,084)

PROPERTY, PLANT AND EQUIPMENT

12 Months Ended

Mar. 29, 2025

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consisted of the following:


(In thousands)	March 29, 2025		March 30, 2024
Land	$	1,985	$	4,130
Building and building improvements	105,079		124,338
Plant equipment and machinery	181,825		204,622
Office equipment and information technology	130,924		129,979
Haemonetics equipment	395,152		456,414
Construction in progress	22,229		39,694
Total	837,194		959,177
Less: accumulated depreciation	(553,142)		(647,815)
Property, plant and equipment, net	$	284,052	$	311,362

Depreciation expense was $60.0 million, $55.8 million and $51.2 million in fiscal 2025, 2024 and 2023, respectively.

In the fourth quarter of fiscal 2025, the Company completed the divestiture of its Whole Blood product line within its Blood Center business unit and all related assets and liabilities were sold. The property, plant and equipment related to the divestiture had a gross value of $40.8 million and a net carrying value of $7.8 million and has been removed from the Consolidated Balance Sheets.

In the first quarter of fiscal 2025, the Company received $19.9 million of cash upon the sale of a manufacturing facility and related assets that previously met held for sale criteria, which resulted in a gain of $14.1 million that was recorded in selling, general and administrative expenses on the Consolidated Statements of Income.

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Income Statement [Abstract]
Net revenues	$ 1,360,824	$ 1,309,055	$ 1,168,660
Cost of goods sold	611,866	617,507	553,563
Gross profit	748,958	691,548	615,097
Operating expenses:
Research and development	62,722	54,435	50,131
Selling, general and administrative	436,789	431,780	376,675
Amortization of acquired intangible assets	48,261	32,031	32,640
Remeasurement of contingent consideration	(23,022)	0	0
Gains on divestiture and sale of assets	0	(2,000)	(382)
Impairment of intangible assets	2,391	10,419	0
Total operating expenses	527,141	526,665	459,064
Operating income	221,817	164,883	156,033
Interest and other expense, net	(9,746)	(13,018)	(14,630)
Income before provision for income taxes	212,071	151,865	141,403
Provision for income taxes	44,392	34,307	26,002
Net income	$ 167,679	$ 117,558	$ 115,401
Net income per share - basic (in dollars per share)	$ 3.33	$ 2.32	$ 2.27
Net income per share - diluted (in dollars per share)	$ 3.31	$ 2.29	$ 2.24
Weighted average shares outstanding
Basic (in shares)	50,330	50,706	50,783
Diluted (in shares)	50,730	51,397	51,420

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Mar. 29, 2025

Accounting Standards Update and Change in Accounting Principle [Abstract]

Fiscal Year

Haemonetics’ fiscal year ends on the Saturday closest to the last day of March. Fiscal years 2025, 2024 and 2023 include 52 weeks with each quarter having 13 weeks.

Principles of Consolidation

The accompanying consolidated financial statements include all accounts including those of its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. In addition, we assess our strategic investments to determine whether they meet the definition of a variable interest entity (“VIE”), and if so, whether the Company has controlling financial interest. Controlling financial interest occurs if the Company has both the power to direct activities of the VIE that most significantly impact the VIE’s economic performance and an obligation to absorb losses of or the right to receive benefits from the VIE that could potentially be significant to the VIE. The Company’s strategic investments did not meet the controlling financial interest criteria, as such no VIEs were consolidated during fiscal 2025, 2024 or 2023.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could vary from the amounts derived from its estimates and assumptions. The Company considers estimates to be critical if they are required to make assumptions about material matters that are uncertain at the time of estimation or if materially different estimates could have been made or it is reasonably likely that the accounting estimate will change from period to period. The following are areas considered to be critical and require management’s judgment: revenue recognition, inventory provisions, intangible asset and goodwill valuation, legal and other judgmental accruals and income taxes.

Contingencies

The Company is currently involved and may become involved in various legal proceedings and claims, including, without limitation, patent infringement, product liability, breach of contract and employee-related matters. Accruals recorded for various contingencies including legal proceedings, employee related litigation, self-insurance and other claims are based on judgment, the probability of losses and, where applicable, the consideration of opinions of internal and/or external legal counsel and actuarially determined estimates. When a loss is probable and a range of loss is established but a best estimate cannot be made, the Company records the minimum loss contingency amount, which could be zero. These estimates are often initially developed substantially earlier than the ultimate loss is known and the estimates are reevaluated each accounting period, as additional information is available. As information becomes known, an additional loss provision is recorded when either a best estimate can be made or the minimum loss amount is increased. When events result in an expectation of a more favorable outcome than previously expected, the best estimate is changed to a lower amount.

Revenue Recognition

The Company's revenue recognition policy is to recognize revenues from product sales, software and services in accordance with the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASC”) Update No. 2014-19, Revenue from Contracts with Customers (Topic 606). Revenue is recognized when obligations under the terms of a contract with a customer are satisfied; this occurs with the transfer of control of the Company’s goods or services. The Company considers revenue to be earned when all of the following criteria are met: it has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the consideration the Company expects to receive for transferring goods or providing services, is determinable and it has transferred control of the promised items to the customer. A promise in a contract to transfer a distinct good or service to the customer is identified as a performance obligation. A contract’s transaction price is allocated to each performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. Some of the Company’s contracts have multiple performance obligations. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation based on the estimated standalone selling prices of the good or service in the contract. For goods or services for which observable standalone selling prices are not available, the Company uses an expected cost plus a margin approach to estimate the standalone selling price of each performance obligation. In software contracts with multiple performance obligations, we account for individual performance obligations separately if they are distinct. We allocate the transaction price to each performance obligation based on our relative standalone selling price out of total consideration of the contract. Standalone selling price is determined utilizing observable prices to the extent available. If the standalone selling price for a performance obligation is not directly observable, we estimate it maximizing the use of observable inputs. For maintenance and support, we determine the standalone selling price based on the price at which we separately sell a renewal contract and the economic relationship between licenses and maintenance.

Product Revenues

The majority of the Company’s performance obligations related to product sales are satisfied at a point in time. Product revenue consists of the sale of its disposable products and the related equipment. The Company’s performance obligation related to product sales is satisfied upon shipment or delivery to the customer based on the specified terms set forth in the customer contract. Shipping and handling activities performed after a customer obtains control of the good are treated as fulfillment activities and are not considered to be a separate performance obligation. Revenue is recognized over time for maintenance plans provided to customers that provide services beyond the Company’s standard warranty period. Payment terms between customers related to product sales vary by the type of customer, country of sale, and the products or services offered and could result in an unbilled receivable or deferred revenue balance depending on whether the performance obligation has been satisfied (or partially satisfied).

For product sales to distributors, the Company recognizes revenue for both equipment and disposables upon shipment to distributors, which is when its performance obligations are complete. The Company's standard contracts with its distributors state that title to the equipment passes to the distributors at point of shipment to a distributor’s location. The distributors are responsible for shipment to the end customer along with any installation, training and acceptance of the equipment by the end customer. Payments from distributors are not contingent upon resale of the product.

The Company also places equipment at customer sites. While the Company retains ownership of this equipment, the customer has the right to use it for a period of time provided they meet certain agreed to conditions. The Company recovers the cost of providing the equipment from the sale of its disposables.

Software and Other Revenues

To a lesser extent, the Company enters into other types of contracts including certain software licensing arrangements to provide software solutions to support its plasma, blood collection and hospital customers. A portion of its software sales are perpetual licenses typically accompanied by implementation services related to software customization as well as other professional and technical services. The Company generally recognizes revenue from the sale of perpetual licenses and related customization services over time (the Company is creating or enhancing an asset that the customer controls) using an input method which requires it to make estimates of the extent of progress toward completion of the contract. When the Company provides other services, including in some instances hosting, technical support and maintenance, it recognizes these fees and charges over time (the customer simultaneously receives and consumes benefits), as performance obligations for these services are satisfied during the contract period. Certain of the Company’s software licensing arrangements are term-based licenses that include a per-collection or a usage-based fee related to the use of the license and the related technical support and hosting services. For these usage-based arrangements, the Company applies the revenue recognition exception resulting in revenue recognition occurring upon the later of actual usage or satisfaction of the related performance obligations. The payment terms for software licensing arrangements vary by customer pursuant to the terms set forth in the customer contract and result in an unbilled receivable or deferred revenue balance depending on whether the performance obligation has been satisfied (or partially satisfied).

Significant Judgments

Revenues from product sales are recorded at the net sales price, which includes estimates of variable consideration related to rebates, product returns and volume discounts. These reserves, which are based on estimates of the amounts earned or to be claimed on the related sales, are recorded as a reduction of revenue and a current liability. The Company’s estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the net sales price is limited to the amount that is probable not to result in a significant reversal in the amount of the cumulative revenue recognized in a future period. Revenue recognized in the current period related to performance obligations satisfied in prior periods was not material. If the Company is unable to estimate the expected rebates reasonably, it records a liability for the maximum potential rebate or discount that could be earned. In circumstances where the Company provides upfront rebate payments to customers, it capitalizes the rebate payments and amortizes the resulting asset as a reduction of revenue using a systematic method over the life of the contract.

Contract Balances

The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables and contract assets, as well as customer advances, customer deposits and deferred revenue (contract liabilities) on the consolidated balance sheets. The difference in timing between billing and revenue recognition primarily occurs in software licensing arrangements, resulting in contract assets and contract liabilities.

Practical Expedients

The Company elected not to disclose the value of transaction price allocated to unsatisfied performance obligations for contracts with an original expected length of one year or less. When applicable, the Company has also elected to use the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component if it is expected, at contract inception, that the period between when the Company transfers a promised good or service to a customer and when the customer pays for that good or service, will be one year or less.

Translation of Foreign Currencies

All assets and liabilities of foreign subsidiaries are translated at the rate of exchange at year-end while sales and expenses are translated at an average rate in effect during the year. The net effect of these translation adjustments is shown in the accompanying financial statements as a component of stockholders’ equity. Foreign currency transaction gains and losses, including those resulting from intercompany transactions, are charged directly to earnings and included in other expense, net on the consolidated statements of income. The impact of foreign exchange on long-term intercompany loans, for which repayment has not been scheduled or planned, are recorded in accumulated other comprehensive loss on the consolidated balance sheet.

Cash and Cash Equivalents

Cash equivalents include various instruments such as money market funds, U.S. government obligations and commercial paper with maturities of three months or less at date of acquisition. Cash and cash equivalents are recorded at cost, which approximates fair market value. As of March 29, 2025, cash and cash equivalents consisted primarily of investments in United States Government Agency and institutional money market funds.

Allowance for Credit Losses

The Company establishes a specific allowance for customers when it is probable that they will not be able to meet their financial obligations. Customer accounts are reviewed individually on a regular basis and reserves are established as deemed appropriate. The Company also maintains a general reserve using a percentage that is established based upon the age of its receivables and its collection history. The Company establishes allowances for balances not yet due and past due accounts based on past experience.

Inventories

Inventories are stated at the lower of cost or net realizable value and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method. The Company has based its provisions for excess, expired and obsolete inventory primarily on its estimates of forecasted net sales. Significant changes in the timing or level of demand for the Company’s products result in recording additional provisions for excess, expired and obsolete inventory. Additionally, uncertain timing of next-generation product approvals, variability in product launch strategies, non-cancelable purchase commitments, product recalls and variation in product utilization all affect the Company’s estimates related to excess, expired and obsolete inventory.

Property, Plant and Equipment


Asset Classification						Estimated Useful Lives
Building						30-40 Years
Building improvements						5-20 Years
Plant equipment and machinery						3-15 Years
Office equipment and information technology						3-10 Years
Haemonetics equipment						3-7 Years

The Company evaluates the depreciation periods of property, plant and equipment to determine whether events or circumstances warrant revised estimates of useful lives. All property, plant and equipment are also tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.

The Company’s installed base of devices includes devices owned by the Company and devices sold to the customer. The asset on its balance sheet classified as Haemonetics equipment consists of medical devices installed at customer sites but owned by Haemonetics. Generally, the customer has the right to use it for a period of time as long as they meet the conditions the Company has established, which among other things, generally include one or more of the following:

•Purchase and consumption of a certain level of disposable products

•Payment of monthly rental fees

•An asset utilization performance metric, such as performing a minimum level of procedures per month per device

Consistent with the impairment tests noted below for other intangible assets subject to amortization, the Company reviews Haemonetics equipment and the related useful lives of such equipment at least once a year, or more frequently if certain conditions arise, to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be

recoverable. To conduct these reviews, the Company estimates the future amount and timing of demand for disposables used with these devices, from which it generates revenues. The Company also considers product life cycle in its evaluation of useful life and recoverability. Changes in expected demand can result in additional depreciation expense, which is classified as cost of goods sold. Any significant unanticipated changes in demand could impact the value of the Company’s devices and its reported operating results.

Leasehold improvements are depreciated over the lesser of their useful lives or the term of the lease. Maintenance and repairs are generally expensed to operations as incurred. When the repair or maintenance costs significantly extend the life of the asset, these costs may be capitalized. When equipment and improvements are sold or otherwise disposed of, the asset cost and accumulated depreciation are removed from the accounts and the resulting gain or loss, if any, is included in the consolidated statements of income.

Goodwill and Intangible Assets

Goodwill represents the excess purchase price over the fair value of the net tangible and other identifiable intangible assets acquired. Goodwill is not amortized and is instead reviewed for impairment at least annually, or on an interim basis between annual tests when events or circumstances indicate that it is more likely than not that the fair value of a reporting unit is less than its carrying value. The Company performs its annual impairment test on the first day of the fiscal fourth quarter for each of its reporting units.

A reporting unit is defined as an operating segment or one level below an operating segment, referred to as a component. The Company determines its reporting units by first identifying its operating segments and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company aggregates components within an operating segment that have similar economic characteristics. The Company’s operating segments are as follows: Plasma, Blood Center and Hospital. The Company’s reporting units are as follows: Plasma, Blood Center, Interventional Technologies and Blood Management Technologies. When the Company completes business combinations, the Company assigns goodwill to the reporting units that it expects to benefit from the respective business combination at the time of acquisition.

Under ASC Update No. 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment entities perform their goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount by either performing a qualitative or quantitative assessment. The Company may elect to perform only a qualitative assessment for its annual impairment test when certain qualitative criteria are met that indicate that it is more likely than not the fair values of each reporting unit exceed their carrying values.

If the Company elects to perform a quantitative test, it determines carrying values of each reporting unit by allocating assets and liabilities, including corporate assets, which relate to a reporting unit’s operations and would be considered in determining its fair value, to the individual reporting units. The Company allocates assets and liabilities not directly related to a specific reporting unit, but from which the reporting unit benefits, based primarily on the respective revenue contribution of each reporting unit.

In addition, when performing a quantitative test, the Company uses the income approach, specifically the discounted cash flow method, to derive the fair value of each of its reporting units in preparing its goodwill impairment assessments. This approach calculates fair value by estimating the after-tax cash flows attributable to a reporting unit and then discounting these after-tax cash flows to a present value using a risk-adjusted discount rate. The Company selected this method as being the most meaningful in preparing its goodwill assessments because the use of the income approach typically generates a more precise measurement of fair value than the market approach. In applying the income approach to its accounting for goodwill, the Company makes assumptions about the amount and timing of future expected cash flows, terminal value growth rates and appropriate discount rates. The amount and timing of future cash flows within the Company’s discounted cash flow analysis is based on its most recent operational budgets, long range strategic plans and other estimates. The terminal value growth rate is used to calculate the value of cash flows beyond the last projected period in the Company’s discounted cash flow analysis and reflects the Company’s best estimates for stable, perpetual growth of its reporting units. The Company uses estimates of market-participant risk adjusted weighted average cost of capital as a basis for determining the discount rates to apply to its reporting units’ future expected cash flows. The Company corroborates the valuations that arose from the discounted cash flow approach by performing both a market multiple valuation and by reconciling the aggregate fair value of its reporting units to its market capitalization at the time of the test. An impairment charge, if any, would then be recognized for the amount by which the carrying value exceeds the reporting unit’s fair value.

During the fourth quarters of fiscal 2025 and 2023, the Company elected to perform quantitative assessments for its annual impairment test, whereas in fiscal 2024, the Company performed a qualitative assessment. In fiscal 2025, 2024 and 2023, the results of the goodwill impairment test performed indicated that the estimated fair value of all of its reporting units exceeded their respective carrying values and there were no reporting units at risk of impairment as of the annual test dates.

The Company reviews intangible assets subject to amortization for impairment indicators at least annually or more frequently if certain conditions arise to determine if any adverse conditions exist that would indicate that the carrying value of an asset or asset group may not be recoverable, or that a change in the remaining useful life is required. Conditions indicating that an impairment exists include, but are not limited to, a change in the competitive landscape, internal decisions to pursue new or different technology strategies, a loss of a significant customer or a significant change in the marketplace including prices paid for its products or the size of the market for its products.

When an impairment indicator exists, the Company tests the intangible asset for recoverability. For purposes of the recoverability test, the Company groups its amortizable intangible assets with other assets and liabilities at the lowest level of identifiable cash flows if the intangible asset does not generate cash flows independent of other assets and liabilities. If the carrying value of the intangible asset (asset group) exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset (asset group), the Company will write the carrying value down to the fair value in the period identified.

The Company generally calculates the fair value of its intangible assets as the present value of estimated future cash flows it expects to generate from the asset using a risk-adjusted discount rate. In determining its estimated future cash flows associated with its intangible assets, the Company uses estimates and assumptions about future revenue contributions, cost structures and remaining useful lives of the asset (asset group).

If the Company determines the estimate of an intangible asset’s remaining useful life should be reduced based on its expected use of the asset, the remaining carrying amount of the asset is amortized prospectively over the revised estimated useful life.

The Company had in-process research and development (“IPR&D”) intangible assets with indefinite lives. IPR&D assets were not amortized prior to being placed in service in fiscal 2025. Prior to amortization, the Company reviewed these assets for impairment at least annually, or on an interim basis between annual tests when events or circumstances indicate that it is more likely than not that the fair value of the asset is less than its carrying value. The Company performed its annual impairment test on the first day of the fiscal fourth quarter for its IPR&D assets. The Company made assumptions about future cash flows, terminal value growth, costs for completion and appropriate discount rates. The Company elected qualitative assessments in fiscal 2025 and 2024, which all indicated that the estimated fair value of the in-process research and development intangible asset exceeded its carrying value and it was not at risk of impairment as of the annual test dates.

Accounting for the Costs of Computer Software to be Sold, Leased, or Otherwise Marketed

ASC Topic 985-20, Software - Costs of Software to be Sold, Leased or Marketed, specifies that costs incurred internally in researching and developing a computer software product should be charged to expense until technological feasibility has been established for the product. Once technological feasibility is established, all software costs should be capitalized until the product is available for general release to customers, at which point capitalized costs are amortized over their estimated useful life of 5 to 10 years. Technological feasibility is established when it has a detailed design of the software and when research and development activities on the underlying device, if applicable, are completed. The Company capitalizes costs associated with both software that it sells as a separate product and software that is embedded in a device.

The Company reviews the net realizable value of capitalized assets periodically to assess the recoverability of amounts capitalized. There were no impairment charges recorded during fiscal 2025, 2024 and 2023. In the future, the net realizable value may be adversely affected by the loss of a significant customer or a significant change in the market place, which could result in an impairment being recorded. Refer to Note 10 Goodwill & Intangible Assets for more information regarding capitalized software.

Research and Development Expenses

All research and development costs are expensed as incurred.

Advertising Costs

All advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the consolidated statements of income.

Shipping and Handling Costs

Shipping and handling costs are included in selling, general and administrative expenses.

Income Taxes

The income tax provision is calculated for all jurisdictions in which the Company operates. The income tax provision process involves calculating current taxes due and assessing temporary differences arising from items that are taxable or deductible in different periods for tax and accounting purposes and are recorded as deferred tax assets and liabilities. Deferred tax assets are evaluated for realizability and a valuation allowance is maintained for the portion of the Company’s deferred tax assets that are not more-likely-than-not realizable. All available evidence, both positive and negative, has been considered to determine whether, based on the weight of that evidence, a valuation allowance is needed against the deferred tax assets. Refer to Note 6, Income Taxes, for further information and discussion of the Company’s income tax provision and balances.

The Company files income tax returns in all jurisdictions in which it operates. The Company records a liability for uncertain tax positions taken or expected to be taken in income tax returns. The Company’s financial statements reflect expected future tax consequences of such positions presuming the taxing authorities’ full knowledge of the position and all relevant facts. The Company records a liability for the portion of unrecognized tax benefits claimed that it has determined are not more-likely-than-not realizable. These tax reserves have been established based on management’s assessment as to the potential exposure attributable to the Company’s uncertain tax positions as well as interest and penalties attributable to these uncertain tax positions. All tax reserves are analyzed quarterly and adjustments are made as events occur that result in changes in judgment.

The Company evaluates at the end of each reporting period whether some or all of the undistributed earnings of its foreign subsidiaries are permanently reinvested. The Company recognizes deferred income tax liabilities to the extent that management asserts that undistributed earnings of its foreign subsidiaries are not permanently reinvested or will not be permanently reinvested in the future. The Company’s position is based upon several factors including management’s evaluation of Haemonetics and its subsidiaries’ financial requirements, the short-term and long-term operational and fiscal objectives of the Company and the tax consequences associated with the repatriation of earnings.

Debt, Policy

Convertible Senior Notes

The Company accounted for convertible senior notes as a single liability measured at its amortized cost. At issuance, the carrying amount is calculated as the proceeds, net of initial debt issuance costs. The difference between the principal amount and carrying value is amortized to interest expense over the term of the convertible senior notes using the effective interest rate method.

A detailed analysis of the terms of the convertible senior notes transactions is required to determine existence of any derivatives that may require separate mark-to-market accounting under applicable accounting guidance.

Derivative Instruments

The Company accounts for its derivative financial instruments in accordance with ASC Topic 815, Derivatives and Hedging (“ASC 815”) and ASC Topic 820, Fair Value Measurements and Disclosures (“ASC 820”). In accordance with ASC 815, the Company records all derivatives on the balance sheet at fair value. The accounting for the change in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative as a hedging instrument for accounting purposes and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. In addition, ASC 815 provides that, for derivative instruments that qualify for hedge accounting, changes in the fair value are either (a) offset against the change in fair value of the hedged assets, liabilities, or firm commitments through earnings or (b) recognized in equity until the hedged item is recognized in earnings, depending on whether the derivative is being used to hedge changes in fair value or cash flows. The ineffective portion of a derivative’s change in fair value is immediately recognized in earnings. The Company does not use derivative financial instruments for trading or speculation purposes.

When the underlying hedged transaction affects earnings, the gains or losses on the forward foreign exchange rate contracts designated as hedges are recorded in net revenues, cost of goods sold, operating expenses and other expense, net in the Company’s consolidated statements of income, depending on the nature of the underlying hedged transactions. The cash flows related to the gains and losses are classified in the consolidated statements of cash flows as part of cash flows from operating activities. For those derivative instruments that are not designated as part of a hedging relationship the Company records the gains or losses in earnings currently. These gains and losses are intended to offset the gains and losses recorded on net monetary assets or liabilities that are denominated in foreign currencies. The Company recorded foreign currency gains of $0.9 million in fiscal 2025, and foreign currency losses of $4.0 million and $1.0 million in fiscal 2024 and 2023, respectively.

On a quarterly basis, the Company assesses whether the cash flow hedges are highly effective in offsetting changes in the cash flow of the hedged item. The Company manages the credit risk of its counterparties by dealing only with institutions that it considers financially sound and considers the risk of non-performance to be remote. Additionally, the Company’s interest rate risk management strategy includes the use of interest rate swaps to mitigate its exposure to changes in variable interest rates. The Company’s objective in using interest rate swaps is to add stability to interest expense and to manage and reduce the risk inherent in interest rate fluctuations.

The Company’s derivative instruments do not subject its earnings or cash flows to material risk, as gains and losses on these derivatives are intended to offset losses and gains on the item being hedged. The Company does not enter into derivative transactions for speculative purposes and it does not have any non-derivative instruments that are designated as hedging instruments pursuant to ASC 815.

Share-Based Compensation

The Company expenses the fair value of share-based awards granted to employees, board members and others, net of estimated forfeitures. To calculate the grant-date fair value of its stock options the Company uses the Black-Scholes option-pricing model and for performance share units it uses Monte Carlo simulation models.

Costs Associated with Exit Activities

The Company records employee termination costs in accordance with ASC Topic 712, Compensation - Nonretirement and Postemployment Benefits, if it pays the benefits as part of an on-going benefit arrangement, which includes benefits provided as part of its established severance policies or that it provides in accordance with international statutory requirements. The Company accrues employee termination costs associated with an on-going benefit arrangement if the obligation is attributable to prior services rendered, the rights to the benefits have vested, the payment is probable and the liability can be reasonably estimated. The Company accounts for employee termination benefits that represent a one-time benefit in accordance with ASC Topic 420, Exit or Disposal Cost Obligations. It records such costs into expense over the employee’s future service period, if any.

Other costs associated with exit activities may include contract termination costs, including costs related to leased facilities to be abandoned or subleased, consultant fees and impairments of long-lived assets. The costs are expensed in accordance with ASC Topic 420 and ASC Topic 360, Property, Plant and Equipment and are included in costs of goods sold and selling, general and administrative costs in its consolidated statement of income. Additionally, costs directly related to the Company’s active restructuring initiatives, including program management costs, accelerated depreciation and costs to transfer product lines among facilities are included within costs of goods sold and selling, general and administrative costs in its consolidated statement of income. Refer to Note 5, Restructuring, for further information and discussion of its restructuring plans.

Valuation of Acquisitions

The Company allocates the amounts it pays for each acquisition to the assets acquired and liabilities assumed based on their estimated fair values at the dates of acquisition, including acquired identifiable intangible assets. The Company bases the estimated fair value of identifiable intangible assets on detailed valuations that use significant assumptions including forecasted cash flows, revenues attributable to existing technology and discount rates. When estimating the significant assumptions to be used in the valuation, the Company includes a consideration of current industry information, market and economic trends, historical results of the acquired business, and other relevant factors. These significant assumptions are forward-looking and could be affected by future economic and market conditions. The Company allocates any excess purchase price over the fair value of the net tangible and intangible assets acquired to goodwill.

Strategic Investments

The Company holds strategic investments, including preferred stock and a special share, in privately held entities. The special share allows the Company to acquire the related entity in accordance with an agreement between the parties. As these equity instruments do not have readily determinable fair values, they have been measured using the measurement alternative, at cost less impairment. The carrying amount for these instruments would be subsequently adjusted for observable price changes, or prices in orderly transactions for an identical investment or similar investment of the same issuer. In addition, these investments are periodically evaluated for impairment. The investments are classified as other long-term assets on the Company’s

Consolidated Balance Sheets and the Company did not record any adjustments to the carrying value of strategic investments in fiscal 2025 or 2024.

Concentration of Credit Risk and Significant Customers

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents and accounts receivable. In fiscal 2025, 2024 and 2023, the Company’s ten largest customers accounted for approximately 42%, 48% and 48% of net revenues, respectively. In fiscal 2025, no customer was greater than 10% of total net revenues. Four customers accounted for greater than 10% of the Plasma segment’s net revenues and two customers accounted for greater than 10% of the Blood Center segment’s net revenues, but did not exceed 10% of total net revenues, in fiscal 2025.

Certain markets and industries can expose the Company to concentrations of credit risk. For example, in the Plasma business unit, sales are concentrated with several large customers. As a result, accounts receivable extended to any one of these biopharmaceutical customers can be significant at any point in time. Also, a portion of the Company’s trade accounts receivable outside the U.S. include sales to government-owned or supported healthcare systems in several countries, which are subject to payment delays. Payment is dependent upon the financial stability and creditworthiness of those countries’ national economies. The Company has not incurred significant losses on government receivables. The Company continually evaluates all government receivables for potential collection risks associated with the availability of government funding and reimbursement practices. If the financial condition of customers or the countries’ healthcare systems deteriorate such that their ability to make payments is uncertain, allowances may be required in future periods.

Recent Accounting Pronouncements

Standards Implemented

In November 2023, the FASB issued ASC Update No. 2023-07, Segment Reporting (Topic 280). The new guidance requires public entities to provide expanded disclosures over significant segment expenses and additional disclosures related to the chief operating decision maker. ASC Update No. 2023-07 is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company adopted the new guidance effective for this report for the fiscal year ended March 29, 2025, and has retrospectively included any additional disclosures in the previous periods included in this report. Refer to Note 18 Segment and Enterprise-Wide Information for the new disclosures.

Standards to be Implemented

In December 2023, the FASB issued ASC Update No. 2023-09, Income Taxes (Topic 740). ASC Update No. 2023-09 requires public entities to provide detailed income tax disclosures, including rate reconciliations and disaggregated income tax payment information, on an annual basis. The updated guidance is effective for fiscal years beginning after December 15, 2024 and early adoption is permitted. ASC Update No. 2023-09 is applicable to Haemonetics beginning with the fiscal 2026 Annual Report on Form 10-K and the Company is currently evaluating the impact to its annual report disclosures.

CAPITAL STOCK

12 Months Ended

Mar. 29, 2025

Share-Based Payment Arrangement [Abstract]

CAPITAL STOCK

Stock Plans

The Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan (the “2019 Equity Plan”) was approved and became effective on July 25, 2019 (the “Effective Date”). The 2019 Equity Plan permits the award of incentive stock options, non-qualified stock options, stock appreciation rights (“SARs”), restricted stock, restricted stock units (including performance-based restricted stock units) and other awards to the Company’s key employees, non-employee directors and certain consultants and advisors of the Company and its subsidiaries. The 2019 Equity Plan is administered by the Compensation Committee of the Board of Directors (the “Committee”), which consists of four independent members of the Company’s Board of Directors, and is the successor to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan, as amended (the “2005 Equity Plan”). Upon the Effective Date, no further awards were granted under the 2005 Equity Plan; however, each outstanding award under the 2005 Equity Plan will remain outstanding under that plan and continue to be governed under its terms and any applicable award agreement.

The 2019 Equity Plan initially had a share reserve of 2,700,000 new shares of common stock, plus the number of shares of common stock reserved for issuance under the 2005 Plan that remained available for grant under the 2005 Plan as of July 25, 2019, an aggregate of 5,759,433 shares as of the Effective Date.

On August 4, 2023, the 2019 Equity Plan was amended and restated to increase the number of shares available for issuance under the Plan by 2,966,231 additional shares, from 1,975,970 shares to 4,942,201 shares of common stock, subject to adjustment as provided by the terms of the 2019 Equity Plan, as amended and restated.

Under the 2019 Equity Plan, as amended and restated, any shares that are subject to the award of stock options or SARs will be counted against the authorized share reserve as one share for every one share issued and any shares that are subject to awards other than stock options, SARs or cash awards will be counted against the authorized share reserve as 2.76 shares for every one share granted. Shares of common stock subject to outstanding grants under the 2005 Equity Plan as of the Effective Date that terminate, expire, or are otherwise canceled without having been exercised will be added to the share reserve at the applicable 2019 Equity Plan ratios. The total shares available for future grant under the 2019 Equity Plan, as amended and restated and giving effect to the applicable adjustment provisions, were 4,496,411 as of March 29, 2025.

Share-Based Compensation

Compensation cost related to share-based transactions is recognized in the consolidated financial statements based on fair value. The total amount of share-based compensation expense, which is recorded on a straight line basis, is as follows:


(In thousands)	2025	2024	2023
Selling, general and administrative expenses	$25,971	$23,662	$21,903
Research and development	1,847	3,106	2,364
Cost of goods sold	1,818	1,564	1,316
	$29,636	$28,332	$25,583

Stock Options

Options are granted to purchase common stock at prices as determined by the Committee, but in no event shall such exercise price be less than the fair market value of the common stock at the time of the grant. Options generally vest in equal installments over a four year period for employees and one year from grant for non-employee directors. Options expire not more than 7 years from the date of the grant. The grant-date fair value of options, adjusted for estimated forfeitures, is recognized as expense on a straight line basis over the requisite service period, which is generally the vesting period. Forfeitures are estimated based on historical experience.

A summary of stock option activity for the fiscal year ended March 29, 2025 is as follows:


	Options Outstanding	Weighted Average Exercise Price per Share		Weighted Average Remaining Life (years)	Aggregate Intrinsic Value ($000’s)
Outstanding at March 30, 2024	1,067,004	$	74.86	3.68	$	16,820
Granted	159,318	95.73
Exercised	(158,135)	47.61
Forfeited/Canceled	(74,600)	85.78
Outstanding at March 29, 2025	993,587	$	81.75	3.50	$	2,249

Exercisable at March 29, 2025	568,514	$	83.49	2.38	$	1,283

Vested or expected to vest at March 29, 2025	914,406	$	81.47	3.40	$	2,144

The total intrinsic value of options exercised was $6.4 million, $12.4 million and $1.9 million during fiscal 2025, 2024 and 2023, respectively.

As of March 29, 2025, there was $10.4 million of total unrecognized compensation cost related to non-vested stock options. This cost is expected to be recognized over a weighted average period of 2.3 years.

The fair value was estimated using the Black-Scholes option-pricing model based on the closing stock price at the grant date and the weighted average assumptions specific to the underlying options. Expected volatility assumptions are based on the historical volatility of the Company’s common stock over the expected term of the option. The risk-free interest rate was selected based upon yields of U.S. Treasury issues with a term equal to the expected life of the option being valued. The expected life of the option was estimated with reference to historical exercise patterns, the contractual term of the option and the vesting period.

The assumptions utilized for option grants during the periods presented are as follows:


	2025			2024			2023
Volatility	43.9		%	45.3		%	45.0		%
Expected life (years)	5.2			5.1			5.0
Risk-free interest rate	4.4		%	3.5		%	2.9		%
Dividend yield	0.0		%	0.0		%	0.0		%
Grant-date fair value per Option	$	43.56		$	39.46		$	24.86

Restricted Stock Units

Restricted Stock Units (“RSUs”) generally vest in equal installments over a three or four period for employees and one year from grant for non-employee directors. The grant-date fair value of RSUs, adjusted for estimated forfeitures, is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The fair market value of RSUs is determined based on the market value of the Company’s shares on the date of grant.

A summary of RSU activity for the fiscal year ended March 29, 2025 is as follows:


	Shares	Weighted Average Grant Date Fair Value
Unvested at March 30, 2024	338,008	$	72.52
Granted	141,568	95.09
Vested	(143,680)	75.04
Forfeited	(32,893)	78.45
Unvested at March 29, 2025	303,003	$	81.27

The weighted-average grant-date fair value of RSUs granted and total fair value of RSUs vested are as follows:


	2025		2024		2023
Grant-date fair value per RSU	$	95.09	$	89.21	$	59.36
Fair value of RSUs vested	$	75.04	$	67.14	$	70.24

As of March 29, 2025, there was $14.7 million of total unrecognized compensation cost related to non-vested restricted stock units. This cost is expected to be recognized over a weighted average period of 1.6 years.

Performance Share Units

The grant date fair value of Performance Share Units (“PSUs”), adjusted for estimated forfeitures, is recognized as expense on a straight line basis from the grant date through the end of the performance period. The value of these PSUs is generally based on relative total shareholder return which equals total shareholder return for the Company as compared with total shareholder return of the PSU comparison group, measured over a three year performance period. The PSUs comparison group consists of the Standard and Poor's (“S&P”) MidCap 400 Index. Depending on the Company’s relative performance during the performance period, a recipient of the award is entitled to receive a number of ordinary shares equal to a percentage, ranging from 0% to 200%, of the award granted. If the Company’s total shareholder return for the performance period is negative, then any share payout will be capped at 100% of the target award, regardless of the Company’s performance relative to the its comparison group. As a result, the Company may issue up to 671,686 shares related to outstanding performance-based awards.

A summary of PSU activity for the fiscal year ended March 29, 2025 is as follows:


	Shares	Weighted Average Grant Date Fair Value
Unvested at March 30, 2024	369,800	$	94.26
Granted(1)	231,758	128.25
Vested(2)	(233,384)	72.35
Forfeited	(32,331)	109.61
Unvested at March 29, 2025	335,843	$	112.10
(1) Includes 116,207 shares issued for awards vested during fiscal 2025 based on achievement of performance metrics.
(2)Includes the vesting of 226,274 and 7,110 shares that were earned for awards granted in fiscal 2022 for various performance periods ending during fiscal 2025, based on actual relative total shareholder return of 200% and 176%, respectively.

The Company uses the Monte Carlo model to estimate the probability of satisfying the performance criteria and the resulting fair value of PSU awards with market conditions. The assumptions used in the Monte Carlo model for PSUs granted during each fiscal year were as follows:


	2025		2024		2023
Expected stock price volatility	35.35	%	48.20	%	52.22	%
Peer group stock price volatility	35.95	%	40.29	%	47.43	%
Correlation of returns	58.08	%	59.93	%	65.45	%

The weighted-average grant-date fair value of PSUs granted is as follows:


	2025		2024		2023
Grant-date fair value per PSU	$	128.25	$	128.83	$	84.96
Fair value of PSUs vested	$	72.35	$	—	$	—

As of March 29, 2025, there was $19.1 million of total unrecognized compensation cost related to non-vested performance share units. This cost is expected to be recognized over a weighted average period of 1.6 years.

Employee Stock Purchase Plan

The Company has an Employee Stock Purchase Plan (the “Purchase Plan”) under which a maximum of 3,200,000 shares (subject to adjustment for stock splits and similar changes) of common stock may be purchased by eligible employees. Substantially all of its full-time employees are eligible to participate in the Purchase Plan.

The Purchase Plan provides for two “purchase periods” within each of its fiscal years, the first commencing on November 1 of each year and continuing through April 30 of the next calendar year, and the second commencing on May 1 of each year and continuing through October 31 of such year. Shares are purchased through an accumulation of payroll deductions (of not less than 2% or more than 15% of compensation, as defined) for the number of whole shares determined by dividing the balance in the employee’s account on the last day of the purchase period by the purchase price per share for the stock determined under the Purchase Plan. The purchase price for shares is the lower of 85% of the fair market value of the common stock at the beginning of the purchase period, or 85% of such value at the end of the purchase period.

The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions:


	2025		2024		2023
Volatility	29.3	%	28.6	%	44.9	%
Expected life (months)	6		6		6
Risk-free interest rate	4.9	%	5.4	%	2.9	%
Dividend Yield	0.0	%	0.0	%	0.0	%

The weighted average grant date fair value of the six-month option inherent in the Purchase Plan was approximately $19.13, $20.27 and $18.10 during fiscal 2025, 2024 and 2023, respectively.

GOODWILL AND INTANGIBLE ASSETS Schedule of Goodwill (Details) - USD ($)	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024
Goodwill [Roll Forward]
Goodwill, carrying amount	$ 565,082,000	$ 466,231,000
Acquisitions	69,542,000	87,079,000
Purchase accounting adjustments	(19,248,000)	12,283,000
Currency translation	(4,726,000)	(511,000)
Divestitures	(6,381,000)
Goodwill, carrying amount	604,269,000	565,082,000
Finite-Lived Intangible Assets, Gross	762,865,000	843,096,000
Intangible assets, accumulated amortization	316,313,000	455,213,000
Finite-Lived Intangible Assets, Net	446,552,000	387,883,000
Non-amortizable intangibles	9,190,000	18,234,000
Plasma
Goodwill [Roll Forward]
Goodwill, carrying amount	29,043,000	29,043,000
Acquisitions	0	0
Purchase accounting adjustments	0	0
Currency translation	0	0
Divestitures	0
Goodwill, carrying amount	29,043,000	29,043,000
Blood Center
Goodwill [Roll Forward]
Goodwill, carrying amount	33,484,000	33,855,000
Acquisitions	0	0
Purchase accounting adjustments	0	0
Currency translation	(136,000)	(371,000)
Divestitures	(6,381,000)
Goodwill, carrying amount	26,967,000	33,484,000
Finite-Lived Intangible Assets, Gross	185,600,000
Finite-Lived Intangible Assets, Net	0
Hospital
Goodwill [Roll Forward]
Goodwill, carrying amount	502,555,000	403,333,000
Acquisitions	69,542,000	87,079,000
Purchase accounting adjustments	(19,248,000)	12,283,000
Currency translation	(4,590,000)	(140,000)
Divestitures	0
Goodwill, carrying amount	$ 548,259,000	$ 502,555,000

INCOME TAXES (Tables)

12 Months Ended

Mar. 29, 2025

Income Tax Disclosure [Abstract]

Schedule Domestic and Foreign Income Before Provision for Income Tax

Domestic and foreign income before provision for income tax is as follows:


(In thousands)	2025		2024		2023
Domestic	$	161,800	$	112,563	$	85,657
Foreign	50,271		39,302		55,746
Total	$	212,071	$	151,865	$	141,403

Schedule of Income Tax Provision Components

The income tax provision (benefit) from continuing operations contains the following components:


(In thousands)	2025		2024		2023
Current
Federal	$	29,818	$	29,113	$	6,461
State	8,112		6,539		4,824
Foreign	12,085		9,532		8,940
Total current	$	50,015	$	45,184	$	20,225
Deferred
Federal	(6,555)		(6,165)		14,298
State	1,774		2,132		(7,678)
Foreign	(842)		(6,844)		(843)
Total deferred	$	(5,623)	$	(10,877)	$	5,777
Total	$	44,392	$	34,307	$	26,002

Schedule of Net Deferred Tax Asset

Tax effected, significant temporary differences comprising the net deferred tax liability are as follows:


(In thousands)	March 29, 2025		March 30, 2024
Deferred tax assets:
Depreciation	$	97	$	1,817
Amortization of intangibles	4,796		3,715
Inventory	2,846		5,502

Accruals, reserves and other deferred tax assets	14,801		18,777
Net operating loss carry-forward	8,842		16,221
Stock based compensation	4,897		3,965
Operating lease liabilities	14,906		16,132
Tax credit carry-forward, net	6,713		7,766
Capitalized research expenses	39,219		31,370
Gross deferred tax assets	97,117		105,265
Less valuation allowance	(11,930)		(10,239)
Total deferred tax assets (after valuation allowance)	85,187		95,026
Deferred tax liabilities:
Depreciation	(35,006)		(35,279)
Amortization of goodwill and intangibles	(87,905)		(96,597)
Unremitted earnings	(1,497)		(1,334)
Operating lease assets	(12,033)		(13,341)

Other deferred tax liabilities	(3,518)		(3,380)
Total deferred tax liabilities	(139,959)		(149,931)
Net deferred tax liabilities	$	(54,772)	$	(54,905)

Schedule of Effective Income Tax Rate Reconciliation


(In thousands)	2025				2024				2023
Tax at federal statutory rate	$	44,535	21.0	%	$	31,892	21.0	%	$	29,695	21.0	%

Impact of foreign operations	(732)		(0.3)	%	(3,631)		(2.4)	%	(2,408)		(1.7)	%
State income taxes net of federal benefit	7,505		3.5	%	7,037		4.6	%	2,939		2.1	%
Change in uncertain tax positions	(1,227)		(0.6)	%	(107)		(0.1)	%	81		0.1	%

Global intangible low taxed income	(1,380)		(0.7)	%	(555)		(0.4)	%	(828)		(0.6)	%
Unremitted earnings	163		0.1	%	171		0.1	%	(91)		(0.1)	%
Deferred statutory rate changes	543		0.3	%	(159)		(0.1)	%	82		0.1	%

Non-deductible executive compensation	5,130		2.4	%	3,256		2.1	%	1,439		1.0	%
Non-deductible expenses	2,845		1.3	%	2,355		1.6	%	827		0.6	%
Stock compensation shortfalls (benefits)	(4,469)		(2.1)	%	(1,841)		(1.2)	%	1,883		1.3	%
Research credits	(2,411)		(1.1)	%	(1,378)		(0.9)	%	(2,073)		(1.5)	%
Contingent consideration	(4,774)		(2.3)	%	—		—	%	—		—	%
Impact of foreign tax law changes	(2,707)		(1.3)	%	(2,739)		(1.8)	%	—		—	%


Valuation allowance	1,744		0.9	%	(393)		(0.2)	%	(5,135)		(3.6)	%
Other, net	(373)		(0.2)	%	399		0.3	%	(409)		(0.3)	%
Income tax provision	$	44,392	20.9	%	$	34,307	22.6	%	$	26,002	18.4	%

Schedule of Unrecognized Tax Benefits Roll Forward

The following table summarizes the activity related to its gross unrecognized tax benefits for the fiscal years ended March 29, 2025, March 30, 2024 and April 1, 2023:


(In thousands)	March 29, 2025		March 30, 2024		April 1, 2023
Beginning Balance	$	3,743	$	3,941	$	3,939
Additions for tax positions of the current year	315		234		292
Additions for tax positions of a prior year	1,242		—		—
Additions for tax positions related to acquired businesses	91		—		—
Reductions of tax positions	(64)		(198)		(290)

Expiration of statute of limitations	(2,505)		(234)		—
Ending Balance	$	2,822	$	3,743	$	3,941

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Pay vs Performance Disclosure
Net income	$ 167,679	$ 117,558	$ 115,401

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

RESTRUCTURING (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023	Apr. 02, 2022
Restructuring Cost and Reserve [Line Items]
Total restructuring and restructuring related costs	$ 21,158	$ 23,588	$ 11,549
Restructuring liability	3,025	11,794	2,150	$ 2,805
Restructuring related costs	7,245	9,499	10,892
2020 Program
Restructuring Cost and Reserve [Line Items]
Total restructuring and restructuring related costs	7,700	9,800	11,500
Restructuring and related cost, cost incurred to date	84,700
Restructuring liability	290	485	1,810	2,460
Portfolio Rationalization
Restructuring Cost and Reserve [Line Items]
Total restructuring and restructuring related costs	13,000	14,000	0
Restructuring and related cost, cost incurred to date	27,000
Restructuring liability	2,735	11,309	0	0
Market and Regional Alignment Initiative
Restructuring Cost and Reserve [Line Items]
Total restructuring and restructuring related costs	600
Restructuring and related cost, cost incurred to date	600
Expected cost	20,000
Expected savings from initiative on an annual basis	30,000
Restructuring liability	$ 0	$ 0	$ 0	$ 0

NOTES PAYABLE AND LONG-TERM DEBT (Schedule of Notes Payable and Long-Term Debt Maturities) (Details) $ in Thousands	Mar. 29, 2025 USD ($)
Debt Disclosure [Abstract]
2026	$ 306,349
2027	6,308
2028	10,999
2029	17,253
2030	904,757
Thereafter	454
Total debt maturities	$ 1,246,120

- Definition

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Statement of Comprehensive Income [Abstract]
Net income	$ 167,679	$ 117,558	$ 115,401
Other comprehensive (loss) income:
Impact of defined benefit plans, net of tax	(599)	(2,327)	2,456
Foreign currency translation adjustment, net of tax	(17,974)	(4,339)	(6,016)
Unrealized gain on cash flow hedges, net of tax	(935)	4,912	4,269
Reclassifications into earnings of cash flow hedge (gains) losses, net of tax	56	(3,497)	(5,136)
Other comprehensive (loss) income	(19,452)	(5,251)	(4,427)
Comprehensive income	$ 148,227	$ 112,307	$ 110,974

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-17

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-4

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482739/220-10-55-15

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

+ Details

COMMITMENTS AND CONTINGENCIES	12 Months Ended
COMMITMENTS AND CONTINGENCIES	Mar. 29, 2025
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES The Company is a party to various legal proceedings and claims arising out of the ordinary course of its business. The Company believes that, except for those matters described below, there are no other proceedings or claims pending against it the ultimate resolution of which could have a material adverse effect on its financial condition or results of operations. At each reporting period, management evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies, for all matters. Legal costs are expensed as incurred. In the fourth quarter of fiscal 2021, a putative class action complaint was filed against the Company in the Circuit Court of Cook County, Illinois by Mary Crumpton, on behalf of herself and similarly situated individuals. The Company removed the case to the United States District Court for the Northern District Illinois. See Mary Crumpton v. Haemonetics Corporation, Case No. 1:21-cv-1402. In her complaint, the plaintiff asserted that between June 2017 and August 2018 she donated plasma at a center operated by one of the Company’s customers, that the center required her to scan her fingerprint on a finger scanner that stored her fingerprint to identify her prior to plasma donation, and that the Company’s eQue donor management software sent her biometric information to a Company-owned server to be collected and stored in a manner that violated her rights under the Illinois Biometric Information Privacy Act (“BIPA”). The plaintiff sought statutory damages, attorneys’ fees and injunctive and equitable relief. During the second quarter of fiscal 2024, the Company entered into a Memorandum of Understanding providing terms that would resolve the litigation and recorded an additional loss contingency related to this matter. In the third quarter of fiscal 2024, the parties requested preliminary court approval of a final settlement agreement, which was granted in February 2024, and the Company recorded an immaterial additional loss contingency related to settlement administration, resulting in an accrual of $8.7 million within other current liabilities in its consolidated balance sheets. In March 2024, administration of the settlement through the third-party administrator commenced and, in April 2025, the administrator notified the parties that distribution of the final settlement funds was underway and that administration would formally close 90 days thereafter. In the first quarter of fiscal 2025, the Company issued payment of the $8.7 million settlement amount following the court’s final approval of the settlement agreement and dismissal of the matter with prejudice. During the fourth quarter of fiscal 2024, a complaint was filed in the U.S. District Court for the District of Delaware by Knoninklijke Philips N.V. and IP2IPO Innovations, Ltd. (together, the “Plaintiffs”) against OpSens, OpSens Medical, Inc., a wholly-owned subsidiary of OpSens, and Haemonetics (1:24-cv-00206-CFC). The complaint alleges, inter alia, that OpSens’ interventional cardiology systems, including its OptoWire and OptoMonitor technology, infringe a single patent held by the Plaintiffs and seeks both injunctive relief and damages. A claim construction hearing in the matter is scheduled to take place in the first quarter of fiscal 2026. The Company believes it has valid and meritorious defenses to the complaint and plans to vigorously defend against the complaint. The Company recorded loss contingencies related to this matter in the first quarter and fourth quarter of fiscal 2025, which did not have a material impact on its Condensed Consolidated Financial Statements. During the first quarter of fiscal 2026, the Company filed a complaint against Terumo BCT in U.S. District Court for the District of Colorado. The complaint alleges that Terumo BCT infringes the Company’s intellectual property rights with respect to its donor-centric blood plasma collection patents, as embodied in our NexSys PCS® with YES® technology and NexSys PCS with Persona® technology. While we will incur costs in the course of pursuing this claim, and the outcome of litigation is inherently uncertain, we believe this is a necessary and appropriate action to safeguard our innovations, protect our intellectual property, and further the growth and development of our business. Product Recall In August 2023, the Company issued a voluntary recall of certain products within the Whole Blood portion of our Blood Center business unit sold to customers in the U.S. and certain foreign jurisdictions. As of March 29, 2025, the Company has recorded cumulative charges of $6.8 million related to inventory, returns and customer claims associated with this recall. Substantially all outstanding claims have been paid as of March 29, 2025.

SEGMENT AND ENTERPRISE-WIDE INFORMATION - Segment Reporting Information by Segment (Details) $ in Thousands	12 Months Ended
	Mar. 29, 2025 USD ($) unit	Mar. 30, 2024 USD ($)	Apr. 01, 2023 USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments \| unit	3
Net revenues	$ 1,360,824	$ 1,309,055	$ 1,168,660
Significant segment expenses and operating performance
Cost of goods sold	611,866	617,507	553,563
Selling, general and administrative	436,789	431,780	376,675
Research and development	62,722	54,435	50,131
Operating income	221,817	164,883	156,033
Amortization of acquired intangible assets	48,261	32,031	32,640
Interest and other expense, net	(9,746)	(13,018)	(14,630)
Income before provision for income taxes	212,071	151,865	141,403
Total net revenues	1,360,824	1,309,055	1,168,660
Depreciation and amortization	115,586	97,215	93,307
Total long-lived assets	284,052	311,362
Plasma
Segment Reporting Information [Line Items]
Net revenues	535,431	569,535	499,916
Significant segment expenses and operating performance
Depreciation and amortization	48,264	45,712	41,612
Total long-lived assets	189,833	211,121
Plasma \| Plasma
Significant segment expenses and operating performance
Total net revenues	535,431	569,535	499,916
Blood Center
Segment Reporting Information [Line Items]
Net revenues	261,124	283,231	287,034
Significant segment expenses and operating performance
Depreciation and amortization	10,077	13,391	13,927
Total long-lived assets	40,337	54,262
Blood Center \| Blood Center
Significant segment expenses and operating performance
Total net revenues	261,124	283,231	287,034
Hospital
Segment Reporting Information [Line Items]
Net revenues	564,269	456,289	381,710
Significant segment expenses and operating performance
Depreciation and amortization	57,245	38,112	37,768
Total long-lived assets	53,882	45,979
Hospital \| Hospital
Significant segment expenses and operating performance
Total net revenues	564,269	456,289	381,710
Apheresis \| Blood Center
Significant segment expenses and operating performance
Total net revenues	213,134	211,173	207,618
Whole Blood \| Blood Center
Significant segment expenses and operating performance
Total net revenues	47,990	72,058	79,416
Interventional Technologies \| Hospital
Significant segment expenses and operating performance
Total net revenues	255,019	174,285	126,717
Blood Management Technologies \| Hospital
Significant segment expenses and operating performance
Total net revenues	309,250	282,004	254,993
Operating Segments [Member] \| Plasma
Significant segment expenses and operating performance
Cost of goods sold	237,050	264,042	254,474
Selling, general and administrative	98,418	109,729	106,006
Research and development	15,453	13,797	14,690
Operating income	184,510	181,967	124,746
Operating Segments [Member] \| Blood Center
Significant segment expenses and operating performance
Cost of goods sold	142,512	165,564	144,364
Selling, general and administrative	60,023	67,339	74,024
Research and development	5,770	7,956	4,374
Operating income	52,819	42,372	64,272
Operating Segments [Member] \| Hospital
Significant segment expenses and operating performance
Cost of goods sold	199,499	167,172	147,831
Selling, general and administrative	241,760	209,680	181,368
Research and development	34,035	27,239	23,096
Operating income	88,975	52,198	29,415
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]
Significant segment expenses and operating performance
Operating income	221,817	164,883	156,033
Amortization of acquired intangible assets	63,217	35,378	32,640
Acquisition, integration and divestiture related costs	(22,904)	(11,249)	411
Restructuring and restructuring related costs	21,158	23,588	11,549
Digital transformation costs	20,273	15,667	4,536
Contingent Consideration	23,022	0	0
Other	$ 43	$ (25,772)	$ (14,086)

ACCUMULATED OTHER COMPREHENSIVE LOSS

12 Months Ended

Mar. 29, 2025

Stockholders' Equity Note [Abstract]

ACCUMULATED OTHER COMPREHENSIVE LOSS

The following is a roll-forward of the components of accumulated other comprehensive loss, net of tax, for the years ended March 29, 2025 and March 30, 2024:


(In thousands)	Foreign currency		Defined benefit plans		Net Unrealized Gain (Loss) on Derivatives		Total
Balance, April 1, 2023	$	(33,935)	$	4,075	$	(521)	$	(30,381)
Other comprehensive (loss) income before reclassifications	(4,339)		(2,327)		4,912		(1,754)
Amounts reclassified from accumulated other comprehensive loss(1)	—		—		(3,497)		(3,497)
Net current period other comprehensive (loss) income	(4,339)		(2,327)		1,415		(5,251)
Balance, March 30, 2024	$	(38,274)	$	1,748	$	894	$	(35,632)
Other comprehensive loss before reclassifications	(17,974)		(599)		(935)		(19,508)
Amounts reclassified from accumulated other comprehensive loss(1)	—		—		56		56
Net current period other comprehensive loss	(17,974)		(599)		(879)		(19,452)
Balance, March 29, 2025	$	(56,248)	$	1,149	$	15	$	(55,084)
(1) Presented net of income taxes, the amounts of which are insignificant.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 29, 2025	Mar. 30, 2024
Current assets:
Cash and cash equivalents	$ 306,763	$ 178,800
Accounts receivable, less allowance for credit losses of $6,300 at March 29, 2025 and $5,695 at March 30, 2024	202,657	206,562
Inventories, net	365,141	317,202
Prepaid expenses and other current assets	60,414	66,339
Total current assets	934,975	768,903
Property, plant and equipment, net	284,052	311,362
Intangible assets, less accumulated amortization of $316,313 at March 29, 2025 and $455,213 at March 30, 2024	455,743	406,117
Goodwill	604,269	565,082
Deferred tax asset	7,803	7,739
Other long-term assets	164,106	136,388
Total assets	2,450,948	2,195,591
Current liabilities:
Notes payable and current maturities of long-term debt	303,558	10,229
Accounts payable	66,999	73,358
Accrued payroll and related costs	59,423	80,708
Other current liabilities	148,133	136,088
Total current liabilities	578,113	300,383
Long-term debt, net of current maturities	921,230	797,564
Deferred tax liability	62,575	62,644
Other long-term liabilities	68,194	75,041
Stockholders’ equity:
Common stock, $0.01 par value; Authorized — 150,000,000 shares; Issued and outstanding — 48,215,899 shares at March 29, 2025 and 50,787,859 shares at March 30, 2024	482	508
Additional paid-in capital	523,264	634,627
Retained earnings	352,174	360,456
Accumulated other comprehensive loss	(55,084)	(35,632)
Total stockholders’ equity	820,836	959,959
Total liabilities and stockholders’ equity	$ 2,450,948	$ 2,195,591

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

12 Months Ended

Mar. 29, 2025

Derivative Instruments and Hedging Activities Disclosure [Abstract]

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

The Company manufactures, markets and sells its products globally. For the fiscal years ended March 29, 2025, March 30, 2024 and April 1, 2023 the percent of the Company’s sales generated outside the U.S. in local currencies were 25.7%, 25.9% and 27.9%, respectively. The Company also incurs certain manufacturing, marketing and selling costs in international markets in local currency.

Accordingly, earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the U.S. Dollar, the Company’s reporting currency. The Company has a program in place that is designed to mitigate the exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize, for a period of time, the impact on its financial results from changes in foreign exchange rates. The Company utilizes foreign currency forward contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily Japanese Yen and Euro, and to a lesser extent Swiss Franc, Mexican Peso, Chinese Yuan, and Canadian Dollar. This does not eliminate the impact of the volatility of foreign exchange rates. However, because the Company generally enters into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation.

Designated Foreign Currency Hedge Contracts

All of the Company’s designated foreign currency hedge contracts as of March 29, 2025 and March 30, 2024 were cash flow hedges under ASC 815, Derivatives and Hedging (“ASC 815”). The Company records the effective portion of any change in the fair value of designated foreign currency hedge contracts in other comprehensive income until the related third-party transaction occurs. Once the related third-party transaction occurs, the Company reclassifies the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, the Company will reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. The Company had designated foreign currency hedge contracts outstanding in the contract amount of $23.6 million as of March 29, 2025 and $74.0 million as of March 30, 2024. As of March 29, 2025, a loss of $1.5 million, net of tax, will be reclassified to earnings within the next twelve months. Substantially all currency cash flow hedges outstanding as of March 29, 2025 mature within twelve months.

Non-Designated Foreign Currency Contracts

The Company manages its exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. It uses foreign currency forward contracts as a part of its strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These foreign currency forward contracts are entered into for periods consistent with currency transaction exposures, generally one month. They are not designated as cash flow or fair value hedges under ASC 815. These forward contracts are marked-to-market with changes in fair value recorded to earnings. The Company had non-designated foreign currency hedge contracts under ASC 815 outstanding in the contract amount of $89.6 million as of March 29, 2025 and $39.9 million as of March 30, 2024.

Interest Rate Swaps

Part of the Company’s interest rate risk management strategy includes the use of interest rate swaps to mitigate its exposure to changes in variable interest rates. The Company’s objective in using interest rate swaps is to add stability to interest expense and to manage and reduce the risk inherent in interest rate fluctuations.

To mitigate the interest rate risk on the Company’s senior unsecured term loan, in September 2022, the Company entered into four interest rate swaps, two of which expired in June 2023 and the remaining two were amended and extended in September 2024. The amendment and extension of the two interest rate swaps did not have a material impact on the consolidated financial statements.

Loans under the 2024 Revised Credit Facilities bear interest at an annual rate equal to the 1-month USD Term SOFR, plus an applicable rate ranging from 1.125% to 1.750% based on the Company’s consolidated net leverage ratio. As a result of the amendment and extension in September 2024, the two modified interest rate swaps have an average blended fixed interest rate of 3.31% plus the applicable rate on approximately 80% of the notional value of the unsecured term loan, until their maturity in April 2029. The Company has determined both of these interest rate swaps are effective and qualify for hedge accounting treatment.

The Company held the following interest rate swaps as of March 29, 2025:


Hedged Item	Original Notional Amount		Notional Amount as of March 29, 2025		Designation Date	Effective Date	Termination Date	Fixed Interest Rate	Estimated Fair Value Assets (Liabilities)
(In thousands)
1-month USD Term SOFR	$	109,900	$	102,944	9/27/2024	9/30/2024	4/30/2029	3.32%	$	1,076
1-month USD Term SOFR	109,900		101,553		9/27/2024	9/30/2024	4/30/2029	3.30%	1,250
Total	$	219,800	$	204,497					$	2,326

For fiscal 2025, the Company recorded a gain of $0.6 million, net of tax, in accumulated other comprehensive income to recognize the effective portion of the fair value of the swaps that qualify as cash flow hedges.

Trade Receivables

In the ordinary course of business, the Company grants trade credit to its customers on normal credit terms. In an effort to reduce its credit risk, the Company (i) establishes credit limits for all customers, (ii) performs ongoing credit evaluations of customers’ financial condition, (iii) monitors the payment history and aging of customers’ receivables and (iv) monitors open orders against an individual customer’s outstanding receivable balance.

The Company’s allowance for credit losses is maintained for trade accounts receivable based on the expected collectability, the historical collection experience, the length of time an account is outstanding, the financial position of the customer and information provided by credit rating services. The Company has not experienced significant customer payment defaults, or identified other significant collectability concerns.

The following is a roll forward of the allowance for credit losses:


	Twelve Months Ended
(In thousands)	March 29, 2025		March 30, 2024		April 1, 2023
Beginning balance	$	5,695	$	4,932	$	2,475
Credit loss	725		840		2,623
Recoveries	(120)		(77)		(166)
Ending balance	$	6,300	$	5,695	$	4,932

Other Fair Value Measurements

Fair value is defined as the exit price that would be received from the sale of an asset or paid to transfer a liability, using assumptions that market participants would use in pricing an asset or liability. The fair value guidance establishes the following three-level hierarchy used for measuring fair value:

•Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.

•Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.

•Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

The Company’s money market funds carried at fair value are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.

Fair Value of Derivative Instruments

The following table presents the effect of the Company’s derivative instruments designated as cash flow hedges and those not designated as hedging instruments under ASC 815 in its consolidated statements of income and comprehensive income for the fiscal year ended March 29, 2025.


Derivative Instruments	Amount of (Loss) Gain Recognized in Accumulated Other Comprehensive Loss		Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Earnings		Location in Consolidated Statements of Income and Comprehensive Income	Amount of Gain Excluded from Effectiveness Testing		Location in Consolidated Statements of Income and Comprehensive Income
(In thousands)
Designated foreign currency hedge contracts, net of tax	$	(1,508)	$	11	Net revenues, COGS and SG&A	$	1,743	Interest and other expense, net
Non-designated foreign currency hedge contracts	$	—	$	—		$	(1,534)	Interest and other expense, net
Designated interest rate swaps, net of tax	$	573	$	(67)	Interest and other expense, net	$	—

The Company did not have fair value hedges or net investment hedges outstanding as of March 29, 2025 or March 30, 2024. As of March 29, 2025, no material deferred taxes were recognized for designated foreign currency hedges.

ASC 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. The Company determines the fair value of its derivative instruments using the framework prescribed by ASC 820, Fair Value Measurements and Disclosures, by considering the estimated amount it would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, current interest rate curves, interest rate volatilities, the creditworthiness of the counterparty for assets, and its creditworthiness for liabilities. In certain instances, the Company may utilize financial models to measure fair value. Generally, the Company uses inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of March 29, 2025, the Company has classified its derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by ASC 815, as discussed below, because these observable inputs are available for substantially the full term of its derivative instruments.

The following tables present the fair value of the Company’s derivative instruments as they appear in its consolidated balance sheets as of March 29, 2025 and March 30, 2024:


(In thousands)	Location in Consolidated Balance Sheet	As of March 29, 2025		As of March 30, 2024
Derivative Assets:
Designated foreign currency hedge contracts	Prepaid expenses and other current assets	$	193	$	1,353
Non-designated foreign currency hedge contracts	Other current assets	85		154
Designated interest rate swaps	Other current assets	1,305		1,673
Designated interest rate swaps	Other long-term assets	1,020		62
		$	2,603	$	3,242
Derivative Liabilities:
Designated foreign currency hedge contracts	Other current liabilities	$	471	$	395
Non-designated foreign currency hedge contracts	Other current liabilities	25		536


		$	496	$	931

Fair Value Measured on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of March 29, 2025 and March 30, 2024.


	As of March 29, 2025
(In thousands)	Level 1		Level 2		Level 3		Total
Assets
Money market funds	$	158,916	$	—	$	—	$	158,916
Designated foreign currency hedge contracts	—		193		—		193
Non-designated foreign currency hedge contracts	—		85		—		85
Designated interest rate swaps	—		2,325		—		2,325

	$	158,916	$	2,603	$	—	$	161,519
Liabilities
Designated foreign currency hedge contracts	$	—	$	471	$	—	$	471
Non-designated foreign currency hedge contracts	—		25		—		25

Contingent consideration	—		—		2,278		2,278
	$	—	$	496	$	2,278	$	2,774

	As of March 30, 2024
	Level 1		Level 2		Level 3		Total
Assets
Money market funds	$	43,073	$	—	$	—	$	43,073
Designated foreign currency hedge contracts	—		1,353		—		1,353
Non-designated foreign currency hedge contracts	—		154		—		154
Designated interest rate swaps	—		1,735		—		1,735
	$	43,073	$	3,242	$	—	$	46,315
Liabilities
Designated foreign currency hedge contracts	$	—	$	395	$	—	$	395
Non-designated foreign currency hedge contracts	—		536		—		536


	$	—	$	931	$	—	$	931

Foreign currency hedge contracts - The fair value of foreign currency hedge contracts was measured using significant other observable inputs and valued by reference to over-the-counter quoted market prices for similar instruments. The Company does not believe that the fair value of these derivative instruments differs significantly from the amount that could be realized upon settlement or maturity, or that the changes in fair value will have a significant effect on its results of operations, financial condition or cash flows.

Interest rate swaps - The fair values of interest rate swaps are measured using the present value of expected future cash flows using market-based observable inputs, including credit risk and interest rate yield curves. The Company does not believe that the fair values of these derivative instruments differ significantly from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a significant effect on its results of operations, financial condition or cash flows.

Contingent consideration - The fair value of contingent consideration liabilities is based on significant unobservable inputs, including management estimates and assumptions, and is measured based on the probability-weighted present value of the payments expected to be made. Accordingly, the fair value of contingent consideration has been classified as level 3 within the fair value hierarchy.

The level 3 fair value measurements of contingent consideration liabilities include the following significant unobservable inputs:

Fair Value at

Valuation

Unobservable

(In thousands)

March 29, 2025

Technique

Input

Range

Revenue-based payments

1,214

Monte Carlo Simulation Model

Discount rate

6.3%

Projected fiscal year of payments

2026 - 2028

Regulatory-based payment

—

Monte Carlo Simulation Model

Discount rate

N/A

Probability of payment

Projected fiscal year of payment

N/A

Event-based payment

1,064

Monte Carlo Simulation Model

Discount rate

5.8%

Projected fiscal year of payment

2026 - 2028

The fair value of contingent consideration associated with acquisitions was $2.3 million at March 29, 2025 and the total was included in Other long-term liabilities.

A reconciliation of the change in the fair value of contingent consideration is included in the following table:


(In thousands)
Balance at March 30, 2024	$	—
Acquisition date fair value of contingent consideration	25,000
Purchase accounting adjustments	300
Change in fair value	(23,022)
Balance at March 29, 2025	$	2,278

Other Fair Value Disclosures

The fair values of the 2026 Notes and 2029 Notes as of March 29, 2025 were $286.3 million and $668.4 million, respectively, which were determined by using the market price on the last trading day of the reporting period and are considered as level 2 in the fair value hierarchy.

The senior unsecured term loan (which is carried at amortized cost), accounts receivable and accounts payable approximate fair value.

RETIREMENT PLANS

12 Months Ended

Mar. 29, 2025

Retirement Benefits [Abstract]

RETIREMENT PLANS

Defined Contribution Plans

The Company has a Savings Plus Plan (the “401k Plan”) that allows its U.S. employees to accumulate savings on a pre-tax basis. In addition, matching contributions are made to the 401k Plan based upon pre-established rates. The Company’s matching contributions amounted to approximately $8.2 million, $8.1 million and $6.9 million in fiscal 2025, 2024 and 2023, respectively. Upon the Company’s Board of Directors’ approval, additional discretionary contributions can also be made. No discretionary contributions were made for the 401k Plan in fiscal 2025, 2024, or 2023.

Some of the Company’s subsidiaries also have defined contribution plans, to which both the employee and the employer make contributions. The employer contributions to these plans totaled $1.0 million, $0.7 million and $0.6 million in fiscal 2025, 2024 and 2023, respectively.

Defined Benefit Plans

ASC Topic 715, Compensation — Retirement Benefits, requires an employer to: (a) recognize in its statement of financial position an asset for a plan’s over-funded status or a liability for a plan’s under-funded status; (b) measure a plan’s assets and its obligations that determine its funded status as of the end of the employer’s fiscal year (with limited exceptions); and (c) recognize changes in the funded status of a defined benefit post retirement plan in the year in which the changes occur. Accordingly, the Company is required to report changes in its funded status in comprehensive loss on its consolidated statement of stockholders’ equity and consolidated statement of comprehensive income.

Benefits under these plans are generally based on either career average or final average salaries and creditable years of service as defined in the plans. The annual cost for these plans is determined using the projected unit credit actuarial cost method that includes actuarial assumptions and estimates that are subject to change.


(In thousands)	2025		2024		2023
Service cost	$	1,630	$	1,316	$	1,453
Interest cost on benefit obligation	630		684		409
Expected return on plan assets	(314)		(264)		(180)
Actuarial loss (gain)	17		(180)		19
Amortization of unrecognized prior service cost	(219)		(215)		(180)
Plan settlements	(104)		—		(330)
Totals	$	1,640	$	1,341	$	1,191

The activity under those defined benefit plans are as follows:


(In thousands)	March 29, 2025		March 30, 2024
Change in Benefit Obligation:
Benefit Obligation, beginning of year	$	(32,323)	$	(25,465)
Service cost	(1,630)		(1,316)
Interest cost	(630)		(684)
Benefits paid	851		2,253
Actuarial loss	(336)		(2,392)
Employee and plan participants contribution	(3,568)		(3,423)
Plan settlements	6,419		34
Foreign currency changes	261		(1,330)
Benefit obligation, end of year	$	(30,956)	$	(32,323)
Change in Plan Assets:
Fair value of plan assets, beginning of year	$	21,851	$	18,463
Company contributions	1,627		1,584
Benefits paid	(663)		(1,788)
Gain on plan assets	482		238
Employee and plan participants contribution	3,600		3,368
Plan settlements	(6,451)		—
Foreign currency changes	392		(14)
Fair value of plan assets, end of year	$	20,838	$	21,851
Funded Status*	$	(10,118)	$	(10,472)
Unrecognized net actuarial gain	(1,056)		(1,288)
Unrecognized prior service cost	(705)		(969)
Net amount recognized	$	(11,879)	$	(12,729)
* Substantially all of the unfunded status is non-current

One of the benefit plans is funded by benefit payments made by the Company through the purchase of reinsurance contracts that do not qualify as plan assets under ASC Topic 715. Accordingly, that plan has no assets included in the information presented above. The total asset value associated with the reinsurance contracts was $7.0 million at March 29, 2025 and March 30, 2024. The total liability for this plan, which is included in the table above, was $7.4 million and $7.8 million as of March 29, 2025 and March 30, 2024, respectively.

The accumulated benefit obligation for all plans was $29.1 million and $30.1 million for fiscal 2025 and 2024, respectively. There were no plans where the plan assets were greater than the accumulated benefit obligation as of March 29, 2025 and March 30, 2024.

The components of the change recorded in the Company’s accumulated other comprehensive loss related to its defined benefit plans, net of tax, are as follows (in thousands):


Balance as of April 2, 2022	$	1,619

Actuarial gain	2,695
Prior service cost	$	46

Plan settlements	(285)
Balance as of April 1, 2023	$	4,075
Actuarial gain	(2,157)
Prior service cost	(170)

Balance as of March 30, 2024	$	1,748
Actuarial loss	(268)
Prior service credit	(242)
Plan settlements	(89)
Balance as of March 29, 2025	$	1,149

The Company expects to amortize $0.3 million from accumulated other comprehensive loss to net periodic benefit cost during fiscal 2026.

The weighted average rates used to determine the net periodic benefit costs and projected benefit obligations were as follows:


	2025		2024		2023
Discount rate	1.87	%	2.05	%	2.43	%
Rate of increased salary levels	2.71	%	1.86	%	1.94	%
Expected long-term rate of return on assets	0.88	%	0.94	%	0.87	%

Assumptions for expected long-term rate of return on plan assets are based upon actual historical returns, future expectations of returns for each asset class and the effect of periodic target asset allocation rebalancing. The results are adjusted for the payment of reasonable expenses of the plan from plan assets.

The Company has no other material obligation for post-retirement or post-employment benefits.

The Company’s investment policy for pension plans is to balance risk and return through a diversified portfolio to reduce interest rate and market risk. Maturities are managed so that sufficient liquidity exists to meet immediate and future benefit payment requirements.

ASC Topic 820, Fair Value Measurements and Disclosures, provides guidance for reporting and measuring the plan assets of the Company’s defined benefit pension plan at fair value as of March 29, 2025. Using the same three-level valuation hierarchy for disclosure of fair value measurements as described in Note 13, Financial Instruments and Fair Value Measurements, all of the assets of the Company’s plan are classified within Level 2 of the fair value hierarchy because the plan assets are primarily insurance contracts.

Expected benefit payments for both plans are estimated using the same assumptions used in determining the Company’s benefit obligation at March 29, 2025. Benefit payments will depend on future employment and compensation levels, average years employed and average life spans, among other factors, and changes in any of these factors could significantly affect these estimated future benefit payments.

Estimated future benefit payments are as follows:


(In thousands)
Fiscal 2026	$	1,553
Fiscal 2027	$	1,551
Fiscal 2028	$	1,599
Fiscal 2029	$	1,756
Fiscal 2030	$	2,274
Fiscal 2031-2035	$	11,174

The Company’s contributions for fiscal 2026 are expected to be consistent with the current year.

LEASES (Details) - USD ($) $ in Thousands	12 Months Ended
LEASES (Details) - USD ($) $ in Thousands	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Renewal Term	10 years
Right-of-use assets	$ 47,492	$ 55,268
Lease liabilities	58,561
Operating Lease, Liability, Current	8,107	8,133
Operating Lease, Liability, Noncurrent	$ 50,454	$ 57,958
Operating Lease, Weighted Average Remaining Lease Term	7 years 6 months	8 years 2 months 12 days
Operating Lease, Weighted Average Discount Rate, Percent	4.99%	5.31%
Operating Lease, Cost	$ 12,100	$ 10,600	$ 11,000
Operating Lease, Payments	11,201	10,636	11,450
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	399	2,450	$ 211
Property, plant and equipment, net	284,052	$ 311,362
2026	10,835
2027	11,376
2028	9,493
2029	7,604
2030	7,452
Thereafter	24,776
Lessee, Operating Lease, Liability, Payments, Due	71,534
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	$ (12,973)
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other current liabilities	Other current liabilities
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other long-term liabilities	Other long-term liabilities
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other long-term assets	Other long-term assets
Operating lease revenue as a percentage of net sales (as a percent)	2.00%
Minimum
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	1 year
Maximum
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	30 years

ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS - Intangible Assets Acquired (Details) - USD ($) $ in Thousands	Apr. 01, 2024	Dec. 12, 2023	Mar. 29, 2025	Mar. 30, 2024
OpSens, Inc.
Business Acquisition [Line Items]
Intangible assets acquired		$ 172,000
Intangible assets		172,000
OpSens, Inc. \| Technology-Based Intangible Assets
Business Acquisition [Line Items]
Intangible assets acquired		$ 114,900		$ 114,900
Weighted-Average Amortization Period		15 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation		20.50%
OpSens, Inc. \| Customer Relationships
Business Acquisition [Line Items]
Intangible assets acquired		$ 52,300		52,300
Weighted-Average Amortization Period		15 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation		18.90%
OpSens, Inc. \| Trademarks
Business Acquisition [Line Items]
Intangible assets acquired		$ 4,800		$ 4,800
Weighted-Average Amortization Period		15 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation		20.50%
Attune Medical
Business Acquisition [Line Items]
Intangible assets	$ 105,800
Attune Medical \| Technology-Based Intangible Assets
Business Acquisition [Line Items]
Intangible assets acquired			$ 96,100
Weighted-Average Amortization Period	10 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation	22.00%
Attune Medical \| Customer Relationships
Business Acquisition [Line Items]
Intangible assets acquired			7,800
Weighted-Average Amortization Period	10 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation	21.50%
Attune Medical \| Trade Names [Member]
Business Acquisition [Line Items]
Intangible assets acquired			$ 1,900
Weighted-Average Amortization Period	10 years
Risk-Adjusted Discount Rates used in Purchase Price Allocation	21.50%

RETIREMENT PLANS (Schedule of Weighted Average Rates Used to Determine Net Periodic Benefit Costs) (Details)	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Retirement Benefits [Abstract]
Discount rate	1.87%	2.05%	2.43%
Rate of increased salary levels	2.71%	1.86%	1.94%
Expected long-term rate of return on assets	0.88%	0.94%	0.87%

GOODWILL AND INTANGIBLE ASSETS Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Finite-Lived Intangible Assets [Line Items]
Aggregate amortization expense	$ 55,600	$ 41,400	$ 42,100
Software development costs capitalized	7,700	6,600
Capitalized costs amortized (placed into service)	6,700	8,600	8,500
Indefinite-lived Intangible Assets [Line Items]
Software costs capitalized, net	94,700	89,400
Impairment of intangible assets	2,391	10,419	0
Non-amortizable intangibles	9,190	18,234
Goodwill impairment	$ 0	0	$ 0
Minimum
Finite-Lived Intangible Assets [Line Items]
Weighted average useful life	5 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Weighted average useful life	15 years
In-process software development
Indefinite-lived Intangible Assets [Line Items]
Non-amortizable intangibles	$ 9,190	$ 4,567

RETIREMENT PLANS (Schedule of Activity Under Defined Benefit Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Change in Benefit Obligation:
Benefit Obligation, beginning of year	$ (32,323)	$ (25,465)
Service cost	(1,630)	(1,316)	$ (1,453)
Interest cost	(630)	(684)	(409)
Defined Benefit Plan, Benefit Obligation, Benefits Paid	851	2,253
Actuarial loss	(336)	(2,392)
Employee and plan participants contribution	(3,568)	(3,423)
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement	(6,419)	34
Foreign currency changes	261	(1,330)
Benefit obligation, end of year	(30,956)	(32,323)	(25,465)
Change in Plan Assets:
Fair value of plan assets, beginning of year	21,851	18,463
Defined Benefit Plan, Plan Assets, Contributions by Employer	1,627	1,584
Defined Benefit Plan, Plan Assets, Benefits Paid	663	1,788
Gain on plan assets	482	238
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	3,600	3,368
Plan settlements	(6,451)	0
Foreign currency changes	392	(14)
Fair value of plan assets, end of year	20,838	21,851	$ 18,463
Funded Status*	(10,118)	(10,472)
Unrecognized net actuarial gain	(1,056)	(1,288)
Unrecognized prior service cost	(705)	(969)
Net amount recognized	$ (11,879)	$ (12,729)

NOTES PAYABLE AND LONG-TERM DEBT (Tables)

12 Months Ended

Mar. 29, 2025

Debt Disclosure [Abstract]

Schedule of Notes Payable and Long-Term Debt

Notes payable and long-term debt consisted of the following:


(In thousands)	March 29, 2025		March 30, 2024
Convertible notes	$	983,951	$	494,813
Term loan, net of financing fees	240,028		261,971
Revolving credit facility	—		50,000
Other borrowings	809		1,009
Less current portion	(303,558)		(10,229)
Long-term debt	$	921,230	$	797,564

Schedule of Notes Payable and Long-Term Debt Maturities


Fiscal year (In thousands)
2026	$	306,349
2027	6,308
2028	10,999
2029	17,253
2030	904,757
Thereafter	454
Total debt maturities	$	1,246,120

LEASES

12 Months Ended

Mar. 29, 2025

Leases [Abstract]

Leases

LEASES

Lessee Activity

The Company has operating leases for office space, land, warehouse and manufacturing space, R&D laboratories, vehicles and certain equipment. Finance leases are not significant. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. The Company accounts for the lease components and the non-lease components as a single lease component. The Company’s leases have remaining lease terms of 1 year to approximately 30 years, some of which may include options to extend the leases for up to 10 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees.

The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.

The following table presents supplemental balance sheet information related to the Company’s operating leases:


(In thousands)	March 29, 2025		March 30, 2024
Assets
Operating lease right-of-use assets in Other long-term assets	$	47,492	$	55,268
Liabilities
Operating lease liabilities in Other current liabilities	$	8,107	$	8,133
Operating lease liabilities in Other long-term liabilities	$	50,454	$	57,958

The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:


	March 29, 2025		March 30, 2024
Weighted average remaining lease term	7.5 years		8.2 years
Weighted average discount rate	4.99	%	5.31	%

The Company’s operating lease costs were $12.1 million, $10.6 million and $11.0 million during fiscal 2025, 2024 and 2023, respectively.

The following table presents supplemental cash flow information related to our operating leases:


(In thousands)	March 29, 2025		March 30, 2024		April 1, 2023
Cash paid for amounts included in the measurement of operating lease liabilities
Operating cash flows used for operating leases	$	11,201	$	10,636	$	11,450
Right of use assets obtained in exchange for new operating lease liabilities	$	399	$	2,450	$	211

The following table presents the maturities of our operating lease liabilities as of March 29, 2025:


Fiscal Year (In thousands)	Operating Leases
2026	$	10,835
2027	11,376
2028	9,493
2029	7,604
2030	7,452
Thereafter	24,776
Total future minimum operating lease payments	71,534
Less: imputed interest	(12,973)
Present value of operating lease liabilities	$	58,561

Lessor Activity

Assets on the Company’s balance sheet classified as Haemonetics equipment primarily consists of medical devices installed at customer sites but owned by Haemonetics. These devices are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as the purchase and consumption of a certain level of disposable products. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where devices are provided under operating lease arrangements, a substantial majority of the entire lease revenue is variable and subject to subsequent non-lease component (disposable products) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Operating lease revenue represents approximately two percent of the Company’s total net sales.

INCOME TAXES

12 Months Ended

Mar. 29, 2025

Income Tax Disclosure [Abstract]

INCOME TAXES

Domestic and foreign income before provision for income tax is as follows:


(In thousands)	2025		2024		2023
Domestic	$	161,800	$	112,563	$	85,657
Foreign	50,271		39,302		55,746
Total	$	212,071	$	151,865	$	141,403

The income tax provision (benefit) from continuing operations contains the following components:


(In thousands)	2025		2024		2023
Current
Federal	$	29,818	$	29,113	$	6,461
State	8,112		6,539		4,824
Foreign	12,085		9,532		8,940
Total current	$	50,015	$	45,184	$	20,225
Deferred
Federal	(6,555)		(6,165)		14,298
State	1,774		2,132		(7,678)
Foreign	(842)		(6,844)		(843)
Total deferred	$	(5,623)	$	(10,877)	$	5,777
Total	$	44,392	$	34,307	$	26,002

The Company conducts business globally and reports its results of operations in a number of foreign jurisdictions in addition to the United States. The Company’s reported tax rate differs from the statutory tax rate due to the jurisdictional mix of earnings in any given period as the foreign jurisdictions in which it operates have tax rates that differ from the U.S. statutory tax rate. The Company’s effective tax rate is adversely impacted by non-deductible expenses including executive compensation and transaction costs, and is favorably impacted by changes in contingent consideration revaluation, the expiration of the statute of limitations with respect to certain uncertain tax position reserves, jurisdictional mix of earnings, impact of foreign tax law changes and research credits generated.

The Company’s subsidiary in Malaysia has been granted a full income tax exemption on manufacturing income that could be in effect for up to ten years, provided certain conditions are satisfied. The income tax exemption was in effect beginning June 1, 2016.

Tax effected, significant temporary differences comprising the net deferred tax liability are as follows:


(In thousands)	March 29, 2025		March 30, 2024
Deferred tax assets:
Depreciation	$	97	$	1,817
Amortization of intangibles	4,796		3,715
Inventory	2,846		5,502

Accruals, reserves and other deferred tax assets	14,801		18,777
Net operating loss carry-forward	8,842		16,221
Stock based compensation	4,897		3,965
Operating lease liabilities	14,906		16,132
Tax credit carry-forward, net	6,713		7,766
Capitalized research expenses	39,219		31,370
Gross deferred tax assets	97,117		105,265
Less valuation allowance	(11,930)		(10,239)
Total deferred tax assets (after valuation allowance)	85,187		95,026
Deferred tax liabilities:
Depreciation	(35,006)		(35,279)
Amortization of goodwill and intangibles	(87,905)		(96,597)
Unremitted earnings	(1,497)		(1,334)
Operating lease assets	(12,033)		(13,341)

Other deferred tax liabilities	(3,518)		(3,380)
Total deferred tax liabilities	(139,959)		(149,931)
Net deferred tax liabilities	$	(54,772)	$	(54,905)

The valuation allowance increase of $1.7 million during fiscal 2025 is primarily due to an increase in the valuation allowance against foreign deferred tax assets and other income tax attributes generated during the fiscal year that are expected to expire unutilized. The Company has assessed, on a jurisdictional basis, the available means of recovering deferred tax assets, including the ability to carry-back net operating losses, the existence of reversing temporary differences, the availability of tax planning strategies and available sources of future taxable income. It has also considered the ability to implement certain strategies that would, if necessary, be implemented to accelerate taxable income and use expiring deferred tax assets. The Company has concluded future taxable income can be considered a source of income to realize a benefit for deferred tax assets in certain jurisdictions. The Company believes it is able to support the deferred tax assets recognized as of the end of the year based on all of the available evidence. The worldwide net deferred tax liability as of March 29, 2025 includes deferred tax liabilities related to amortizable tax basis in goodwill and other indefinite lived assets, which can only be used as a source of income to benefit other indefinite lived deferred tax assets.

As of March 29, 2025, the Company maintains a valuation allowance against certain U.S. foreign tax credit carryforwards and U.S. state net operating loss and tax credit carryforwards that are not more-likely-than-not realizable, as well as a valuation allowance against the deferred tax assets of certain foreign subsidiaries.

In connection with certain acquisitions, the Company has acquired net operating loss and tax credit carryforwards, which may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50 percent as defined under Section 382 and 383 of the U.S. Internal Revenue Code of 1986, respectively, as well as similar state provisions. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. The Company conducted Section 382 studies covering the periods of inception through the respective acquisition dates. The studies concluded that ownership changes occurred during those periods which limit the amount of the Company’s net operating losses and tax credit carryforwards that can be utilized before expiring. The remaining carryforwards disclosed in the deferred tax table above represent the amount of attributes that can be utilized based on the results of the studies. The Company does not believe it has had any additional ownership change that would result in additional limitation. Subsequent ownership changes may further affect the limitation in future years.

As of March 29, 2025, the Company has U.S. federal net operating loss carryforwards of $6.7 million, all of which will begin to expire in fiscal 2026. The Company has U.S. state net operating losses of $56.8 million of which $56.0 million will expire at various times between fiscal 2027 and fiscal 2044 and $0.8 million can be carried forward indefinitely. The Company has federal and state tax credits of $0.5 million and $6.2 million, respectively, which will begin to expire in fiscal 2030 and fiscal 2026, respectively.

As of March 29, 2025, the Company has Canadian federal and provincial net operating loss carryforwards of $9.4 million and $7.7 million, respectively, which will expire from fiscal 2036 through fiscal 2045. The Company has other foreign net operating losses of approximately $4.0 million that are available to reduce future income which can be carried forward indefinitely. The Company has foreign research tax credits of $1.3 million which will begin to expire in fiscal 2027.

As of March 29, 2025, substantially all of the unremitted earnings of the Company have been taxed in the U.S. The Company has not provided U.S. deferred income taxes or foreign withholding taxes on unremitted earnings of foreign subsidiaries of approximately $90.8 million as such amounts are considered to be indefinitely reinvested in the business. The accumulated earnings in the foreign subsidiaries are primarily utilized to fund working capital requirements as its subsidiaries continue to expand their operations and to fund future foreign acquisitions. The Company does not believe it is practicable to estimate the amount of income taxes payable on the earnings that are indefinitely reinvested in foreign operations, however a significant portion of the unremitted earnings could be remitted without a future tax cost.

The income tax provision differs from the tax provision computed at the U.S. federal statutory income tax rate due to the following:


(In thousands)	2025				2024				2023
Tax at federal statutory rate	$	44,535	21.0	%	$	31,892	21.0	%	$	29,695	21.0	%

Impact of foreign operations	(732)		(0.3)	%	(3,631)		(2.4)	%	(2,408)		(1.7)	%
State income taxes net of federal benefit	7,505		3.5	%	7,037		4.6	%	2,939		2.1	%
Change in uncertain tax positions	(1,227)		(0.6)	%	(107)		(0.1)	%	81		0.1	%

Global intangible low taxed income	(1,380)		(0.7)	%	(555)		(0.4)	%	(828)		(0.6)	%
Unremitted earnings	163		0.1	%	171		0.1	%	(91)		(0.1)	%
Deferred statutory rate changes	543		0.3	%	(159)		(0.1)	%	82		0.1	%

Non-deductible executive compensation	5,130		2.4	%	3,256		2.1	%	1,439		1.0	%
Non-deductible expenses	2,845		1.3	%	2,355		1.6	%	827		0.6	%
Stock compensation shortfalls (benefits)	(4,469)		(2.1)	%	(1,841)		(1.2)	%	1,883		1.3	%
Research credits	(2,411)		(1.1)	%	(1,378)		(0.9)	%	(2,073)		(1.5)	%
Contingent consideration	(4,774)		(2.3)	%	—		—	%	—		—	%
Impact of foreign tax law changes	(2,707)		(1.3)	%	(2,739)		(1.8)	%	—		—	%


Valuation allowance	1,744		0.9	%	(393)		(0.2)	%	(5,135)		(3.6)	%
Other, net	(373)		(0.2)	%	399		0.3	%	(409)		(0.3)	%
Income tax provision	$	44,392	20.9	%	$	34,307	22.6	%	$	26,002	18.4	%

The Company recorded an income tax expense of $44.4 million, representing an effective tax rate of 20.9%. The effective tax rate is unfavorably impacted by state taxes, non-deductible executive compensation and disallowed stock compensation and transaction expenses, offset by the favorable impact of changes in contingent consideration revaluation, the expiration of the statute of limitations with respect to certain uncertain tax position reserves, jurisdictional mix of earnings, impact of foreign tax law changes and research credits generated.

The 15% global minimum tax under the Organization for Economic Cooperation and Development’s (“OECD”) Pillar Two Global Anti-Base Erosion Rule is currently effective in certain jurisdictions in which we operate. The OECD continues to issue guidance on the Pillar Two framework and various countries continue to enact legislation with respect to their application of the framework. We have considered the Pillar Two rules in effect in the countries in which we operate and have reflected the effect of the rules in the impact of foreign operations.

Unrecognized Tax Benefits

Unrecognized tax benefits represent uncertain tax positions for which reserves have been established. As of March 29, 2025, the Company had $2.8 million of unrecognized tax benefits, of which $1.8 million would impact the effective tax rate, if recognized. As of March 30, 2024, the Company had $3.7 million of unrecognized tax benefits, of which $3.1 million would impact the effective tax rate, if recognized. As of April 1, 2023, the Company had $3.9 million of unrecognized tax benefits, of which $3.2 million would impact the effective tax rate, if recognized.

The following table summarizes the activity related to its gross unrecognized tax benefits for the fiscal years ended March 29, 2025, March 30, 2024 and April 1, 2023:


(In thousands)	March 29, 2025		March 30, 2024		April 1, 2023
Beginning Balance	$	3,743	$	3,941	$	3,939
Additions for tax positions of the current year	315		234		292
Additions for tax positions of a prior year	1,242		—		—
Additions for tax positions related to acquired businesses	91		—		—
Reductions of tax positions	(64)		(198)		(290)

Expiration of statute of limitations	(2,505)		(234)		—
Ending Balance	$	2,822	$	3,743	$	3,941

As of March 29, 2025, the Company anticipates that the liability for unrecognized tax benefits for uncertain tax positions could change by an insignificant amount in the next twelve months.

The Company’s historical practice has been and continues to be to recognize interest and penalties related to federal, state and foreign income tax matters in income tax expense. Approximately $0.1 million and $0.3 million of gross interest and penalties were accrued at March 29, 2025 and March 30, 2024, respectively, and are not included in the amounts above. Additionally, a benefit of $0.3 million, an expense of $0.1 million, and an expense of $0.1 million of accrued interest and penalties were included in the income tax provision for each of the years ended March 29, 2025, March 30, 2024 and April 1, 2023, respectively.

The Company conducts business globally and, as a result, files federal, state and foreign income tax returns in multiple jurisdictions. In the normal course of business, it is subject to examination by taxing authorities throughout the world. With a few exceptions, the Company is no longer subject to U.S. federal, state, or local income tax examinations for years before fiscal 2022 and foreign income tax examinations for years before fiscal 2020. To the extent that the Company has tax attribute carry-forwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service, state, or foreign tax authorities to the extent utilized in a future period.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

DOCUMENT AND ENTITY INFORMATION - USD ($)	12 Months Ended
DOCUMENT AND ENTITY INFORMATION - USD ($)	Mar. 29, 2025	May 16, 2025	Sep. 28, 2024
Document And Entity Information [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Mar. 29, 2025
Current Fiscal Year End Date	--03-29
Document Transition Report	false
Entity File Number	001-14041
Entity Registrant Name	HAEMONETICS CORPORATION
Entity Incorporation, State or Country Code	MA
Entity Tax Identification Number	04-2882273
Entity Address, Address Line One	125 Summer Street,
Entity Address, City or Town	Boston,
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02110
City Area Code	(781)
Local Phone Number	848-7100
Title of 12(b) Security	Common stock, $0.01 par value per share
Trading Symbol	HAE
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Public Float			$ 3,983,480,579
Entity Common Stock, Shares Outstanding		48,036,996
Documents Incorporated by Reference	Portions of the definitive proxy statement for our Annual Meeting of Shareholders to be filed with the Securities and Exchange Commission within 120 days after the close of our fiscal year are incorporated by reference in Part III of this report.
Entity Central Index Key	0000313143
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	FY
Amendment Flag	false

RETIREMENT PLANS (Schedule of Components of Net Periodic Benefit Costs of Defined Benefit Pension Plans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Retirement Benefits [Abstract]
Service cost	$ 1,630	$ 1,316	$ 1,453
Interest cost on benefit obligation	$ 630	684	409
DefinedBenefitPlanNetPeriodicBenefitCostCreditExpectedReturnLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag	Expected return on plan assets
Expected return on plan assets	$ (314)	(264)	(180)
DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag	Actuarial loss (gain)
Actuarial loss (gain)	$ 17	(180)	19
DefinedBenefitPlanNetPeriodicBenefitCostCreditAmortizationOfPriorServiceCostCreditStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag	Amortization of unrecognized prior service cost
Amortization of unrecognized prior service cost	$ (219)	(215)	(180)
Plan settlements	(104)	0	(330)
Totals	$ 1,640	$ 1,341	$ 1,191
DefinedBenefitPlanNetPeriodicBenefitCostCreditInterestCostStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag	Interest cost on benefit obligation
DefinedBenefitPlanNetPeriodicBenefitCostCreditSettlementGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleListNotDisclosedFlag	Plan settlements

CAPITAL STOCK (Schedule of Assumptions Used to Estimate Fair Value) (Details) - $ / shares	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility	29.30%	28.60%	44.90%
Expected term	6 months	6 months	6 months
Risk-free interest rate	4.90%	5.40%	2.90%
Dividend Yield	0.00%	0.00%	0.00%
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility	43.90%	45.30%	45.00%
Expected term	5 years 2 months 12 days	5 years 1 month 6 days	5 years
Risk-free interest rate	4.40%	3.50%	2.90%
Dividend Yield	0.00%	0.00%	0.00%
Fair value per option (in dollars per share)	$ 43.56	$ 39.46	$ 24.86
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted Average Grant Date Fair Value (in dollars per share), Granted	95.09	89.21	59.36
Weighted Average Grant Date Fair Value (in dollars per share), Vested	$ 75.04	$ 67.14	$ 70.24
Performance Share Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected stock price volatility	35.35%	48.20%	52.22%
Peer group stock price volatility	35.95%	40.29%	47.43%
Correlation of returns	58.08%	59.93%	65.45%
Weighted Average Grant Date Fair Value (in dollars per share), Granted	$ 128.25	$ 128.83	$ 84.96
Weighted Average Grant Date Fair Value (in dollars per share), Vested	$ 72.35	$ 0	$ 0

AUDIT INFORMATION	12 Months Ended
AUDIT INFORMATION	Mar. 29, 2025
Audit Information [Abstract]
Auditor Name	Ernst & Young LLP
Auditor Location	Boston, Massachusetts
Auditor Firm ID	42

DESCRIPTION OF THE BUSINESS AND BASIS OF PRESENTATION (Details) $ in Thousands		12 Months Ended
	Jan. 13, 2025 USD ($)	Mar. 29, 2025 USD ($) unit	Mar. 30, 2024 USD ($)	Apr. 01, 2023 USD ($)
Debt Instrument [Line Items]
Number of business units \| unit		3
Proceeds from divestiture and sale of assets		$ 43,291	$ 1,500	$ 850
Inventories, net		365,141	317,202
Property, plant and equipment, net		284,052	311,362
Goodwill		604,269	$ 565,082	$ 466,231
Revision of Prior Period, Reclassification, Adjustment
Debt Instrument [Line Items]
Inventories, net		(26,400)
Property, plant and equipment, net		(7,800)
Goodwill		(6,400)
Accrued Liabilities		$ (100)
Disposal Group, Not Discontinued Operations \| Whole Blood
Debt Instrument [Line Items]
Proceeds from divestiture and sale of assets	$ 43,300
Business Combination, Contingent Consideration, Asset	$ 22,500

RESTRUCTURING

12 Months Ended

Mar. 29, 2025

Restructuring and Related Activities [Abstract]

RESTRUCTURING

On an ongoing basis, the Company reviews the global economy, the healthcare industry, and the markets in which it competes to identify opportunities for efficiencies, enhance commercial capabilities, align its resources and offer its customers better solutions. In order to realize these opportunities, the Company undertakes restructuring-type activities to transform its business.

Operational Excellence Program

In July 2019, the Board of Directors of the Company approved the Operational Excellence Program (the “2020 Program”) and delegated authority to the Company’s management to determine the detail of the initiatives that will comprise the program. During fiscal 2022, the Company revised the program to improve product and service quality, reduce cost principally in its manufacturing and supply chain operations and ensure sustainability while helping to offset impacts from a previously announced customer loss, rising inflationary pressures and effects of the COVID-19 pandemic. The program is closed as of March 29, 2025. During fiscal 2025, 2024 and 2023, the Company incurred $7.7 million, $9.8 million and $11.5 million of restructuring and restructuring related costs under this program, respectively. Total cumulative charges under this program are $84.7 million as of March 29, 2025.

Portfolio Rationalization Initiatives

In November 2023, the Company announced its plans to end of life the ClotPro analyzer system within the Hospital business unit and certain products within the Blood Center business unit, primarily in Whole Blood, including the associated manufacturing operations and closure of certain other facilities. The initiative is closed as of March 29, 2025. During fiscal 2025, 2024 and 2023, the Company incurred $13.0 million, $14.0 million and no restructuring and restructuring related costs under this initiative, respectively. Total cumulative charges under this initiative are $27.0 million as of March 29, 2025.

Market and Regional Alignment

In May 2025, the Board of Directors of the Company approved a new market and regional alignment initiative and delegated authority to the Company’s management to determine the details of the specific actions that will comprise the initiative. This strategic initiative is designed to improve operational performance and reduce costs by directing the Company’s resources toward the markets and geographies that offer the greatest growth and portfolio advancement opportunities. We expect to incur aggregate restructuring and restructuring-related charges of approximately $20 million associated with this initiative, approximately half of which we expect will consist of severance and other employee costs and the remainder of which will consist of other exit costs, primarily related to third party arrangements. These charges, substantially all of which will result in cash outlays, will be incurred as the specific actions required to execute on the initiative are identified and approved and are expected to continue through the end of fiscal 2027. We expect savings from this initiative of approximately $30 million on an annualized basis once the initiative is completed. The amounts and timing of estimated costs and savings are subject to change until finalized. The actual amounts and timing may vary materially based on various factors.

During the fourth quarter of fiscal 2025, the Company incurred $0.6 million of restructuring related costs related to the first action under this initiative, which were approved by our Board of Directors in January 2025. Total cumulative charges under this program are $0.6 million as of March 29, 2025.


(In thousands)	Portfolio Rationalization		2020 Program		Market and Regional Alignment		Prior Programs		Total
Balance at April 2, 2022	$	—	$	2,460	$	—	$	345	$	2,805
Costs incurred, net of reversals	—		576		—		81		657
Payments	—		(1,226)		—		(86)		(1,312)

Balance at April 1, 2023	$	—	$	1,810	$	—	$	340	$	2,150
Costs incurred, net of reversals	13,915		450		—		(276)		14,089
Payments	(2,606)		(1,775)		—		(64)		(4,445)

Balance at March 30, 2024	$	11,309	$	485	$	—	$	—	$	11,794
Costs incurred, net of reversals	12,797		566		550		—		13,913
Payments	(12,755)		(761)		(550)		—		(14,066)
Non-cash adjustments	(8,616)		—		—		—		(8,616)
Balance at March 29, 2025	$	2,735	$	290	$	—	$	—	$	3,025

The following presents the restructuring costs by line item during fiscal 2025, 2024 and 2023 within our accompanying consolidated statements of income and comprehensive income:


(In thousands)	2025		2024		2023
Cost of goods sold	$	11,328	$	11,286	$	(215)
Research and development	(61)		456		—
Selling, general and administrative expenses	2,646		2,347		872
Total	$	13,913	$	14,089	$	657

As of March 29, 2025, the Company had a restructuring liability of $3.0 million, all of which is payable within the next twelve months.

In addition to the restructuring expenses included in the table above, the Company also incurred costs of $7.2 million, $9.5 million and $10.9 million in fiscal 2025, 2024 and 2023, respectively, that do not constitute restructuring costs under ASC 420,

Exit and Disposal Cost Obligations, and which the Company instead refers to as restructuring related costs. These costs consist primarily of expenditures directly related to the restructuring actions.

The following presents the restructuring related costs by line item during fiscal 2025, 2024 and 2023 within our accompanying consolidated statements of income and comprehensive income:


(In thousands)	2025		2024		2023
Cost of goods sold	$	3,304	$	5,734	$	7,991
Research and development	1,649		1,750		1,050
Selling, general and administrative expenses	2,292		2,015		1,851
Total	$	7,245	$	9,499	$	10,892

The tables below present restructuring and restructuring related costs by reportable segment:


Restructuring costs
(In thousands)	2025		2024		2023
Plasma	$	258	$	1,015	$	(48)
Blood Center	4,742		5,606		—
Hospital	1,664		3,863		165
Corporate	7,249		3,605		540
Total	$	13,913	$	14,089	$	657

Restructuring related costs
(In thousands)	2025		2024		2023
Plasma	$	281	$	1,050	$	1,385
Blood Center	154		286		75
Hospital	143		408		546
Corporate	6,667		7,755		8,886
Total	$	7,245	$	9,499	$	10,892

Total restructuring and restructuring related costs	$	21,158	$	23,588	$	11,549

REVENUE Performance Obligations (Details)	Mar. 29, 2025
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-03
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Timing of satisifaction	12 months

CAPITAL STOCK (Schedule of Share-Based Compensation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized	$ 29,636	$ 28,332	$ 25,583
Selling, general and administrative expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized	25,971	23,662	21,903
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized	1,847	3,106	2,364
Cost of Goods Sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense recognized	$ 1,818	$ 1,564	$ 1,316

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

SEGMENT AND ENTERPRISE-WIDE INFORMATION

12 Months Ended

Mar. 29, 2025

Segment Reporting [Abstract]

SEGMENT AND ENTERPRISE-WIDE INFORMATION

The Company determines its reportable segments by first identifying its operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. The Company’s reporting structure aligns with its operating structure of three global business units and the information that is regularly reviewed by the Company’s chief operating decision maker (“CODM”), identified as the Company’s Chief Executive Officer.

The Company’s reportable and operating segments are as follows:

•Plasma

•Blood Center

•Hospital

The CODM measures and evaluates the operating segments based on operating income for purposes of assessing business performance and allocating resources. Certain corporate expenses and amounts considered to be non-recurring or non-operational are excluded from segment operating income. These items include acquisition, integration and divestiture related costs, amortization of acquired assets, restructuring costs, restructuring related costs, digital transformation costs related to the upgrade of our enterprise resource planning system, impairments and write downs, accelerated device depreciation and related costs, costs related to compliance with the European Union Medical Device Regulation (“MDR”) and In Vitro Diagnostic Regulation (“IVDR”), unusual or infrequent and material litigation-related charges and gains, losses on dispositions and sale of assets, remeasurement of the contingent consideration liability and unusual or infrequent gains such as on repurchases of convertible notes or divestitures. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. During the fourth quarter of fiscal 2025, the CODM began reviewing financial information including allocations of certain corporate costs including global functional support and overhead costs determined to benefit the segments. The prior period segment disclosures have been recast to reflect the new presentation.

We do not track our assets by segment, and as a result it is not practical to show assets or depreciation by segment. Consequently, our CODM does not review assets by segment when assessing business performance and allocating resources.

Selected information by reportable segment is presented below:


(In thousands)	2025		2024		2023
Net sales
Plasma	$	535,431	$	569,535	$	499,916
Blood Center	261,124		283,231		287,034
Hospital	564,269		456,289		381,710
Net sales by business unit	$	1,360,824	$	1,309,055	$	1,168,660



Significant segment expenses and operating performance
Plasma
Cost of goods sold	$	237,050	$	264,042	$	254,474
Selling, general and administrative	98,418		109,729		106,006
Research and development	15,453		13,797		14,690
Plasma operating income	$	184,510	$	181,967	$	124,746
Blood Center
Cost of goods sold	$	142,512	$	165,564	$	144,364
Selling, general and administrative	60,023		67,339		74,024
Research and development	5,770		7,956		4,374
Blood Center operating income	$	52,819	$	42,372	$	64,272
Hospital
Cost of goods sold	$	199,499	$	167,172	$	147,831
Selling, general and administrative	241,760		209,680		181,368
Research and development	34,035		27,239		23,096
Hospital operating income	$	88,975	$	52,198	$	29,415



Corporate and unallocated expenses
Amortization of acquired assets	$	(63,217)	$	(35,378)	$	(32,640)
Acquisition, integration and divestiture related costs	(22,904)		(11,249)		411
Restructuring and restructuring related costs	(21,158)		(23,588)		(11,549)
Digital transformation costs	(20,273)		(15,667)		(4,536)
Contingent Consideration	23,022		—		—







Other(1)	43		(25,772)		(14,086)
Operating income	221,817		164,883		156,033
Interest and other expense, net	(9,746)		(13,018)		(14,630)
Income before provision for income taxes	$	212,071	$	151,865	$	141,403

(1) Comprised of write downs of certain assets, MDR and IVDR costs, Litigation-related charges, gain on repurchase of convertible notes, gain on sale of property, plant and equipment, impairment of intangible assets, PCS2® related charges and gain on divestiture.

Net revenues by business unit are as follows:


(In thousands)		2025		2024		2023
	Plasma	$	535,431	$	569,535	$	499,916

	Apheresis	213,134		211,173		207,618
	Whole Blood	47,990		72,058		79,416
	Blood Center	261,124		283,231		287,034

	Interventional Technologies	255,019		174,285		126,717
	Blood Management Technologies	309,250		282,004		254,993

	Hospital	$	564,269	$	456,289	$	381,710



Total net revenues		$	1,360,824	$	1,309,055	$	1,168,660


(In thousands)	2025		2024		2023
Depreciation and amortization
Plasma	$	48,264	$	45,712	$	41,612
Blood Center	10,077		13,391		13,927
Hospital	57,245		38,112		37,768
Total depreciation and amortization (excluding impairment charges)	$	115,586	$	97,215	$	93,307


(In thousands)	March 29, 2025		March 30, 2024
Long-lived assets(1)
Plasma	$	189,833	$	211,121
Blood Center	40,337		54,262
Hospital	53,882		45,979
Total long-lived assets	$	284,052	$	311,362
(1) Long-lived assets are comprised of property, plant and equipment.

Selected information by operating regions is presented below:


(In thousands)	March 29, 2025		March 30, 2024
Long-lived assets(1)
United States	$	217,212	$	246,473
Japan	1,250		1,597
Europe	20,024		15,310
Rest of Asia	28,705		26,728
Other	16,861		21,254
Total long-lived assets	$	284,052	$	311,362
(1) Long-lived assets are comprised of property, plant and equipment.


(In thousands)	2025		2024		2023
Net revenues
United States	$	1,010,918	$	970,007	$	842,897
Japan	62,408		58,087		61,295
Europe	175,655		160,142		156,680
Rest of Asia	92,305		107,536		104,135
Other	19,538		13,283		3,653
Total net revenues	$	1,360,824	$	1,309,055	$	1,168,660

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

+ Details

GOODWILL AND INTANGIBLE ASSETS Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2023	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Non-amortizable:
Non-amortizable intangibles		$ 9,190	$ 18,234
Amortizable:
Finite-Lived Intangible Assets, Gross		762,865	843,096
Accumulated Amortization		316,313	455,213
Net		446,552	387,883
Amortization of acquired intangible assets		55,600	41,400	$ 42,100
Fiscal 2026		51,563
Fiscal 2027		47,344
Fiscal 2028		45,568
Fiscal 2029		44,320
Fiscal 2030		43,410
Goodwill and Intangible Asset Impairment	$ 10,400
In-process software development
Non-amortizable:
Non-amortizable intangibles		9,190	4,567
In-process research and development
Non-amortizable:
Non-amortizable intangibles			13,667
Patents and other
Amortizable:
Finite-Lived Intangible Assets, Gross		19,678	24,504
Accumulated Amortization		6,796	11,820
Net		12,882	12,684
Capitalized software
Amortizable:
Finite-Lived Intangible Assets, Gross		85,528	84,837
Accumulated Amortization		76,185	69,491
Net		9,343	15,346
Developed technology
Amortizable:
Finite-Lived Intangible Assets, Gross		506,143	464,291
Accumulated Amortization		156,123	178,413
Net		350,020	285,878
Customer contracts and related relationships
Amortizable:
Finite-Lived Intangible Assets, Gross		135,561	255,144
Accumulated Amortization		70,842	190,033
Net		64,719	65,111
Trade names
Amortizable:
Finite-Lived Intangible Assets, Gross		15,955	14,320
Accumulated Amortization		6,367	5,456
Net		$ 9,588	$ 8,864

ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)

12 Months Ended

Mar. 29, 2025

Stockholders' Equity Note [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

The following is a roll-forward of the components of accumulated other comprehensive loss, net of tax, for the years ended March 29, 2025 and March 30, 2024:


(In thousands)	Foreign currency		Defined benefit plans		Net Unrealized Gain (Loss) on Derivatives		Total
Balance, April 1, 2023	$	(33,935)	$	4,075	$	(521)	$	(30,381)
Other comprehensive (loss) income before reclassifications	(4,339)		(2,327)		4,912		(1,754)
Amounts reclassified from accumulated other comprehensive loss(1)	—		—		(3,497)		(3,497)
Net current period other comprehensive (loss) income	(4,339)		(2,327)		1,415		(5,251)
Balance, March 30, 2024	$	(38,274)	$	1,748	$	894	$	(35,632)
Other comprehensive loss before reclassifications	(17,974)		(599)		(935)		(19,508)
Amounts reclassified from accumulated other comprehensive loss(1)	—		—		56		56
Net current period other comprehensive loss	(17,974)		(599)		(879)		(19,452)
Balance, March 29, 2025	$	(56,248)	$	1,149	$	15	$	(55,084)
(1) Presented net of income taxes, the amounts of which are insignificant.

INCOME TAXES (Schedule of Income Tax Provision Components) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Current
Federal	$ 29,818	$ 29,113	$ 6,461
State	8,112	6,539	4,824
Foreign	12,085	9,532	8,940
Total current	50,015	45,184	20,225
Deferred
Federal	(6,555)	(6,165)	14,298
State	1,774	2,132	(7,678)
Foreign	(842)	(6,844)	(843)
Total deferred	(5,623)	(10,877)	5,777
Income tax provision	$ 44,392	$ 34,307	$ 26,002

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Mar. 30, 2024

Accounting Standards Update and Change in Accounting Principle [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Fiscal Year

Haemonetics’ fiscal year ends on the Saturday closest to the last day of March. Fiscal years 2025, 2024 and 2023 include 52 weeks with each quarter having 13 weeks.

Principles of Consolidation

Use of Estimates

Contingencies

Revenue Recognition

Product Revenues

Software and Other Revenues

Significant Judgments

Contract Balances

Practical Expedients

Translation of Foreign Currencies

Cash and Cash Equivalents

Allowance for Credit Losses

Inventories

Property, Plant and Equipment


Asset Classification						Estimated Useful Lives
Building						30-40 Years
Building improvements						5-20 Years
Plant equipment and machinery						3-15 Years
Office equipment and information technology						3-10 Years
Haemonetics equipment						3-7 Years

•Purchase and consumption of a certain level of disposable products

•Payment of monthly rental fees

•An asset utilization performance metric, such as performing a minimum level of procedures per month per device

Goodwill and Intangible Assets

Cloud computing implementation costs

ASC Topic 350-40, Goodwill and Other, Internal-Use Software, specifies that certain costs incurred in the application development stage to implement cloud computing arrangements hosted by a third-party vendor are required to be capitalized. The Company includes these costs in other long-term assets. The costs are amortized using the straight-line method over the

expected contract term, including extension periods and is included in selling, general and administrative expense in the Consolidated Statements of Income.

Other long-term assets as of March 29, 2025 included approximately $44.0 million of capitalized implementation costs related to a new global enterprise resource planning system. There were $22.9 million of implementation costs capitalized as of March 30, 2024. Amortization expense was $2.3 million and $0.9 million in fiscal 2025 and 2024, respectively. There was no amortization expense for fiscal 2023.

Accounting for the Costs of Computer Software to be Sold, Leased, or Otherwise Marketed

Other Current Liabilities

Other current liabilities represent items payable or expected to settle within the next twelve months. The items included in the fiscal year end balances were:


(In thousands)	March 29, 2025		March 30, 2024


Contract liabilities	43,348		31,242




All other	104,785		104,846
Total	$	148,133	$	136,088

Other Long-Term Liabilities

Other long-term liabilities represent items that are not payable or expected to settle within the next twelve months.

Research and Development Expenses

All research and development costs are expensed as incurred.

Advertising Costs

All advertising costs are expensed as incurred and are included in selling, general and administrative expenses in the consolidated statements of income. Advertising expenses were $7.7 million, $7.1 million and $7.2 million in fiscal 2025, 2024 and 2023, respectively.

Shipping and Handling Costs

Shipping and handling costs are included in selling, general and administrative expenses.

Income Taxes

Convertible Senior Notes

Derivative Instruments

Share-Based Compensation

Costs Associated with Exit Activities

Valuation of Acquisitions

Strategic Investments

Consolidated Balance Sheets and the Company did not record any adjustments to the carrying value of strategic investments in fiscal 2025 or 2024.

Concentration of Credit Risk and Significant Customers

Recent Accounting Pronouncements

Standards Implemented

Standards to be Implemented

In November 2024, the FASB issued ASC Update No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40). ASC Update No. 2024-03 requires detailed cost and expense information disaggregated in the financial statement notes. The updated guidance is effective for fiscal years beginning after December 15, 2026 and interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. ASC Update No. 2024-03 is applicable to the Company beginning with the fiscal 2028 Annual Report on Form 10-K and the Company is currently evaluating the impact to its interim and annual report disclosures.

RESTRUCTURING (Schedule of Restructuring Reserve by Type of Cost) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 11,794	$ 2,150	$ 2,805
Costs incurred, net of reversals	13,913	14,089	657
Payments	(14,066)	(4,445)	(1,312)
Non-cash adjustments	(8,616)
Ending Balance	3,025	11,794	2,150
Restructuring related costs	7,245	9,499	10,892
Total restructuring and restructuring related costs	21,158	23,588	11,549
Plasma
Restructuring Reserve [Roll Forward]
Costs incurred, net of reversals	258	1,015	(48)
Restructuring related costs	281	1,050	1,385
Blood Center
Restructuring Reserve [Roll Forward]
Costs incurred, net of reversals	4,742	5,606	0
Restructuring related costs	154	286	75
Hospital
Restructuring Reserve [Roll Forward]
Costs incurred, net of reversals	1,664	3,863	165
Restructuring related costs	143	408	546
All Other
Restructuring Reserve [Roll Forward]
Costs incurred, net of reversals	7,249	3,605	540
Restructuring related costs	6,667	7,755	8,886
2020 Program
Restructuring Reserve [Roll Forward]
Beginning Balance	485	1,810	2,460
Costs incurred, net of reversals	566	450	576
Payments	(761)	(1,775)	(1,226)
Non-cash adjustments	0
Ending Balance	290	485	1,810
Total restructuring and restructuring related costs	7,700	9,800	11,500
Prior Programs
Restructuring Reserve [Roll Forward]
Beginning Balance	0	340	345
Costs incurred, net of reversals	0	(276)	81
Payments	0	(64)	(86)
Non-cash adjustments	0
Ending Balance	0	0	340
Portfolio Rationalization
Restructuring Reserve [Roll Forward]
Beginning Balance	11,309	0	0
Costs incurred, net of reversals	12,797	13,915	0
Payments	(12,755)	(2,606)	0
Non-cash adjustments	(8,616)
Ending Balance	2,735	11,309	0
Total restructuring and restructuring related costs	13,000	14,000	0
Market and Regional Alignment Initiative
Restructuring Reserve [Roll Forward]
Beginning Balance	0	0	0
Costs incurred, net of reversals	550	0	0
Payments	(550)	0	0
Non-cash adjustments	0
Ending Balance	0	0	0
Total restructuring and restructuring related costs	600
Cost of Goods Sold
Restructuring Reserve [Roll Forward]
Costs incurred, net of reversals	$ 11,328	$ 11,286	$ (215)
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of goods sold	Cost of goods sold	Cost of goods sold
Restructuring related costs	$ 3,304	$ 5,734	$ 7,991
Research and development
Restructuring Reserve [Roll Forward]
Costs incurred, net of reversals	$ (61)	$ 456	$ 0
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Research and development	Research and development	Research and development
Restructuring related costs	$ 1,649	$ 1,750	$ 1,050
Selling, general and administrative expenses
Restructuring Reserve [Roll Forward]
Costs incurred, net of reversals	$ 2,646	$ 2,347	$ 872
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, general and administrative	Selling, general and administrative	Selling, general and administrative
Restructuring related costs	$ 2,292	$ 2,015	$ 1,851

INVENTORIES

12 Months Ended

Mar. 29, 2025

Inventory Disclosure [Abstract]

INVENTORIES

Inventories are stated at the lower of cost or net realizable value and include the cost of material, labor and manufacturing overhead. Cost is determined with the first-in, first-out method.


(In thousands)	March 29, 2025		March 30, 2024
Raw materials	$	128,574	$	134,150
Work-in-process	14,956		15,488
Finished goods	221,611		167,564
Total inventories	$	365,141	$	317,202

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)

12 Months Ended

Mar. 29, 2025

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Interest Rate Derivatives

The Company held the following interest rate swaps as of March 29, 2025:


Hedged Item	Original Notional Amount		Notional Amount as of March 29, 2025		Designation Date	Effective Date	Termination Date	Fixed Interest Rate	Estimated Fair Value Assets (Liabilities)
(In thousands)
1-month USD Term SOFR	$	109,900	$	102,944	9/27/2024	9/30/2024	4/30/2029	3.32%	$	1,076
1-month USD Term SOFR	109,900		101,553		9/27/2024	9/30/2024	4/30/2029	3.30%	1,250
Total	$	219,800	$	204,497					$	2,326

Accounts Receivable, Allowance for Credit Loss

The following is a roll forward of the allowance for credit losses:


	Twelve Months Ended
(In thousands)	March 29, 2025		March 30, 2024		April 1, 2023
Beginning balance	$	5,695	$	4,932	$	2,475
Credit loss	725		840		2,623
Recoveries	(120)		(77)		(166)
Ending balance	$	6,300	$	5,695	$	4,932

Schedule of Effect of Derivative Instruments Designated as Cash Flow Hedges and Those Not Designated as Hedging Instruments


Derivative Instruments	Amount of (Loss) Gain Recognized in Accumulated Other Comprehensive Loss		Amount of Gain (Loss) Reclassified from Accumulated Other Comprehensive Loss into Earnings		Location in Consolidated Statements of Income and Comprehensive Income	Amount of Gain Excluded from Effectiveness Testing		Location in Consolidated Statements of Income and Comprehensive Income
(In thousands)
Designated foreign currency hedge contracts, net of tax	$	(1,508)	$	11	Net revenues, COGS and SG&A	$	1,743	Interest and other expense, net
Non-designated foreign currency hedge contracts	$	—	$	—		$	(1,534)	Interest and other expense, net
Designated interest rate swaps, net of tax	$	573	$	(67)	Interest and other expense, net	$	—

Schedule of Fair Value of Derivative Instruments as They Appear in Consolidated Balance Sheets

The following tables present the fair value of the Company’s derivative instruments as they appear in its consolidated balance sheets as of March 29, 2025 and March 30, 2024:


(In thousands)	Location in Consolidated Balance Sheet	As of March 29, 2025		As of March 30, 2024
Derivative Assets:
Designated foreign currency hedge contracts	Prepaid expenses and other current assets	$	193	$	1,353
Non-designated foreign currency hedge contracts	Other current assets	85		154
Designated interest rate swaps	Other current assets	1,305		1,673
Designated interest rate swaps	Other long-term assets	1,020		62
		$	2,603	$	3,242
Derivative Liabilities:
Designated foreign currency hedge contracts	Other current liabilities	$	471	$	395
Non-designated foreign currency hedge contracts	Other current liabilities	25		536


		$	496	$	931

Schedule of Financial Assets and Financial Liabilities Measured at Fair Value on a Recurring Basis

Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of March 29, 2025 and March 30, 2024.


	As of March 29, 2025
(In thousands)	Level 1		Level 2		Level 3		Total
Assets
Money market funds	$	158,916	$	—	$	—	$	158,916
Designated foreign currency hedge contracts	—		193		—		193
Non-designated foreign currency hedge contracts	—		85		—		85
Designated interest rate swaps	—		2,325		—		2,325

	$	158,916	$	2,603	$	—	$	161,519
Liabilities
Designated foreign currency hedge contracts	$	—	$	471	$	—	$	471
Non-designated foreign currency hedge contracts	—		25		—		25

Contingent consideration	—		—		2,278		2,278
	$	—	$	496	$	2,278	$	2,774

	As of March 30, 2024
	Level 1		Level 2		Level 3		Total
Assets
Money market funds	$	43,073	$	—	$	—	$	43,073
Designated foreign currency hedge contracts	—		1,353		—		1,353
Non-designated foreign currency hedge contracts	—		154		—		154
Designated interest rate swaps	—		1,735		—		1,735
	$	43,073	$	3,242	$	—	$	46,315
Liabilities
Designated foreign currency hedge contracts	$	—	$	395	$	—	$	395
Non-designated foreign currency hedge contracts	—		536		—		536


	$	—	$	931	$	—	$	931

The level 3 fair value measurements of contingent consideration liabilities include the following significant unobservable inputs:

Fair Value at

Valuation

Unobservable

(In thousands)

March 29, 2025

Technique

Input

Range

Revenue-based payments

1,214

Monte Carlo Simulation Model

Discount rate

6.3%

Projected fiscal year of payments

2026 - 2028

Regulatory-based payment

—

Monte Carlo Simulation Model

Discount rate

N/A

Probability of payment

Projected fiscal year of payment

N/A

Event-based payment

1,064

Monte Carlo Simulation Model

Discount rate

5.8%

Projected fiscal year of payment

2026 - 2028

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

The fair value of contingent consideration associated with acquisitions was $2.3 million at March 29, 2025 and the total was included in Other long-term liabilities.

A reconciliation of the change in the fair value of contingent consideration is included in the following table:


(In thousands)
Balance at March 30, 2024	$	—
Acquisition date fair value of contingent consideration	25,000
Purchase accounting adjustments	300
Change in fair value	(23,022)
Balance at March 29, 2025	$	2,278

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Cash Flows from Operating Activities:
Net income	$ 167,679	$ 117,558	$ 115,401
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	115,586	97,215	93,307
Amortization of fair value inventory step-up	14,956	3,347	0
Share-based compensation expense	29,636	28,332	25,583
Impairment of intangible assets	2,391	10,419	607
Gain on repurchase of convertible senior notes, net	(12,600)	0	0
Gains on sales of property, plant and equipment	(15,698)	(1,013)	(943)
Remeasurement of contingent consideration	(23,022)	0	(504)
Deferred income taxes	(5,219)	(11,039)	4,783
Other non-cash operating activities	9,978	11,633	9,321
Change in operating assets and liabilities:
Change in accounts receivable	6,956	(24,193)	(24,421)
Change in inventories	(64,704)	(60,061)	30,754
Change in prepaid income taxes	226	(983)	1,688
Change in other assets and other liabilities	(25,232)	(34,046)	(22,334)
Change in accounts payable and accrued expenses	(19,208)	44,582	39,816
Net cash provided by operating activities	181,725	181,751	273,058
Cash Flows from Investing Activities:
Capital expenditures	(39,278)	(38,125)	(191,327)
Proceeds from divestiture and sale of assets	43,291	1,500	850
Proceeds from sale of property, plant and equipment	23,253	1,810	1,608
Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment	(21,112)	(28,171)	81,136
Acquisitions	150,906	243,852	2,850
Other investments	(17,143)	(15,551)	(33,205)
Net cash used in investing activities	(161,895)	(322,389)	(143,788)
Cash Flows from Financing Activities:
Proceeds from issuance of convertible notes	700,000	0	0
Repurchase of convertible senior notes	(185,500)	0	0
Purchase of capped call related to convertible notes	(88,200)	0	0
Term loan borrowings	250,000	0	280,000
Term loan redemption	(262,500)	0	(280,000)
Repayment of term loan borrowings	(4,688)	(12,250)	(9,625)
Proceeds from revolving facility	0	110,000	50,000
Payments on revolving facility	(50,000)	(60,000)	(50,000)
Debt issuance costs	(23,135)	0	(1,118)
Contingent consideration payments	0	(849)	(21,593)
Proceeds from employee stock purchase plan	8,333	7,214	7,016
Cash used to net share settle employee equity awards	(10,243)	(5,885)	0
Share repurchases	(225,000)	0	(75,000)
Other financing activities	(249)	(73)	(44)
Net cash provided by (used in) financing activities	108,818	38,157	(100,364)
Effect of exchange rates on cash and cash equivalents	(685)	(3,185)	(3,936)
Net Change in Cash and Cash Equivalents	127,963	(105,666)	24,970
Cash and Cash Equivalents at Beginning of Year	178,800	284,466	259,496
Cash and Cash Equivalents at End of Year	306,763	178,800	284,466
Supplemental Disclosures of Cash Flow Information:
Interest paid	16,534	20,901	13,587
Income taxes paid	$ 49,293	$ 52,706	$ 17,967

ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS (Tables)

12 Months Ended

Mar. 29, 2025

Business Combinations [Abstract]

Schedule of Business Acquisitions, by Acquisition

The purchase price of $243.9 million, net of $10.6 million of cash acquired, consists of the amounts presented below, which represent the final determination of the fair value of the identifiable assets acquired and liabilities assumed:


(In thousands)	December 12, 2023
Accounts receivable	$	5,960
Inventories	12,075
Prepaid expenses and other current assets	2,062
Property, plant and equipment	3,028
Intangible assets	172,000
Goodwill	79,400
Other long-term assets	4,705
Total assets acquired	$	279,230
Accounts payable	3,251
Accrued payroll and related costs	1,723
Other liabilities	9,746
Deferred tax liability	14,805
Other long-term liabilities	5,853
Total liabilities assumed	$	35,378
Net assets acquired	$	243,852

Intangible assets acquired consist of the following:


(In thousands)	Amount		Weighted-Average Amortization Period	Risk-Adjusted Discount Rates used in Purchase Price Allocation
Developed technology	$	114,900	15 years	20.5	%
Customer contracts and related relationships	52,300		15 years	18.9	%
Trade names	4,800		15 years	20.5	%
Total	$	172,000

Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination

Intangible assets acquired consist of the following:


(In thousands)	Amount		Weighted-Average Amortization Period	Risk-Adjusted Discount Rates used in Purchase Price Allocation
Developed technology	$	96,100	10 years	22.0	%
Customer contracts and related relationships	7,800		10 years	21.5	%
Trade names	1,900		10 years	21.5	%
Total	$	105,800

NOTES PAYABLE AND LONG-TERM DEBT (Schedule of Notes Payable and Long-Term Debt) (Details) - USD ($)		12 Months Ended
	Jul. 26, 2022	Mar. 29, 2025	Mar. 30, 2024	Mar. 05, 2021
Debt Instrument [Line Items]
Total debt maturities		$ 1,246,120,000
Less current portion		(303,558,000)	$ (10,229,000)
Long term debt		921,230,000	797,564,000
Term loan, net of financing fees
Debt Instrument [Line Items]
Total debt maturities		240,028,000	261,971,000
Bank loans and other borrowings
Debt Instrument [Line Items]
Total debt maturities		809,000	1,009,000
Convertible notes
Debt Instrument [Line Items]
Total debt maturities		983,951,000	494,813,000
Face amount of debt		700,000,000		$ 500,000,000
Debt Instrument, Interest Rate, Stated Percentage				0.00%
Unsecured Debt \| Revised Credit Agreement
Debt Instrument [Line Items]
Face amount of debt	$ 250,000,000
Interest costs capitalized		5,900,000
Unsecured Debt \| Revised Credit Agreement \| Minimum
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Floor	0.00%
Debt Instrument, Interest Rate, Stated Percentage	1.125%
Unsecured Debt \| Revised Credit Agreement \| Maximum
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.75%
Line of Credit
Debt Instrument [Line Items]
Total debt maturities		0
Line of Credit \| Revised Credit Agreement \| Revolving Credit Facility
Debt Instrument [Line Items]
Interest costs capitalized		20,800,000
Line of Credit \| Revised Credit Agreement \| Revolving Credit Facility \| Minimum
Debt Instrument [Line Items]
Commitment fee	0.125%
Line of Credit \| Revised Credit Agreement \| Revolving Credit Facility \| Maximum
Debt Instrument [Line Items]
Commitment fee	0.25%
Revolving Credit Facility
Debt Instrument [Line Items]
Total debt maturities		$ 0	$ 50,000,000
Commitment fee		0.20%
Revolving Credit Facility \| Minimum
Debt Instrument [Line Items]
Commitment fee		0.125%
Revolving Credit Facility \| Maximum
Debt Instrument [Line Items]
Commitment fee		0.25%

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedules of Derivatives) (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Thousands	Mar. 29, 2025	Mar. 30, 2024
Assets
Money market funds	$ 158,916	$ 43,073
Assets fair value	161,519	46,315
Liabilities
Liabilities fair value	2,774	931
Level 1
Assets
Money market funds	158,916	43,073
Assets fair value	158,916	43,073
Liabilities
Liabilities fair value	0	0
Level 2
Assets
Money market funds	0	0
Assets fair value	2,603	3,242
Liabilities
Liabilities fair value	496	931
Fair Value, Inputs, Level 3
Liabilities
Liabilities fair value	2,278	0
Designated as Hedging Instrument
Assets
Derivative Assets	2,603	3,242
Liabilities
Derivative Liabilities	496	931
Foreign Exchange Contract \| Designated as Hedging Instrument
Assets
Derivative Assets	193	1,353
Liabilities
Derivative Liabilities	471	395
Foreign Exchange Contract \| Designated as Hedging Instrument \| Level 1
Assets
Derivative Assets	0	0
Liabilities
Derivative Liabilities	0	0
Foreign Exchange Contract \| Designated as Hedging Instrument \| Level 2
Liabilities
Derivative Liabilities		395
Foreign Exchange Contract \| Not Designated as Hedging Instrument
Assets
Derivative Assets	85	154
Liabilities
Derivative Liabilities	25	536
Foreign Exchange Contract \| Not Designated as Hedging Instrument \| Level 1
Assets
Derivative Assets	0	0
Liabilities
Derivative Liabilities	0	0
Foreign Exchange Contract \| Other Current Assets \| Designated as Hedging Instrument
Assets
Derivative Assets		1,353
Foreign Exchange Contract \| Other Current Assets \| Designated as Hedging Instrument \| Level 2
Assets
Derivative Assets	193	1,353
Foreign Exchange Contract \| Other Current Assets \| Not Designated as Hedging Instrument
Assets
Derivative Assets		154
Foreign Exchange Contract \| Other Current Assets \| Not Designated as Hedging Instrument \| Level 2
Assets
Derivative Assets	85	154
Foreign Exchange Contract \| Other Current Liabilities \| Designated as Hedging Instrument
Liabilities
Derivative Liabilities		395
Foreign Exchange Contract \| Other Current Liabilities \| Designated as Hedging Instrument \| Level 2
Liabilities
Derivative Liabilities	471
Foreign Exchange Contract \| Other Current Liabilities \| Not Designated as Hedging Instrument
Liabilities
Derivative Liabilities		536
Foreign Exchange Contract \| Other Current Liabilities \| Not Designated as Hedging Instrument \| Level 2
Liabilities
Derivative Liabilities	25	536
Interest Rate Swap \| Not Designated as Hedging Instrument
Assets
Derivative Assets	2,325	1,735
Interest Rate Swap \| Not Designated as Hedging Instrument \| Level 1
Assets
Derivative Assets	0	0
Interest Rate Swap \| Other Current Assets \| Designated as Hedging Instrument
Assets
Derivative Assets		1,673
Interest Rate Swap \| Other Current Assets \| Designated as Hedging Instrument \| Level 2
Assets
Derivative Assets	1,305
Interest Rate Swap \| Other Current Assets \| Not Designated as Hedging Instrument \| Level 2
Assets
Derivative Assets	2,325	1,735
Interest Rate Swap \| Other Noncurrent Assets \| Designated as Hedging Instrument
Assets
Derivative Assets		62
Interest Rate Swap \| Other Noncurrent Assets \| Designated as Hedging Instrument \| Level 2
Assets
Derivative Assets	1,020
Contingent Consideration
Liabilities
Liabilities fair value	2,278
Contingent Consideration \| Fair Value, Inputs, Level 3
Liabilities
Liabilities fair value	$ 2,278	$ 0

NOTES PAYABLE AND LONG-TERM DEBT

12 Months Ended

Mar. 29, 2025

Debt Disclosure [Abstract]

NOTES PAYABLE AND LONG-TERM DEBT

Notes payable and long-term debt consisted of the following:


(In thousands)	March 29, 2025		March 30, 2024
Convertible notes	$	983,951	$	494,813
Term loan, net of financing fees	240,028		261,971
Revolving credit facility	—		50,000
Other borrowings	809		1,009
Less current portion	(303,558)		(10,229)
Long-term debt	$	921,230	$	797,564

Convertible Senior Notes

2026 Notes

On March 5, 2021, the Company issued $500.0 million aggregate principal amount of 0% convertible senior notes due 2026 (the “2026 Notes”). The 2026 Notes are governed by the terms of the Indenture between the Company and U.S. Bank Trust Company, National Association, as trustee. The 2026 Notes will mature on March 1, 2026, unless earlier converted, redeemed or repurchased.

In the first quarter of fiscal 2025, the Company repurchased $200.0 million of the aggregate principal amount for $185.5 million, resulting in a gain of $14.5 million related to the discount on repurchase. As the repurchase of the 2026 Notes met the criteria for extinguishment accounting, $1.9 million of unamortized debt issuance costs were allocated to the repurchase, resulting in a net gain of $12.6 million, which was recorded in Interest and other income (expense), net on the Consolidated Statements of Income.

Holders may convert their notes at their option at any time prior to the close of business on the business day immediately preceding September 1, 2025 only under the following circumstances:

•During any calendar quarter (and only during such calendar quarter) beginning after June 30, 2021, if, the last reported sale price per share of the Company’s common stock exceeds 130% of the applicable conversion price on each applicable trading day for at least 20 trading days (whether or not consecutive) in the period of the 30 consecutive trading day period ending on, and including, the last trading day of the immediately preceding calendar quarter;

•During the five business day period after any five consecutive trading day period in which, for each day of that period, the trading price per $1,000 principal amount of the 2026 Notes for such trading day was less than 98% of the product of the last reported sale price of the Company’s common stock and the applicable conversion rate on such trading day;

•The Company issues to common stockholders any rights, options, or warrants, entitling them, for a period of not more than 60 days, to purchase shares of common stock at a price per share less than the average closing sale price of 10 consecutive trading days, or the Company’s election to make a distribution to common stockholders exceeding 10% of the previous day’s closing sale price;

•Upon the occurrence of specified corporate events, as set forth in the indenture governing the 2026 Notes; or

•Prior to the related redemption date if the Company calls the 2026 Notes for redemption.

On or after September 1, 2025, until the close of business on the scheduled trading day immediately preceding the maturity date, holders may convert all or a portion of their 2026 Notes, in multiples of $1,000 principal amount, at any time, regardless of the foregoing circumstances. The conversion rate for the 2026 Notes is 5.7033 shares of common stock per $1,000 principal amount of notes (which is equal to an initial conversion price of approximately $175.34 per share of the Company’s common stock), subject to adjustment as set forth in the Indenture. Upon conversion, the Company will pay cash up to the aggregate principal amount of the notes to be converted and pay or deliver, as the case may be, cash, common stock or a combination of cash and common stock, at the Company’s election, in respect of the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount of the notes being converted. If a make-whole adjustment event, as described in the Indenture, occurs and a holder elects to convert its 2026 Notes in connection with such make-whole adjustment event, such holder may be entitled to an increase in the conversion rate as described in the Indenture.

During fiscal 2025, the conditions allowing holders of the 2026 Notes to convert have not been met. The 2026 Notes were therefore not convertible as of March 29, 2025 and were classified as short-term debt on the Company’s consolidated balance sheets.

The 2026 Notes will be redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after March 5, 2024 and on or before the 40th scheduled trading day immediately before the maturity date, if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which the Company provides notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately before the date the Company sends the related redemption notice at a redemption price equal to 100% of the principal amount of the 2026 Notes to be redeemed, plus accrued and unpaid interest to, but excluding the redemption date. Upon the occurrence of certain fundamental changes involving the Company, holders of the 2026 Notes may require the Company to repurchase for cash all or part of their 2026 Notes at a repurchase price equal to 100% of the principal amount of the 2026 Notes to be repurchased, plus

accrued and unpaid interest.

As of March 29, 2025, the $300.0 million principal balance was netted down by $1.5 million of remaining debt issuance costs, resulting in a net convertible note payable of $298.5 million. Interest expense related to the 2026 Notes was $1.4 million for

fiscal 2025 which is entirely attributable to the amortization of the debt issuance costs. The remaining debt issuance costs are amortized at an effective interest rate of 0.5%.

2029 Notes

On May 28, 2024, the Company issued $700.0 million aggregate principal amount of 2.5% convertible senior notes due 2029 (the “2029 Notes”). The 2029 Notes are governed by the terms of the Indenture between the Company and U.S. Bank Trust Company, National Association, as trustee. The total net proceeds from the sale of the 2029 Notes, after deducting the initial purchasers’ discounts and debt issuance costs, were $682.8 million, with a portion of funds used to repay the entirety of the balance on the revolving credit facility under the Company’s second amended and restated credit agreement, to repurchase a portion of the Company’s 2026 Notes, to complete capped call transactions in connection with the issuance of the 2029 Notes, as described further below, with the remaining proceeds available for other working capital requirements. The 2029 Notes will mature on June 1, 2029, unless earlier converted, redeemed or repurchased.

Holders may convert their notes at their option at any time prior to the close of business on the business day immediately preceding December 1, 2028 only under the following circumstances:

•During any calendar quarter (and only during such calendar quarter) beginning after September 30, 2024, if, the last reported sale price per share of the Company’s common stock exceeds 130% of the applicable conversion price on each applicable trading day for at least 20 trading days (whether or not consecutive) in the period of the 30 consecutive trading day period ending on, and including, the last trading day of the immediately preceding calendar quarter;

•During the five business day period after any five consecutive trading day period in which, for each day of that period, the trading price per $1,000 principal amount of the 2029 Notes for such trading day was less than 98% of the product of the last reported sale price of the Company’s common stock and the applicable conversion rate on such trading day;

•Upon the occurrence of specified corporate events, as set forth in the indenture governing the 2029 Notes; or

•Prior to the related redemption date if the Company calls the 2029 Notes for redemption.

On or after December 1, 2028, until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or a portion of their 2029 Notes, in multiples of $1,000 principal amount, at any time, regardless of the foregoing circumstances. The conversion rate for the 2029 Notes is 8.5385 shares of common stock per $1,000 principal amount of notes (which is equal to an initial conversion price of approximately $117.12 per share of the Company’s common stock), subject to adjustment as set forth in the Indenture. Upon conversion, the Company will pay cash up to the aggregate principal amount of the notes to be converted and pay or deliver, as the case may be, cash, common stock or a combination of cash and common stock, at the Company’s election, in respect of the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount of the notes being converted. If a make-whole adjustment event, as described in the Indenture, occurs and a holder elects to convert its 2029 Notes in connection with such make-whole adjustment event, such holder may be entitled to an increase in the conversion rate as described in the Indenture.

During fiscal 2025, the conditions allowing holders of the 2029 Notes to convert have not been met. The 2029 Notes were therefore not convertible as of March 29, 2025 and were classified as long-term debt on the Company’s consolidated balance sheets.

The 2029 Notes will be redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after June 5, 2027 and on or before the 50th scheduled trading day immediately before the maturity date, if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date on which the Company provides notice of redemption, during any 30 consecutive trading day period ending on, and including, the trading day immediately before the date the Company sends the related redemption notice at a redemption price equal to 100% of the principal amount of the 2029 Notes to be redeemed, plus accrued and unpaid interest to, but excluding the redemption date. Upon the occurrence of certain

fundamental changes involving the Company, holders of the 2029 Notes may require the Company to repurchase for cash all or part of their 2029 Notes at a repurchase price equal to 100% of the principal amount of the 2029 Notes to be repurchased, plus

accrued and unpaid interest.

As a result of the issuance of the 2029 Notes, the Company recorded debt issuance costs of $17.2 million, which will be amortized to interest expense over the contractual term of the 2029 Notes at an effective interest rate of 3.0%.

As of March 29, 2025, the $700.0 million principal balance was netted down by $14.6 million of remaining debt issuance costs, resulting in a net convertible note payable of $685.4 million. Interest expense related to the 2029 Notes was $17.3 million for the fiscal year ended March 29, 2025, which includes nominal interest expense and the amortization of the debt issuance costs.

Capped Calls

In connection with the issuance of the 2026 Notes and the 2029 Notes, the Company entered into capped call transactions with certain counterparties (“Capped Calls”). The 2026 Notes Capped Calls each have an initial strike price of approximately $175.34 per share, and the 2029 Notes Capped Calls each have an initial strike price of approximately $117.12 per share, both are subject to certain adjustments, which correspond to the initial conversion price of the convertible notes. The 2026 Notes Capped Calls have initial cap prices of $250.48 per share, and the 2029 Notes Capped Calls have initial cap prices of $180.18 per share, both subject to certain adjustments. The Capped Calls are expected to partially offset the potential dilution to the Company’s common stock upon any conversion of the 2026 Notes and 2029 Notes, with such offset subject to a cap based on the cap price. The 2026 Notes Capped Calls cover approximately 2.85 million shares of the Company’s common stock, and the 2029 Notes Capped Calls cover approximately 5.98 million shares of the Company’s common stock, both subject to anti-dilution adjustments. For accounting purposes, the Capped Calls are separate transactions, and not part of the 2026 Notes and 2029 Notes. As these transactions meet certain accounting criteria, the Capped Calls are recorded in stockholders’ equity and are not accounted for as derivatives. The cost of $88.2 million incurred to purchase the 2029 Notes Capped Calls was recorded as a reduction to additional paid-in capital and will not be remeasured for the year ended March 29, 2025.

Credit Facilities

On July 26, 2022, the Company entered into an amended and restated credit agreement to refinance its credit facilities initially entered into in 2018 and extended their maturity dates through June 2025. The amended and restated credit agreement provided for a $750.0 million senior unsecured term loan and a $420.0 million senior unsecured revolving credit facility (together the “2022 Revised Credit Facilities”) with applicable interest rates during the period established using an annual rate equal to the Adjusted Term SOFR Rate plus ranging from 1.125% to 1.750% based on the Company’s consolidated net leverage ratio, as specified in the agreement.

On April 30, 2024, the Company entered into a second amended and restated credit agreement with certain lenders to refinance the 2022 Revised Credit Facilities and extend their maturity date through April 2029. The second amended and restated credit agreement provides for a $250.0 million senior unsecured term loan, the proceeds of which, along with $12.5 million of cash on hand, were used to retire the balance of the term loan under the 2022 Revised Credit Facilities, and a $750.0 million senior unsecured revolving credit facility (together, the “2024 Revised Credit Facilities”). Loans under the 2024 Revised Credit Facilities bear interest at an annual rate equal to the Adjusted Term SOFR Rate (as specified in the second amended and restated credit agreement), which is subject to a floor of 0%, plus an applicable rate ranging from 1.125% to 1.750% based on the Company’s consolidated net leverage ratio (as specified in the second amended and restated credit agreement) at the applicable measurement date. The revolving credit facility carries an unused fee that ranges from 0.125% to 0.250% annually based on the Company’s consolidated net leverage ratio at the applicable measurement date. The 2024 Revised Credit Facilities mature on April 30, 2029. The principal amount of the term loan under the 2024 Revised Credit Facilities amortizes quarterly through the maturity date at a rate of 2.5% for the first three years following the closing date, 5.0% for the fourth year following the closing date and 7.5% for the fifth year following the closing date, with the unpaid balance due at maturity.

Under the 2024 Revised Credit Facilities, the Company is required to maintain a consolidated leverage ratio not to exceed 4.0:1.0 or, upon two occasions during the term of the facility, 4.5:1.0 for the four consecutive fiscal quarters ended immediately following acquisitions meeting certain criteria specified in the agreement.

The Company applied modification accounting for the credit facility refinancing, which resulted in the capitalization of an additional $5.9 million in lender fees and third-party costs. For fiscal 2025, the Company recognized $20.8 million of interest expense and amortization of debt issuance costs related to its credit facilities.

At March 29, 2025, $245.3 million was outstanding under the term loan with an effective interest rate of 5.7%, which was netted down by the $5.3 million of remaining debt discount, resulting in a net note payable of $240.0 million. There were no outstanding borrowings under the revolving credit facility at March 29, 2025. The Company also had $18.9 million of uncommitted operating lines of credit to fund its global operations under which there were no outstanding borrowings as of March 29, 2025.

Under the 2024 Revised Credit Facilities, the Company is required to maintain certain leverage and interest coverage ratios specified in the second amended and restated credit agreement as well as other customary non-financial affirmative and negative covenants. The Company is required to satisfy these covenants, on a pro forma basis, in connection with any new borrowings (including any letter of credit issuances) on the revolving credit facility as of the time of such borrowings. The Consolidated Interest Coverage Ratio is calculated as the consolidated EBITDA divided by consolidated interest expense while the Consolidated Net Leverage ratio is calculated as consolidated total debt minus liquidity, divided by consolidated EBITDA. Consolidated EBITDA includes EBITDA adjusted by non-recurring and unusual transactions specifically as defined in the 2024 Revised Credit Facilities.

The 2024 Revised Credit Facilities also contain usual and customary non-financial affirmative and negative covenants that include certain restrictions with respect to subsequent indebtedness, liens, loans and investments (including acquisitions), financial reporting obligations, mergers, consolidations, dispositions, dissolutions or liquidation, asset sales, affiliate transactions, change of its business, capital expenditures, share repurchase and other restricted payments. These covenants are subject to exceptions and qualifications set forth in the second amended and restated credit agreement.

Any failure to comply with the financial and operating covenants of the 2024 Revised Credit Facilities would prevent the Company from being able to borrow additional funds and would constitute a default, which could result in, among other things, the amounts outstanding including all accrued interest and unpaid fees, becoming immediately due and payable. In addition, the 2024 Revised Credit Facilities include customary events of default, in certain cases subject to customary cure periods. The Company was in compliance with the consolidated net leverage and interest coverage ratios specified in the 2024 Revised Credit Facilities as well as all other bank covenants as of March 29, 2025.

Commitment Fee

Pursuant to the 2024 Revised Credit Facilities, the Company is required to pay, on the last day of each calendar quarter, a commitment fee on the unused portion of the revolving credit facility. The commitment fee is subject to a pricing grid based on the Company’s consolidated leverage ratio. The commitment fee ranges from 0.125% to 0.250%. The current commitment fee on the undrawn portion of the revolving credit facility is 0.200%.

Interest

Interest expense was $35.9 million, $19.5 million and $13.0 million for fiscal 2025, 2024 and 2023, respectively. Accrued interest associated with the outstanding debt is included as a component of other current liabilities in the accompanying consolidated balance sheets. As of both March 29, 2025 and March 30, 2024, the Company had an insignificant amount of accrued interest associated with the outstanding debt.

The future aggregate amount of debt maturities are as follows:


Fiscal year (In thousands)
2026	$	306,349
2027	6,308
2028	10,999
2029	17,253
2030	904,757
Thereafter	454
Total debt maturities	$	1,246,120

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

INCOME TAXES (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
INCOME TAXES (Narrative) (Details) - USD ($) $ in Thousands	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023	Apr. 02, 2022
Income Taxes [Line Items]
Foregin source income	$ 50,271	$ 39,302	$ 55,746
Valuation allowance	(1,744)	393	5,135
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	2,411	1,378	$ 2,073
Unremitted earnings	1,497	1,334
Tax credit carry-forward, net	6,713	$ 7,766
Undistributed foreign earnings of subsidiaries	$ 90,800
U.S. federal statutory income tax rate	21.00%	21.00%	21.00%
Unremitted earnings	$ 163	$ 171	$ (91)
Provision for income taxes	44,392	34,307	26,002
Unrecognized tax benefits	2,822	3,743	3,941	$ 3,939
Unrecognized tax benefits that will impact effective tax rate	1,800	3,100	3,200
Unrecognized tax benefits increases	315	234	292
Accrued interest and penalties	100	300
Income Tax Examination, Penalties and Interest Included in Income Tax Expense	300	$ 100	$ 100
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	(1,700)
Domestic Tax Jurisdiction
Income Taxes [Line Items]
Operating loss carry-forwards	6,700
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	500
State and Local Jurisdiction
Income Taxes [Line Items]
Operating loss carry-forwards	56,800
Operating loss carry-forwards subject to expiration	56,000
Operating loss carry-forwards not subject to expiration	800
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	6,200
Foreign Tax Jurisdiction
Income Taxes [Line Items]
Operating loss carry-forwards	4,000
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount	1,300
Foreign Tax Authority, Provincial
Income Taxes [Line Items]
Operating loss carry-forwards	7,700
Canada Revenue Agency
Income Taxes [Line Items]
Operating loss carry-forwards	$ 9,400
Malaysia
Income Taxes [Line Items]
Tax grant or holiday term	10 years

RETIREMENT PLANS (Schedule of Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Components of Change Recorded in Accumulated Other Comprehensive Income Related to Defined Benefit Plans, Net of Tax [Roll Forward]
Impact of defined benefit plans, net of tax, balance	$ 1,748	$ 4,075	$ 1,619
Actuarial gain	(268)	(2,157)	2,695
Prior service cost	(242)	(170)	46
Other Comprehensive Income (Loss), Defined Benefit Plan, Settlement and Curtailment Gain (Loss), after Tax	(89)		(285)
Impact of defined benefit plans, net of tax, balance	$ 1,149	$ 1,748	$ 4,075

ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS

12 Months Ended

Mar. 29, 2025

Business Combinations [Abstract]

Acquisitions and Strategic Investments

ACQUISITIONS, DIVESTITURES AND STRATEGIC INVESTMENTS

Acquisitions

Attune Medical

On March 5, 2024, the Company entered into a definitive agreement to acquire Advanced Cooling Therapy, Inc., d/b/a Attune Medical (“Attune Medical”), the manufacturer of the ensoETM® proactive esophageal cooling device, pursuant to which among other things, the Company agreed to acquire all of the issued and outstanding common shares of Attune Medical. On April 1, 2024, the Company completed its acquisition of Attune Medical for total consideration of $187.7 million, which included an upfront cash payment of $162.0 million, or $150.5 million net of cash acquired, the fair value of contingent consideration of $25.3 million, and $0.4 million of working capital adjustments. The contingent consideration is based on sales growth over the next three years, which is uncapped, and the achievement of certain other milestones. Refer to Note 13 Acquisitions, Divestitures and Strategic Investments for further information regarding the contingent consideration liability. The Company financed the acquisition through a combination of cash on hand and borrowings under its senior unsecured revolving credit facility.

Attune Medical's ensoETM technology is designed for use across a range of medical conditions involving patient cooling or warming, including treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery, among others. The Company’s addition of the Esophageal Protection product line through its acquisition of Attune Medical expands the Hospital business unit’s presence in electrophysiology and complements its Vascular Closure product line within Interventional Technologies, which is included in the Hospital reportable segment.

Purchase Price Allocation

The Company accounted for the acquisition as a business combination, and in accordance with FASB ASC Topic 805, Business Combinations (Topic 805), recorded the assets acquired and liabilities assumed at their fair values as of the acquisition date. The fair value of assets acquired and liabilities assumed have been recognized based on management’s estimates and assumptions using the information regarding facts and circumstances that existed at the closing date.

The purchase price of $176.2 million, net of $11.5 million of cash acquired, consists of the amounts presented below, which represent the final determination of the fair value of the identifiable assets acquired and liabilities assumed:


(In thousands)	April 1, 2024
Accounts receivable	$	3,784
Inventories	26,300
Prepaid expenses and other current assets	906
Property, plant and equipment	200
Intangible assets	105,800
Goodwill	70,256

Total assets acquired	$	207,246
Accounts payable	2,260
Accrued payroll and related costs	2,129
Other liabilities	496
Deferred tax liability	26,155

Total liabilities assumed	$	31,040
Net assets acquired	$	176,206

The Company determined that the identifiable intangible assets were developed technology, customer contracts and related relationships and trade names. The fair values of intangible assets were based on valuation techniques with estimates and assumptions developed by the Company. Developed technology was valued using the excess earnings method. Customer contracts and related relationships were valued using the distributor method. The trademark was valued using the relief from royalty method. The cash flows used in the valuation of the intangible assets were based on estimates used to price the transaction. In developing the discount rates applied to the cash flow projections, the discount rates were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital and then adjusted to reflect the relative risk of the asset.

The excess of the purchase price over the tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill. As a result of the acquisition of Attune Medical, the Company recognized goodwill of $70.3 million based on expected synergies from integration into our Hospital business. The goodwill is not deductible for tax purposes and relates entirely to the Hospital reportable segment.

Intangible assets acquired consist of the following:


(In thousands)	Amount		Weighted-Average Amortization Period	Risk-Adjusted Discount Rates used in Purchase Price Allocation
Developed technology	$	96,100	10 years	22.0	%
Customer contracts and related relationships	7,800		10 years	21.5	%
Trade names	1,900		10 years	21.5	%
Total	$	105,800

The Company recorded a long-term net deferred tax liability of $26.2 million primarily related to fair value adjustments recorded associated with definite-lived intangible assets and inventory in which there is no tax basis, partially offset by deferred tax assets primarily related to net operating losses acquired.

Acquisition-Related Costs

The Company incurred $9.8 million of acquisition-related costs during fiscal 2025 in connection with the Attune Medical acquisition. These costs related to legal and other professional fees, which were recognized in selling, general and administrative on the Consolidated Statements of Income.

The Company’s consolidated financial statements include the results of Attune Medical from the date the acquisition was completed. Pro forma financial information has not been presented as the acquisition is not material to the Company’s overall financial results.

For information regarding the remeasurement of the contingent consideration liability refer to Note 13. Financial Instruments and Fair Value Measurements.

OpSens Inc.

On October 10, 2023, the Company entered into an Arrangement Agreement with OpSens Inc. (“OpSens”), a medical device cardiology-focused company delivering solutions based on its proprietary optical technology, pursuant to which, among other things, the Company agreed to acquire all of the issued and outstanding common shares of OpSens. On December 12, 2023, the Company completed its acquisition of OpSens for total consideration of approximately $254.5 million, or $243.9 million, net of cash acquired. The Company financed the acquisition through a combination of cash on hand and borrowings under its senior unsecured revolving credit facility.

OpSens offers commercially and clinically validated optical technology for use primarily in interventional cardiology. OpSens’ core products include the SavvyWire®, a sensor-guided 3-in-1 guidewire for transcatheter aortic valve replacement (“TAVR”) procedures, advancing the workflow of the procedure and enabling potentially shorter hospital stays for patients; and the OptoWire®, a pressure guidewire that aims to improve clinical outcomes by accurately and consistently measuring Fractional Flow Reserve (“FFR”) and diastolic pressure ratio (“dPR”) to aid clinicians in the diagnosis and treatment of patients with

coronary artery disease. OpSens also manufactures a range of fiber optic sensor solutions used in medical devices and other critical industrial applications. The addition of OpSens expands the Hospital business unit portfolio in the interventional cardiology market and is included in the Hospital reportable segment.

Purchase Price Allocation


(In thousands)	December 12, 2023
Accounts receivable	$	5,960
Inventories	12,075
Prepaid expenses and other current assets	2,062
Property, plant and equipment	3,028
Intangible assets	172,000
Goodwill	79,400
Other long-term assets	4,705
Total assets acquired	$	279,230
Accounts payable	3,251
Accrued payroll and related costs	1,723
Other liabilities	9,746
Deferred tax liability	14,805
Other long-term liabilities	5,853
Total liabilities assumed	$	35,378
Net assets acquired	$	243,852

The Company determined that the identifiable intangible assets were developed technology, customer contracts and related relationships and trade names. The fair values of intangible assets were based on valuation techniques with estimates and assumptions developed by the Company. Developed technology and customer contracts and related relationships were valued using the excess earnings method. Trademarks were valued using the relief from royalty method. The cash flows used in the valuation of the intangible assets were based on estimates used to price the transaction. In developing the discount rates applied to the cash flow projections, the discount rates were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital and then adjusted to reflect the relative risk of the asset.

The excess of the purchase price over the tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill. As a result of the acquisition of OpSens, the Company recognized goodwill of $79.4 million based on expected synergies from integration into our Hospital business. The goodwill is not deductible for tax purposes and relates entirely to the Hospital reportable segment.

Intangible assets acquired consist of the following:


(In thousands)	Amount		Weighted-Average Amortization Period	Risk-Adjusted Discount Rates used in Purchase Price Allocation
Developed technology	$	114,900	15 years	20.5	%
Customer contracts and related relationships	52,300		15 years	18.9	%
Trade names	4,800		15 years	20.5	%
Total	$	172,000

The Company recorded a net long-term deferred tax liability of $14.8 million, primarily as a result of fair value adjustments recorded associated with definite-lived intangible assets and inventory in which there is no tax basis.

Acquisition-Related Costs

The Company incurred $6.6 million of acquisition-related costs for fiscal 2024 in connection with the OpSens acquisition. These costs related to legal and other professional fees, which were recognized in selling, general and administrative on the Consolidated Statements of Income.

The Company’s consolidated financial statements include the results of OpSens from the date the acquisition was completed. Pro forma financial information has not been presented as the acquisition is not material to the Company’s overall financial results.

Divestiture of the Whole Blood Product Line

On December 3, 2024, the Company announced that it had entered into a definitive agreement to sell its Whole Blood product line and related assets within its Blood Center reportable segment to GVS, S.p.A (“GVS”), a manufacturer of filter solutions for applications in the healthcare and life sciences sectors. The divested assets include the Company’s complete portfolio of proprietary whole blood collection, processing and filtration solutions, along with the Company’s manufacturing facility in Covina, California where certain of these products are produced, and related equipment and assets located at the Company’s manufacturing facility in Tijuana, Mexico.

On January 13, 2025, the Company completed the transaction with GVS in exchange for upfront cash consideration of $43.3 million, after customary post-closing adjustments, and up to $22.5 million in contingent consideration, based on sales growth over the next three years and the achievement of certain other milestones.

The assets that were derecognized in connection with the sale consisted of $26.4 million of inventory, $7.8 million of property, plant and equipment and $6.4 million of goodwill, which were previously classified as held for sale in Prepaid expenses and other current assets in the Consolidated Balance Sheets in the third quarter of fiscal 2025.

In connection with the sale, the Company recognized a gain from the sale of the business in Interest and other expense, net in the Consolidated Statements of Income for the year ended March 29, 2025. The gain was not material and included the cash receipts of $43.3 million less net assets transferred to GVS or otherwise derecognized and net of transaction costs of $0.1 million.

As part of the sale, the Company entered into a Transition Services Agreement (“TSA”) with GVS to ensure a smooth transition of business operations. Under the TSA, the Company will continue to provide certain regulatory, quality, logistical and operational support services to GVS for a maximum period of 36 months following the transaction closing to facilitate GVS's integration of the acquired business. Under the TSA, the Company is entitled to be reimbursed for the costs incurred plus a mark-up and has recorded net income and expenses related to the agreement in selling, general and administrative in the Consolidated Statements of Income, which were immaterial for fiscal 2025.

In addition to the TSA, Haemonetics and GVS entered into a Contract Manufacturing Agreement (“CMA”), under which Haemonetics will continue to manufacture certain whole blood filtration products for GVS for a maximum term of 18 months. The CMA allows GVS to gradually transition manufacturing operations while ensuring supply continuity for customers. Under

the CMA, the Company is entitled to be reimbursed for the costs incurred plus a mark-up and has recorded net income and expenses related to the agreement in selling, general and administrative in the Consolidated Statements of Income, which were immaterial for fiscal 2025.

Strategic Investments

As part of the Company’s business development activities, it holds strategic investments in certain entities. During fiscal years 2025, 2024 and 2023, the Company made investments in Vivasure Medical LTD (“Vivasure”), totaling €9.5 million, €5.0 million and €30.0 million, respectively. The investments include both preferred stock and a special share that allows the Company to acquire Vivasure in accordance with an agreement between the parties. In addition, the Company has made certain other strategic investments totaling $7.0 million and $7.6 million during fiscal years 2025 and 2024. The Company’s strategic investments are classified as other long-term assets on the consolidated balance sheets and the Company did not record any adjustments to the carrying value of our strategic investments in fiscal 2025, fiscal 2024 or fiscal 2023.

EARNINGS PER SHARE (Share Repurchase Plan) (Details) $ / shares in Units, shares in Thousands, $ in Thousands				1 Months Ended		3 Months Ended	12 Months Ended
	Apr. 07, 2025 shares	Aug. 28, 2024 USD ($) $ / shares shares	Aug. 16, 2022 USD ($) $ / shares	Apr. 30, 2025 USD ($)	Feb. 28, 2025 USD ($) $ / shares shares	Nov. 04, 2022 shares	Mar. 29, 2025 shares	Apr. 01, 2023 shares	Aug. 31, 2022 USD ($)
Accelerated Share Repurchases [Line Items]
Shares repurchased (in shares) \| shares							3,031	997
2022 Share Repurchase Program
Accelerated Share Repurchases [Line Items]
Share Repurchase Program, Period in Force							3 years
Share Repurchase Program, Authorized, Amount \| $									$ 300,000
Accelerated Share Repurchases, Settlement (Payment) or Receipt \| $			$ 75,000
Repurchase price (in dollars per share) \| $ / shares			$ 75.20
Shares repurchased (in shares) \| shares						1,000
2024 Accelerated Share Repurchase Program
Accelerated Share Repurchases [Line Items]
Accelerated Share Repurchases, Settlement (Payment) or Receipt \| $		$ 75,000
Repurchase price (in dollars per share) \| $ / shares		$ 74.36
Shares repurchased (in shares) \| shares		1,000
February 2025 Accelerated Share Repurchase Program
Accelerated Share Repurchases [Line Items]
Accelerated Share Repurchases, Settlement (Payment) or Receipt \| $					$ 150,000
Repurchase price (in dollars per share) \| $ / shares					$ 59.34
Shares repurchased (in shares) \| shares					2,000
Accelerated Share Repurchases, Percent of Total Contract Repurchased					0.80
February 2025 Accelerated Share Repurchase Program \| Subsequent Event
Accelerated Share Repurchases [Line Items]
Shares repurchased (in shares) \| shares	400
April 2025 Share Repurchase Program \| Subsequent Event
Accelerated Share Repurchases [Line Items]
Share Repurchase Program, Period in Force				3 years
Accelerated Share Repurchases, Settlement (Payment) or Receipt \| $				$ 500,000

CAPITAL STOCK (Schedule of Summary of Equity Awards other than Options Activity) (Details) - $ / shares	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023	Apr. 02, 2022
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Shares, Beginning Balance (in shares)	338,008
Shares, Granted (in shares)	141,568
Shares, Vested (in shares)	(143,680)
Shares, Forfeited (in shares)	(32,893)
Shares, Ending Balance (in shares)	303,003	338,008
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted Average Grant Date Fair Value (in dollars per share), Beginning Balance	$ 72.52
Weighted Average Grant Date Fair Value (in dollars per share), Granted	95.09	$ 89.21	$ 59.36
Weighted Average Grant Date Fair Value (in dollars per share), Vested	75.04	67.14	70.24
Weighted Average Grant Date Fair Value (in dollars per share), Forfeited	78.45
Weighted Average Grant Date Fair Value (in dollars per share), Ending Balance	$ 81.27	$ 72.52
Restricted Stock Units (RSUs) \| Minimum \| Employees
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Award vesting period	3 years
Performance Share Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Shares, Beginning Balance (in shares)	369,800
Shares, Granted (in shares)	231,758			116,207
Performance shares target, percentage	100.00%
Shares, Vested (in shares)	(233,384)
Shares, Forfeited (in shares)	(32,331)
Shares, Ending Balance (in shares)	335,843	369,800
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]
Weighted Average Grant Date Fair Value (in dollars per share), Beginning Balance	$ 94.26
Weighted Average Grant Date Fair Value (in dollars per share), Granted	128.25	$ 128.83	84.96
Weighted Average Grant Date Fair Value (in dollars per share), Vested	72.35	0	$ 0
Weighted Average Grant Date Fair Value (in dollars per share), Forfeited	109.61
Weighted Average Grant Date Fair Value (in dollars per share), Ending Balance	$ 112.10	$ 94.26
Performance Share Units (PSUs) \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Performance shares target, percentage	0.00%
Performance Period One \| Performance Share Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Performance shares target, percentage	200.00%
Shares, Vested (in shares)	(226,274)
Performance Period Two \| Performance Share Units (PSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Performance shares target, percentage	176.00%
Shares, Vested (in shares)	(7,110)

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 29, 2024	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Property, Plant and Equipment [Line Items]
Total		$ 837,194	$ 959,177
Less: accumulated depreciation		(553,142)	(647,815)
Property, plant and equipment, net		284,052	311,362
Depreciation expense		60,000	55,800	$ 51,200
Proceeds from sale of property, plant and equipment	$ 19,900	23,253	1,810	1,608
Gain (Loss) on Disposition of Property Plant Equipment	$ 14,100	15,698	1,013	$ 943
Revision of Prior Period, Reclassification, Adjustment
Property, Plant and Equipment [Line Items]
Total		40,800
Property, plant and equipment, net		(7,800)
Land
Property, Plant and Equipment [Line Items]
Total		1,985	4,130
Building and building improvements
Property, Plant and Equipment [Line Items]
Total		105,079	124,338
Plant equipment and machinery
Property, Plant and Equipment [Line Items]
Total		181,825	204,622
Office equipment and information technology
Property, Plant and Equipment [Line Items]
Total		130,924	129,979
Haemonetics equipment
Property, Plant and Equipment [Line Items]
Total		395,152	456,414
Construction in Progress
Property, Plant and Equipment [Line Items]
Total		$ 22,229	$ 39,694

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Allowance for Credit Losses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 29, 2025	Mar. 30, 2024	Apr. 01, 2023
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Beginning balance	$ 5,695	$ 4,932	$ 2,475
Inventory reserve adjustment	725	840	2,623
Write-offs	(120)	(77)	(166)
Ending balance	$ 6,300	$ 5,695	$ 4,932

LEASES (Tables)

12 Months Ended

Mar. 29, 2025

Leases [Abstract]

Assets and Liabilities Lessee [Table Text Block]

The following table presents supplemental balance sheet information related to the Company’s operating leases:


(In thousands)	March 29, 2025		March 30, 2024
Assets
Operating lease right-of-use assets in Other long-term assets	$	47,492	$	55,268
Liabilities
Operating lease liabilities in Other current liabilities	$	8,107	$	8,133
Operating lease liabilities in Other long-term liabilities	$	50,454	$	57,958

Lessee, Operating Leases, Other Information [Table Text Block]

The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:


	March 29, 2025		March 30, 2024
Weighted average remaining lease term	7.5 years		8.2 years
Weighted average discount rate	4.99	%	5.31	%

Lease, Cost [Table Text Block]

The following table presents supplemental cash flow information related to our operating leases:


(In thousands)	March 29, 2025		March 30, 2024		April 1, 2023
Cash paid for amounts included in the measurement of operating lease liabilities
Operating cash flows used for operating leases	$	11,201	$	10,636	$	11,450
Right of use assets obtained in exchange for new operating lease liabilities	$	399	$	2,450	$	211

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

The following table presents the maturities of our operating lease liabilities as of March 29, 2025:


Fiscal Year (In thousands)	Operating Leases
2026	$	10,835
2027	11,376
2028	9,493
2029	7,604
2030	7,452
Thereafter	24,776
Total future minimum operating lease payments	71,534
Less: imputed interest	(12,973)
Present value of operating lease liabilities	$	58,561

INVENTORIES (Schedule of Inventories) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 30, 2024	Mar. 29, 2025
Inventory Disclosure [Abstract]
Raw materials	$ 134,150	$ 128,574
Work-in-process	15,488	14,956
Finished goods	167,564	221,611
Total inventories	317,202	$ 365,141
Inventory Recall Expense	$ 4,400

CAPITAL STOCK (Tables)

12 Months Ended

Mar. 29, 2025

Share-Based Payment Arrangement [Abstract]

Schedule of Stock-Based Compensation Cost


(In thousands)	2025	2024	2023
Selling, general and administrative expenses	$25,971	$23,662	$21,903
Research and development	1,847	3,106	2,364
Cost of goods sold	1,818	1,564	1,316
	$29,636	$28,332	$25,583

Schedule of Summary of Stock Option Activity

A summary of stock option activity for the fiscal year ended March 29, 2025 is as follows:


	Options Outstanding	Weighted Average Exercise Price per Share		Weighted Average Remaining Life (years)	Aggregate Intrinsic Value ($000’s)
Outstanding at March 30, 2024	1,067,004	$	74.86	3.68	$	16,820
Granted	159,318	95.73
Exercised	(158,135)	47.61
Forfeited/Canceled	(74,600)	85.78
Outstanding at March 29, 2025	993,587	$	81.75	3.50	$	2,249

Exercisable at March 29, 2025	568,514	$	83.49	2.38	$	1,283

Vested or expected to vest at March 29, 2025	914,406	$	81.47	3.40	$	2,144

Schedule of Assumptions Utilized for Estimating Fair Value of Option Grants

The assumptions utilized for option grants during the periods presented are as follows:


	2025			2024			2023
Volatility	43.9		%	45.3		%	45.0		%
Expected life (years)	5.2			5.1			5.0
Risk-free interest rate	4.4		%	3.5		%	2.9		%
Dividend yield	0.0		%	0.0		%	0.0		%
Grant-date fair value per Option	$	43.56		$	39.46		$	24.86

Schedule of Summary of Restricted Stock Units Activity

A summary of RSU activity for the fiscal year ended March 29, 2025 is as follows:


	Shares	Weighted Average Grant Date Fair Value
Unvested at March 30, 2024	338,008	$	72.52
Granted	141,568	95.09
Vested	(143,680)	75.04
Forfeited	(32,893)	78.45
Unvested at March 29, 2025	303,003	$	81.27

The weighted-average grant-date fair value of RSUs granted and total fair value of RSUs vested are as follows:


	2025		2024		2023
Grant-date fair value per RSU	$	95.09	$	89.21	$	59.36
Fair value of RSUs vested	$	75.04	$	67.14	$	70.24

Schedule of Performance Share Unit awards

A summary of PSU activity for the fiscal year ended March 29, 2025 is as follows:


	Shares	Weighted Average Grant Date Fair Value
Unvested at March 30, 2024	369,800	$	94.26
Granted(1)	231,758	128.25
Vested(2)	(233,384)	72.35
Forfeited	(32,331)	109.61
Unvested at March 29, 2025	335,843	$	112.10
(1) Includes 116,207 shares issued for awards vested during fiscal 2025 based on achievement of performance metrics.
(2)Includes the vesting of 226,274 and 7,110 shares that were earned for awards granted in fiscal 2022 for various performance periods ending during fiscal 2025, based on actual relative total shareholder return of 200% and 176%, respectively.

Schedule of Share-based Payment Award, Equity Other Than Options, Valuation Assumptions

The assumptions used in the Monte Carlo model for PSUs granted during each fiscal year were as follows:


	2025		2024		2023
Expected stock price volatility	35.35	%	48.20	%	52.22	%
Peer group stock price volatility	35.95	%	40.29	%	47.43	%
Correlation of returns	58.08	%	59.93	%	65.45	%

The weighted-average grant-date fair value of PSUs granted is as follows:


	2025		2024		2023
Grant-date fair value per PSU	$	128.25	$	128.83	$	84.96
Fair value of PSUs vested	$	72.35	$	—	$	—

Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions

The fair values of shares purchased under the Employee Stock Purchase Plan are estimated using the Black-Scholes single option-pricing model with the following weighted average assumptions:


	2025		2024		2023
Volatility	29.3	%	28.6	%	44.9	%
Expected life (months)	6		6		6
Risk-free interest rate	4.9	%	5.4	%	2.9	%
Dividend Yield	0.0	%	0.0	%	0.0	%